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D. Abstract
Context: Asthma is a chronic disease that affects approximately 300 million
people worldwide. Although wide range of drug is available, the relief provided
by them is mainly symptomatic and short lived. Moreover, the side effects of
these drugs are also quite disturbing. Hence, a continuous search is on going
to identify effective and safe remedies to treat bronchial asthma. Ayurveda is
a great Indian tradition and have an important role in discovery of new
medicines. There are many natural herbs that can be used for asthma
treatment. Solanum xanthocarpum (SX) (Solanaceae), Aegle marmelos (AM)
(Rutaceae), Caesalpinia bonducella (CB) (Caesalpiniaceae), and Murraya
koenigii (MK) (Rutaceae) are traditionally used to treat asthma.
Objective: Although these plants possess diverse pharmacological actions,
the scientific data on anti-asthmatic actions of this plant has got little attention.
An attempt has been made to evaluate antiasthmatic activity of polyherbal
formulations and ethanolic extract of four medicinal plants. Moreover,
synergistic effect of combination of these extracts at sub-effective doses was
evaluated.
Materials and methods: Different groups of guinea pigs (350-500 g) of either
sex were subjected to acetylcholine (n = 5) and histamine-induced (n = 10)
airway constriction and Wistar albino rats (n = 6) of either sex were employed
for carrageenan-, dextran-, formaldehyde-, and histamine-induced paw
oedemas, mast cell stabilizing activity, and cotton pellet-induced granuloma
tests.
Results: Polyherbal formulations showed potent bronchodilator activity on
histamine-and acetylcholine-induced airway constriction in guinea pigs,
protected mast cell from degranulation induced by compound 48/80, inhibited
acute, sub-acute, and chronic inflammation in rats. Interestingly, Combination
of ethanolic extract (EE) of SX, AM, CB, and MK at sub-effective dose
produced synergistic actions in all the models. The LD50 of the EESX, EEAM,
and polyherbal formulations I and II was calculated to be 2262.7 mg/kg,
whereas, LD50 of the EECB and EEMK was calculated to be 1131.4 by oral
route. These LD50 values fall within the practically non-toxic range.
Abstract
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Discussion and conclusion: The present study for the first time indicates
anti-asthmatic, acute, sub-acute and chronic anti-inflammatory, and mast cell
stabilizing activities of polyherbal formulations and four Indian medicinal
plants, confirming their traditional claims. The antiasthmatic action of
polyherbal formulations could be due to the inhibition of the synthesis, release
or action of histamine and acetylcholine or mast cell membrane stabilizing
effect.
Key Words: Antiasthmatic, Antihistaminic, Anti-inflammatory, Compound
48/80, Mast cell stabilization, Polyherbal formulation.
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1. Introduction
Asthma is a disease of the human respiratory system in which the airways
constrict and become narrow, often in response to a "trigger" such as
exposure to an allergen, cold air, exercise, or emotional stress. Asthma
affects 7% of the total population and approx 300 million worldwide. During
attacks (exacerbations), the smooth muscle cells in the bronchi constrict, and
the airways become inflamed and swollen with difficulty in breathing. Asthma
causes 4,000 deaths a year in the US alone. Attacks can be prevented by
avoiding triggering factors and by drug treatment (Prasad et al., 2009).
 There is limited information on field epidemiology of bronchial asthma
in Indian adults. A field study was conducted by Aggarwal et al. (2009) at
Chandigarh, Delhi, Kanpur, and Bangalore. The results of the study indicated
that from 73605 respondents (37682 men, 35923 women), one or more
respiratory symptoms were present in 4.3-10.5% subjects. Asthma was
diagnosed in 2.28%, 1.69%, 2.05 and 3.47% respondents respectively at
Chandigarh, Delhi, Kanpur, and Bangalore, with overall prevalence of 2.38%.
Female sex, advancing age, usual residence in urban area, lower socio-
economic status, history suggestive of atopy, history of asthma in a first
degree relative, and all forms of tobacco smoking were shown as responsible
ailments of asthma. Prevalence estimates of asthma in adults in this study
pointed a high overall national burden of disease (Aggarwal et al., 2009).
Asthma is one of the commonest chronic diseases of affluent societies.
The striking increase in prevalence of asthma over recent decades in affluent
societies and the rarity of this disease in less affluent populations confirms the
importance of environmental and other factors in the cause of asthma,
although which environmental and other factors are responsible is still not
clear. The studies showed that genetic factors are also important in
determining individual susceptibility to asthma. The results of genetic studies
suggest that there are many genes with moderate effects rather than a few
major genes. Asthmatic airways show inflammation with CD4+ helper cells,
mast cells, and eosinophils, characterizing the inflammatory response.
Inhaled corticosteroids remain the cornerstone of treatment with the addition
of long-acting ?-agonists as the next step if symptoms continue. Leukotriene
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antagonists, the only new drugs to reach the market in the past decade, have
modest effects. A better understanding of the mechanisms underlying asthma
and the genetic and environmental factors that predispose individuals to
asthma will play a key role in understanding better preventative strategies and
new therapeutic approaches (Tattersfield et al., 2002).
It has been estimated that about 6000 articles are published every year
about asthma in various indexed journals. The increasing prevalence of
asthma has led to extensive research into its cause, pathophysiology, and
management (Tattersfield et al., 2002).
A few patients have asthma as part of a wider problem such as allergic
bronchopulmonary aspergillosis (Stevens et al., 2000), Churg-Strauss
syndrome (Conron & Beynon, 2000) and aspirin-induced asthma (Szczeklik et
al., 2000). Table 1.1 shows the main features of these disorders.
Table 1.1 Syndromes associated with asthma
Associated asthma
syndrome
Main features
Allergic
Bronchopulmonary
aspergillosis
· Asthma
· High blood eosinophil count-usually 1-3 X109/L
· Recurrent pulmonary infiltrates
· Positive skin prick test to Aspergillus fumigatus
· Positive blood precipitins to A. fumigatus
· Responds to high dose prednisolone and often
requires regular oral corticosteroids
· Itraconazole might help
Churg-Strauss
Syndrome
· Asthma, usually long standing, increasing in
severity, and requiring oral corticosteroids
· High eosinophil count (usually >1·5X109/L)
· Eosinophilic lung infiltrates,
· Systemic vasculitis (mononeuritis multiplex, skin,
gastrointestinal tract, kidneys, heart, and eyes)
· In patients already taking corticosteroids, the
clinical features might be mild
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· Responds to high-dose prednisolone and
cyclophosphamide
· 50% of patients have a positive antineutrophil
antibody, specifically to myeloperoxidase
· Has been reported after some drugs including
macrolide antibiotics and leukotrienes antagonists,
although a causal association is still not established
Aspirin-sensitive
asthma
· Bronchoconstriction occurs in response to aspirin
and other
Non-steroidal anti-inflammatory drugs
· The response can be rapid and life-threatening
· Asthma is chronic and severe
· Some patients also bronchoconstrict in response to
hydrocortisone
· Some response to leukotriene antagonists
· Patients should be told to avoid all non-steroidal
anti-inflammatory drugs
1.1 Historical background
The modern school of thought regarding asthma as a disease is so
powerful that it is difficult to imagine asthma, as it was once conceptualized.
During the seventeenth century, Once English physicians Thomas Willis and
Sir John Floyer began arguing that asthma was different from other breathing
disorders and is the same from person to person. They mentioned that
asthma, as a specific form of disordered breathing, must be treated differently
from other forms of breathlessness cases. By the late nineteenth century,
physicians believed that asthma was a disease which had a specific set of
causes, clinical consequences, and requirements for treatment, despite the
diversity of individual experiences as shown in Table 1.2. Because of the
spectrum of severity within asthma, some people with asthma only rarely
experience symptoms, usually in response to triggers, where as other more
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severe cases may have marked airflow obstruction at all times (Prasad et al.,
2009).
Table 1.2. Classification of asthma (Prasad et al., 2009)
Severity
Symptom
frequency
Symptoms
at night
Peak
expiratory
flow
rate or FEV1
of
predicted
Variability of
peak
expiratory
flow rate
or FEV1
Intermittent
< once a
week
? twice per
month
? 80%
predicted
< 20%
Mild
persistent
> once per
week but <
once per day
> twice per
month
? 80%
predicted
20–30%
Moderate
persistent
Daily
> once per
week
60–80%
predicted
> 30%
Severe Daily Frequent
< 60%
predicted
> 30%
 Asthma exists in two states: the steady-state of chronic asthma, and
the acute state of an asthma exacerbation. The symptoms are different
depending on what state the patient is in. Common symptoms of asthma in a
steady-state include: nighttime coughing, shortness of breath with exertion but
no dyspnea at rest, a chronic 'throat-clearing' type cough, and complaints of a
tight feeling in the chest. Severity often correlates to an increase in intensity of
symptoms. Symptoms can worsen gradually and rather insidiously, up to the
point of an acute exacerbation of asthma. It is a common misconception that
wheezing is common in patients with asthma-some never wheeze, and their
disease may be confused with another Chronic Obstructive Pulmonary
Disease (COPD) such as emphysema or chronic bronchitis. An acute
exacerbation of asthma is commonly referred to as an asthma attack. The
cardinal symptoms of an attack are shortness of breath (dyspnea), wheezing,
and chest tightness (Saunders, 2005). Some patients present primarily with
coughing, and in the late stages of an attack, air motion may be so impaired
that no wheezing may be heard.  When present the cough may sometimes
produce clear sputum. The onset may be sudden, with a sense of constriction
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in the chest, breathing becomes difficult, and wheezing occurs (primarily upon
expiration, but can be in both respiratory phases) (Table 1.3). Asthma is
classified according to the frequency of symptoms, Forced Expiratory Volume
(FEV1) and peak expiratory flow rate (PEFR) (Yawn, 2008). Though
symptoms may be very severe during an acute exacerbation, between attacks
a patient may show few or even no signs of the disease (Martinez, 2007).
Table 1.3: Severity of asthma attack (Prasad et al., 2009)
Sign/Symptom Mild Moderate Severe
Imminent
respiratory
arrest
Alertness
May show
agitation
Agitated Agitated Confused/Drowsy
Breathlessness On walking On talking
Even at
rest
Absent
Talks in  Sentences  Phrases Words
Wheeze Moderate Loud Loud
Accessory
muscle
Usually, not
used
Used Used
Respiratory
rate (/min)
Increased Increased Often >30
Pulse rate
(/min)
100 100-120 >120
<60
(Bradycardia)
PaO2 Normal >60
<60
,possible
cyanosis
<60 ,possible
cyanosis
PaCO2 <45 <45 >45 >45
1.2 Epidemiology
Asthma has no standard definition. Attempts to define asthma have
generally resulted in descriptive statements invoking notions of variable
airflow obstruction over short periods of time, sometimes in association with
markers of airway hyper-responsiveness and cellular pathology of the airway
(Tattersfield et al., 2002).
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Asthma is diagnosed clinically on the basis of symptoms of wheeze,
dyspnea, and cough, and by objective evidence of variable airflow obstruction.
Allergic asthma can present for the first time at any age, but incidence is
highest in childhood (Dodge & Burrows, 1980). Asthma in childhood
frequently remits during adolescence but can recur in adult life (Jenkins et al.,
1994). Asthma in adults tends to persist for life and is probably associated
with an accelerated decline in lung function (Lange et al., 1998). Deaths from
asthma are now uncommon, especially in children and young adults; in the
past they have occurred in epidemics thought to have been caused by use of
high dose formulations of relatively unselective ?-agonist drugs (Stolley &
Schinnar, 1978)
Asthma is an airway disease that can be classified physiologically as a
variable and partially reversible obstruction to air flow, and pathologically with
overdeveloped mucus glands, airway thickening due to scarring and
inflammation, and bronchoconstriction, the narrowing of the airways in the
lungs due to the tightening of surrounding smooth muscle. Bronchial
inflammation also causes narrowing due to edema and swelling caused by an
immune response to allergens (Prasad et al., 2009).
1.3 Bronchoconstriction
During an asthma episode, inflamed airways react to environmental
triggers such as smoke, dust, or pollen. The airways narrow and produce
excess mucus, making it difficult to breath. In essence, asthma is the result of
an immune response in the bronchial airways (Maddox & Schwartz, 2002).
The airways of asthma patients are "hypersensitive" to certain triggers, also
known as ‘stimuli’ (see below). (It is usually classified as type I
hypersensitivity). In response to exposure to these triggers, the bronchi (large
airways) contract into spasm (an "asthma attack"). Inflammation soon follows,
leading to a further narrowing of the airways and excessive mucus production,
which leads to coughing and other breathing difficulties. Bronchospasm may
resolve spontaneously in 1–2 hours, or in about 50% of subjects, may
become part of a 'late' response, where this initial insult is followed 3–12
hours later with further bronchoconstriction and inflammation (Saunders,
2005). The normal caliber of the bronchus is maintained by a balanced
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functioning of these systems, which both operate reflexively. The
parasympathetic reflex loop consists of afferent nerve endings which originate
under the inner lining of the bronchus. Whenever these afferent nerve endings
are stimulated (for example, by dust, cold air or fumes) impulses travel to the
brain-stem vagal center, then down the vagal efferent pathway to again reach
the bronchial small airways. Acetylcholine is released from the efferent nerve
endings. This acetylcholine results in the excessive formation of inositol 1, 4,
5-trisphosphate (IP3) in bronchial smooth muscle cells which leads to muscle
shortening and this initiates bronchoconstriction (Tattersfield et al., 2002).
1.4 Triggers of asthma (Stimulus that aggravate asthma response)
v Allergens from nature typically inhaled, which include waste from
common household pests, the house dust mite and cockroach, as well
as grass pollen, mold spores, and pet epithelial cells (Adkinson et al.,
2008).
v Indoor air pollution from volatile organic compounds, including
perfumes and perfumed products. Examples include soap,
dishwashing liquid, laundry detergent, fabric softener, paper tissues,
paper towels, toilet paper, shampoo, hairspray, hair gel, cosmetics,
facial cream, sun cream, deodorant, cologne, shaving cream,
aftershave lotion, air freshener and candles, and products such as oil-
based paint (Adkinson et al., 2008).
v Association between some medications, including aspirin, (Jenkins et
al., 2004), ß-adrenergic antagonists (ß-blockers) (Miller & Zipes, 2007),
and food allergies such as milk, peanuts, and eggs with asthma have
been shown. However, not all people with food or other allergies have
asthma (Adkinson et al., 2008).
v Use of fossil fuel related allergenic air pollution, such as ozone,
nitrogen dioxide, and sulfur dioxide, which is thought to be one of the
major reasons for the high prevalence of asthma in urban areas
(Saunders, 2005).
v Various industrial compounds and other chemicals, notably sulfites;
chlorinated swimming pools generate chloramines-monochloramine,
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dichloramine and trichloramine in the air around them, which are
known to induce asthma (Mery & Nowak, 2002).
v Early childhood infections, especially viral upper respiratory tract
infections. Children who suffer from frequent respiratory infections prior
to the age of six are at higher risk of developing asthma, particularly if
they have a parent with the condition. However, persons of any age
can have asthma triggered by colds and other respiratory infections
even though their normal stimuli might be from another category (e.g.
pollen) and absent at the time of infection. In many cases, significant
asthma may not even occur until the respiratory infection is in its
waning stage, and the person is seemingly improving (Saunders,
2005). In children, the most common triggers are viral illnesses such as
those that cause the common cold.
v Exercise or intense use of respiratory system in one or other way can
also stimulate asthma attack. These are thought to be primarily in
response to the exposure of the airway epithelium to cold, dry air.
v Hormonal changes in adolescent girls and adult women associated
with their menstrual cycle can lead to a worsening of asthma. Some
women also experience a worsening of their asthma during pregnancy,
whereas others find no significant changes, and in other women their
asthma diminished during their pregnancy (Saunders, 2005).
v There is growing evidence that psychological stress is a trigger. It can
modulate the immune system, causing an increased inflammatory
response to allergens and pollutants. Cold weather can make it harder
for patients to breathe. Whether high altitude helps or worsens asthma
is debatable and may vary from person to person (Chen & Miller,
2007).
1.5 Bronchial inflammation
The mechanisms behind allergic asthma- i.e., asthma resulting from an
immune response to inhaled allergens - are the best understood of the causal
factors. In both people with asthma and people who are free of the disease,
inhaled allergens that find their way to the inner airways are ingested by a
type of cell known as antigen-presenting cells (APCs). APCs then "present"
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pieces of the allergen to other immune system cells. In most people, these
other immune cells (T0 cells) "check" and usually ignore the allergen
molecules. In asthma patients, however, these cells transform into a different
type of cell (Th2), for reasons that are not well understood. The resultant Th2
cells activate an important arm of the immune system, known as the humoral
immune system. The humoral immune system produces antibodies against
the inhaled allergen. Later, when a patient inhales the same allergen, these
antibodies "recognize" it and activate a humoral response. Inflammation
results: chemicals are produced that cause the wall of the airway to thicken,
cells which produce scarring to proliferate and contribute to further 'airway
remodeling', causes mucus producing cells to grow larger and produce more
and thicker mucus, and the cell-mediated arm of the immune system is
activated. Inflamed airways are more hyper-reactive, and will be more prone
to bronchospasm. The "hygiene hypothesis" postulates that an imbalance in
the regulation of these Th2 cell types in early life leads to a long-term
domination of the cells involved in allergic responses over those involved in
fighting infection. The suggestion is that for a child being exposed to microbes
early in life, taking fewer antibiotics, living in a large family, and growing up in
the country stimulate the Th1 response and reduce the odds of developing
asthma (Ippets & Guilbert, 2009).
1.6 Factors that provoke asthma
 The factors that commonly provoke asthma are allergens, upper
respiratory tract infection, exercise, perfume and fumes, and changes in
temperature and humidity. Some agents provoke asthma less frequently, but
are important to restrict their use. These include drugs (aspirin and other non-
steroidal anti-inflammatory drugs, ?-blockers), food additives (e.g.
metabisulphite and tartrazine), and some food and drinks (e.g. peanuts,
alcohol) (Ayres & Clark, 1983) and Cola (Wilson et al., 1972).
Some substances found in the workplace cause asthma because of
specific sensitisation, and occupational asthma accounts for up to 10% of
asthma in young adults in Europe (Kogevinas et al., 1999). Occupational
asthma is preventable and can lead to severe irreversible airway obstruction if
the patient is not removed from the sensitizing agent. An occupational history
Introduction
Dept. of Pharm. Sci., Saurashtra University, Rajkot, Gujarat, India
10
should be taken from all patients with asthma and the history should be
supplemented, when occupational asthma is suspected, with frequent peak-
flow measurements during days when the patient is and is not at work. Table
1.4 shows some of the common occupational substances that provoke
asthma, although more than 200 sensitizing agents have been identified
(Chan-Yeung & Malo, 1994).
Table 1.4 Some occupational agents causing asthma
Agents Occupations at risk
Isocyanates Plastic foam, ink, paints,
adhesives
Platinum salts Platinum refining
Acid anhydride and amine
hardening agents, including epoxy
resin
curing agents
Many industries using adhesives,
plastics, resins, etc
Soldering flux Electronics industry
Proteolytic enzymes Biological washing powder
manufacturing
Small animals, including insects Research laboratories
Dust, meal, or flour from barley,
oats, rye, wheat, and maize
Bakers, flour milling
Antibiotics, cimetidine, ispaghula
powder, ipecacuanha
Drug manufacturing
Wood dusts Working with hard woods
Castor bean dust Oil industry, merchant seamen
Azodicarbonamide Blowing agent, foam plastics
It is now well-established that environmental factors play a major part
in the cause of asthma and allergy; family studies showed that a strong
component of asthma risk is genetically determined. In the developed
countries genetic factors are the major detectable determinants of individual
disease risk whereas in the developing countries, the emergence of asthma
probably reflects the strong effect of environmental exposures associated with
economic development (Tattersfield et al., 2002).
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1.6.1 Genetics
Over 100 genes have been associated with asthma in genetic association
studies. However, such studies must be repeated to ensure the findings are
not due to chance. Through the end of 2005, 25 genes had been associated
with asthma in six or more separate populations (Ober & Hoffjan, 2006). Many
of these genes are related to the immune system or to modulating
inflammation. However, even among this list of highly replicated genes
associated with asthma, the results have not been consistent among all of the
populations that have been tested. This indicated that these genes were not
associated with asthma under every condition, and that researchers need to
do further investigation to figure out the complex interactions that cause
asthma. One theory is that asthma is a collection of several diseases, and that
genes might have a role in only subsets of asthma. For example, one group of
genetic differences (single nucleotide polymorphisms in 17q21) was
associated with asthma that develops in childhood (Bouzigon et al., 2008).
It has been suggested that susceptibility to asthma is determined by many
genes that have a moderate effect (Tattersfield et al., 2002). Identification of
the precise gene involved has been difficult but, important genes are thought
to exist on chromosomes 5q23–31 (Lonjou et al., 2000), 11q (Doull et al.,
1996), and 12q (Wilkinson et al., 1998). The chromosomes and respective
candidate genes likely to be involved in pathophysiology of the disease are
given in Table 1.5 (Moffatt et al., 1994; Doull et al., 1996; Moffatt & Cookson,
1997; Wilkinson et al., 1998; Lonjou et al., 2000; Ober et al., 2000). A major
challenge for the future is to identify how genes that predispose individuals to
asthma interact with environmental factors to cause disease. Gene therapy is
unlikely to be a sensible approach for most patients for a disease that can
usually be controlled with simple and safe drugs. On contrary, this approach
could, however, be worthwhile for some patients with severe disease, perhaps
by use of over-expression of anti-inflammatory mediators in the lung.
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v Some common genes associated with asthma (Prasad et al., 2009)
Ø GSTM1
Ø IL10
Ø CTLA-4
Ø SPINK5
Ø LTC4S
Ø LTA
Ø GRPA
Ø NOD1
Ø CC16
Ø GSTP1
Ø STAT6
Ø NOS1
Ø CCL5
Ø TBXA2R
Ø TGFB1
Ø IL4
Ø IL13
Ø CD14
Ø ADRB2 (ß-2 adrenergic
receptor)
Ø HLA-DRB1
Ø TNF
Ø FCER1B
Ø IL4R
Ø ADAM33
Table.1.5 Examples of candidate genes implicated in development of
asthma
Chromosome Candidate genes
5q Th2 cytokine cluster (interleukin 4, 5, 9, 13)
6q Tumour necrosis factor ?, MHC
11q Clara cell secretory protein, high affinity IgE
receptor ? subunit ((Fc?RI?)
12q Interferon ?
14q T cell receptor ??? complex
16q Interleukin-4R?
20q ADAM33
1.6.2 Environment
Many environmental risk factors have been associated with asthma
development and morbidity in children, but a few stands out as well-replicated
or that has a meta-analysis of several studies to support their direct
association. Environmental tobacco smoke, especially maternal cigarette
smoking, is associated with high risk of asthma prevalence and asthma
morbidity, wheeze, and respiratory infections (Gold DR, 2005). Poor air
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quality, from traffic pollution, has been repeatedly associated with increased
asthma morbidity and has a suggested association with asthma development
that needs further research. Recent studies show a relationship between
exposure to air pollutants (e.g. from automobile exhaust) and childhood
asthma. This research finds that the occurrence of the disease and
exacerbation of childhood asthma are affected by outdoor pollutants (Salam
et al., 2008). Caesarean sections have been associated with asthma when
compared with vaginal birth; a meta-analysis found a 20% increase in asthma
prevalence in children delivered by Caesarean section compared to those
who were not (Tattersfield et al., 2002). It was proposed that this is due to
modified bacterial exposure during Caesarean section compared with vaginal
birth, which modifies the immune system (as described by the hygiene
hypothesis). Biological stress has long been suspected of being an asthma
trigger, but only in recent decades has convincing scientific evidence
substantiated this hypothesis. Rather than stress directly causing the asthma
symptoms, it is thought that stress modulates the immune system to increase
the magnitude of the airway inflammatory response to allergens and irritants
(Chen & Miller, 2007). Antibiotic use early in life has been linked to
development of asthma in several examples; it is thought that antibiotics make
one susceptible to development of asthma because they modify gut flora, and
thus the immune system (as described by the hygiene hypothesis) (Marra et
al., 2006). The hygiene hypothesis is a hypothesis about the cause of asthma
and other allergic disease, and is supported by epidemiologic data for asthma.
For example, asthma prevalence has been increasing in developed countries
along with increased use of antibiotics, Caesarean sections, and cleaning
products (Thavagnanam et al., 2007). Use of these things may negatively
affect exposure to beneficial bacteria and other immune system modulators
that are important during development, and thus may cause increased risk for
asthma and allergy. Recently, scientists connected the rise in prevalence of
asthma, to the rise in use of paracetamol, suggesting the possibility that
paracetamol can cause asthma (Eneli et al., 2005). It has been suggested
that viral infections are also correlated to asthma episodes (Gold DR, 2005).
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 A more affluent and educated lifestyle has many characteristics that
could be involved in the cause of asthma and allergy, but which of these are
responsible has not been clearly established. Exposure to organism D.
pteronyssinus, living in warm and insulated housing and sleeping on soft
pillows and mattresses is shown to be associated with more severe asthma
symptoms in sensitized individuals (Peat et al., 1996). However, such an
association does not account for the more general increase in prevalence of
sensitization to other allergens or explain why, in less affluent populations,
sensitization to D. pteronyssinus can be common but have little relation to the
risk of asthma (Yemaneberhan et al., 1997).
Results from observational studies (Fogarty & Britton, 2000) have
shown that diets low in foods providing vitamin E, vitamin C, magnesium, and
?-3 polyunsaturated fats, or high in sodium and ?-6 polyunsaturates, are
associated with increased risk of asthma. However, investigators of
intervention studies have failed to provide consistent evidence of a causal
association, either for individual nutrients or the foods that contain them.
Obesity is an independent and reversible risk factor for asthma, more so in
women than men, and apparently without any effect on allergy (Camargo et
al., 1999; Stenius-Aarniala et al., 2000).
Ambient pollutants have a complex role in asthma. Asthma symptoms
are exacerbated to varying degrees by exposure to particulates, sulphur
dioxide, and nitrogen oxides, but the substantial reduction in ambient levels of
these pollutants over a period in which asthma prevalence has increased in
many countries, including the UK (Anonymous, 1994) argues against a major
causal effect, as does the low prevalence of allergic asthma in East Germany
before unification (von Mutius et al., 1992) and in other eastern European
countries when ambient levels of these pollutants were high (Björkstén et al.,
1998). If a causal association with pollution exists, the major source of
pollution will probably be from the indoor rather than the outdoor environment,
with exposure to nitrogen oxides, particulates, and volatile organic
compounds including formaldehyde, moulds, and other biological or synthetic
exposures being important. Asthma arising from these and other exposures in
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the occupational environment is well recognized and accounts for a small but
important proportion of cases of incident asthma in adults.
Many other factors have been implicated in the cause of asthma and
allergy, including lower maternal age, maternal diet and smoking, duration of
breast feeding, prematurity, and low birth weight, but none of these factors
has been shown to contribute substantially to the rise in asthma prevalence
over recent decades. Thus, despite extensive investigation and clear
evidence of the importance of environmental effects, the major environmental
causes of asthma have still to be identified (Tattersfield et al., 2002).
The increasing prevalence of asthma and recognition of the burden it
imposes on patients and health services has led to extensive research into its
cause, pathophysiology, and management.
1.7 Pathophysiology of asthma
 The fundamental problem in asthma appears to be immunological:
young children in the early stages of asthma show signs of excessive
inflammation in their airways. Epidemiological findings give clues as to the
pathogenesis: the incidence of asthma seems to be increasing worldwide, and
asthma is now very much more common in affluent countries.
 In 1968 Andor Szentivanyi first described The Beta Adrenergic Theory
of Asthma; in which blockage of the ?2 receptors of pulmonary smooth muscle
cells, causes asthma (Szentivanyi, 1968). Szentivanyi's Beta Adrenergic
Theory is a citation classic (Richard, 2006) using the Science Citation Index
and has been cited more times than any other article in the history of the
Journal of Allergy and Clinical Immunology, a renowned journal dedicated to
allergy and immunology. In 1995, Szentivanyi and colleagues demonstrated
that Ig E blocks ?2 receptors (Szentivanyi, 1993). Since, overproduction of Ig
E is central to all atopic diseases, this was a watershed moment in the world
of allergy (Kowalak et al., 2001).
The pathology of asthma is characterized by various changes in the
airways including mucus plugging, shedding of epithelial cells, thickening of
the basement membrane, engorgement of the vessels, and angiogenesis,
inflammatory cell infiltration, and smooth muscle hypertrophy and hyperplasia
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(Hogg, 1993). The pathogenesis of asthma can be broadly subdivided into
inflammatory and remodeling components.
1.7.1 Inflammatory component
The inflammatory features of asthma consist of a dense inflammatory infiltrate
in which eosinophils, mast cells, and CD4+ helper T lymphocytes predominate
(Hogg, 1993). Neutrophilic infiltration also arises during asthma exacerbations
(Fahy et al., 1995) and in the late response to allergen challenge. Dendritic
cells seem to be the key cells for antigen presentation in asthma (Jahnsen et
al., 2001). Antigens then cause cross-linking of Ig E and as a consequence
mast cells are activated and degranulate. Mast cells are important in the acute
airway responses to allergens and may also contribute to remodeling in
chronic asthma (Williams & Galli, 2000).
A defining characteristic of asthma is the presence of many activated
eosinophils (Lee et al., 2001) which are thought to contribute to airway
epithelial damage by release of products such as eosinophil major basic
protein. However, the central role for eosinophils as effector cells in asthma
has been challenged. Administration of antibodies against interleukin 5 to
patients with asthma greatly reduces systemic and sputum eosinophilia, but
has a negligible effect on airflow and airway hyper-responsiveness (Leckie et
al., 2000). Similarly, administration of interleukin 12, which drives
differentiation of T cells to a Th1 rather than a Th2 phenotype, reduced
eosinophil numbers, but not airway responsiveness in patients with asthma
(Bryan et al., 2000).
The role of T lymphocytes is less controversial. T lymphocytes play an
important role in the airway inflammation. T-helper lymphocytes differentiate
into two main phenotypes, Th1 and Th2, which produce distinct profiles of
cytokines and chemokines. Th1 cells produce interferon ?, whereas Th2 cells
produce interleukin 4, 5, and 13. Th2 cells are potent stimulators of Ig E
production from B lymphocytes. Results of studies (Grunig et al., 1998;
Tournoy et al., 2001) in mice have suggested that Th2 cytokines have key
roles, and results of bronchoscopic lavage studies (Walker et al., 1992) in
human beings have shown increased concentrations of these cytokines.
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Inflammatory cells are recruited into the airways by chemokines, which
exert some degree of selectivity in the cells they attract. Eosinophil
chemotractants include eotaxin, interleukin 5, RANTES (i.e., regulated by
activation, normal T-cell expressed and secreted), and monocyte
chemotractant proteins 3 and 4, whereas neutrophils are recruited mainly by
interleukin 8 (Lukacs et al., 1999). These chemokines are produced by
inflammatory and structural cells such as airway smooth muscle cells and
airway epithelium (Johnson & Knox, 1997; Folkerts & Nijkamp, 1998; Lukacs
et al., 1999). Inflammatory cells bind to adhesion molecules on bronchial
vessel endothelium and subsequently undergo a process of transmigration
into the airway interstitium (Hellewell, 1999). Airway cells also release survival
factors, such as granulocyte macrophage colony stimulating factor (GM-CSF),
which extend the life of inflammatory cells at the site of inflammation (Turlej et
al., 2001).
1.7.2 Remodelling component
Acute inflammatory diseases usually resolve with repair processes restoring
normal structure and function. In chronic asthma, this process becomes
disturbed and ineffective repair leads to remodeling involving several
structures (Elias et al., 1999). Epithelial damage and loss of its protective
barrier function exposes the deeper airway structures to environmental
insults, and both inflammatory and structural cells produce several growth
factors that lead to angiogenesis, proliferation of smooth muscle in the airway,
thickening of basement membranes, and fibrosis (Elias et al., 1999). The
increase in the mass of smooth muscles in the airway increases bronchial
responsiveness by increasing force in response to bronchoconstrictor stimuli
and by reduction of the airway’s diameter (Knox, 1994). Important cytokines
and enzymes during the remodeling process include transforming growth
factor ?, epidermal growth factor, and matrix metalloproteinases (Elias et al.,
1999).
1.8 Diagnosis and assessment
 Ascertainment of whether asthma is present is usually straightforward,
and is based on a characteristic history and variability in lung function. In
young children it can take some time to ascertain whether the child has
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persistent asthma rather than wheezy bronchitis (Stolley & Schinnar, 1978). In
older patients, distinguishing severe chronic asthma from COPD can be
difficult and the two disorders sometimes merge in those who have smoked
cigarettes. Asthma can also be diagnosed incorrectly, especially in patients
with inappropriate hyperventilation, dysfunction of the vocal cords, or
obstruction of the upper airway. Diagnosis of asthma still relies on
demonstration of variability (measurement of asthma severity) in lung function
over time or improvement after a bronchodilator, prednisolone, or high-dose
inhaled corticosteroid. Such variability can be measured with spirometry in the
clinic or by regular peak flow measurements at home. Demonstration of
bronchoconstriction after vigorous exercise can be useful in young people,
whereas an increase in blood eosinophils could point to asthma in older
patients. Other features associated with asthma, such as non-specific
bronchial hyperresponsiveness to agents such as methacholine, are not
specific enough to be a useful diagnostic test. The essential treatment for
asthma includes oxygen, nebulised ?2 agonists, and oral or intravenous
corticosteroids to patients.
1.9 Management
 A patient might have poorly controlled asthma due to poor
management, severe asthma, or both. Poor compliance with treatment,
especially inhaled corticosteroids, continues to be an important cause of poor
asthma control and much effort is needed to ensure that patients understand
why prophylactic treatment needs to be taken regularly and the dangers of
poor compliance (Rona, 2000). Several developments have contributed to
better asthma management including development of guidelines (The British
Guidelines on Asthma Management, 1997), better use of peak-flow meters,
and recognition of the need to improve patient education.
 Patients with asthma should be advised strongly not to smoke and to
lose weight, if overweight, since these measures improve asthma control
(Stenius-Aarniala et al., 2000). Inactivated influenza vaccine is recommended
and is safe in patients with asthma (The American Lung Assosiation Asthma
Clinical Research Centers, 2001). Avoidance of allergens can be helpful for
patients with specific allergen sensitivities. Complementary approaches to
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treatment, such as Yoga, help some patients, but overall, the effect seems to
be small (Kleijnen et al., 1991; Lewith, 1998).
1.10 Pharmacotherapy
 Drugs should be given by inhalation when possible so that the same
beneficial effect can be achieved with a much smaller dose, thus causing
lower systemic drug concentrations and fewer systemic adverse effects. Over
the past two decades, many groups have tried to develop new types of drug
for asthma, but only the leukotriene modifiers are on the market.
 Most asthma guidelines include a stepwise approach to asthma
treatment, which ranges from ?-agonists alone for very mild intermittent
asthma to oral corticosteroids for severe chronic asthma. A schematic
hierarchy of the drugs considered most appropriate for different levels of
asthma severity is shown in Figure 1.1. Treatment should be determined by
symptoms, exacerbations, and lung function. There is some controversy
about inhaled corticosteroids, which are very effective at suppressing
inflammation in asthma. Symptoms and airway obstruction usually reappear
when the drugs are discontinued (Haahtela et al., 1994; Pauwels et al., 1997;
O’Byrne et al., 2001).
Figure 1.1. Treatment hierarchy used to add further drugs as asthma
becomes increasingly severe (Tattersfield et al., 2002)
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1.10.1 Inhaled corticosteroids
Inhaled corticosteroids are the cornerstone of treatment for asthma.
They are especially helpful in patients with mild or moderate asthma,
improving lung function, and reducing symptoms and exacerbations (Haahtela
et al., 1994; Pauwels et al., 1997; O’Byrne et al., 2001) and they have been
shown to reduce readmissions for asthma (Blais et al., 1998) and asthma
deaths (Suissa et al., 2000). Inhaled corticosteroids are recommended for all
patients requiring more than one puff a day from their ?-agonist inhaler.
 However, there are two limitations of inhaled corticosteroids. First,
although small doses of an inhaled corticosteroid are very effective, the added
benefit from higher doses is limited. Doubling (Greening et al., 1994) or
quadrupling (Pauwels et al., 1997) the dose of an inhaled corticosteroid can
improve asthma control, but it is usually better to add in a long-acting ?-
agonist (Greening et al., 1994; Pauwels et al., 1997; O’Byrne et al., 2001).
Second, long-term high doses of inhaled corticosteroids can cause systemic
adverse effects, including reduced bone mineral density (Wong et al., 2000)
which is likely to predispose patients to osteoporotic fractures as they get
older, and an increase in cataracts (Cumming et al., 1997) and glaucoma
(Garbe et al., 1997). Since inhaled corticosteroids reduce the need for oral
corticosteroids, which have many more adverse effects, the goal of treatment
is to give the minimum dose of inhaled corticosteroid to maintain good control.
Most patients with asthma can be managed on a low dose, which will produce
maximum or near maximum benefit with minimum risk of long-term adverse
effects (Figure 1.2). Fluticasone is twice as potent as beclometasone and
budesonide. The dose of corticosteroids vary depending on the severity of
asthma but will rarely be above 800 µg beclometasone or budesonide a day
(equivalent to 400 µg of fluticasone a day) and usually preferred less than 400
µg a day (equivalent to 200 µg fluticasone a day) for most of patients.
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Figure 1.2 Relation between beneficial and adverse effects with
increasing doses of inhaled corticosteroids (X=dose at which
maximum benefit is achieved with minimum side effects)
(Tattersfield et al., 2002).
1.10.2 ?-agonists
Short-acting ?-agonists such as salbutamol and terbutaline are very
effective in prevention of exercise-induced asthma and for relieving acute
attacks of asthma. They do not provide benefit when given regularly (Drazen
et al., 1996) and are debatable, as some patients can even deteriorate (Sears
et al., 1990). Patients should therefore take short-acting ?-agonists only as
required.
 By contrast with short acting ?-agonists, regular use of the long-acting
?- agonists, salmeterol and formoterol, improves asthma control and reduces
asthma exacerbations (Greening et al., 1994; Pauwels et al., 1997; Taylor et
al., 1998). Both drugs are effective for longer than 12 h and should be taken
twice daily. The main clinical difference between the two drugs is that
formoterol has a rapid onset of action, similar to that of salbutamol, raising the
possibility that formoterol could be used for symptom control in addition to
regular administration. Asthma control was better with formoterol when
Introduction
Dept. of Pharm. Sci., Saurashtra University, Rajkot, Gujarat, India
22
compared with terbutaline for relief of asthma (Tattersfield et al., 2001) and it
is now licensed for up to 72 µg a day. Thus, these drugs are now introduced
at an earlier point in asthma management-i.e, for patients who remain
symptomatic despite 400–800 µg of an inhaled corticosteroid. Both long-
acting ?-agonists can be given in combination with an inhaled corticosteroid
which improves patient compliance.
1.10.3 Theophylline, ipratropium, cromoglycate, and
nedocromil
 Theophylline is effective in asthma and has some anti-inflammatory
activity (Sullivan et al., 1994). It is less effective than the long acting ?-
agonists (Fjellbirkeland et al., 1994) however, and its narrow therapeutic
window and interactions with other drugs make it a less attractive option.
More selective phosphodiesterase inhibitors have been developed (Torphy,
1998) but have not yet shown clear benefit over theophylline. Ipratropium and
oxitropium are also effective bronchodilators but usually add little in patients
with stable asthma who are already taking a ?-agonist. Sodium cromoglicate
and nedocromil have also been used in mild to moderate asthma therapy.
1.10.4 Prednisolone and steroid-sparing drugs
 Oral corticosteroids cause much morbidity and patients on long-term
oral steroids need careful assessment to be sure that such treatment is
necessary. For those who require prednisolone, prophylaxis against
osteoporosis needs to be considered, ideally with a measure of bone mineral
density. Bisphosphonates and hormone replacement therapy decrease the
loss of bone mineral density seen with oral corticosteroids (Dawson-Hughes,
2001). Some immunosuppressive drugs (methotrexate, ciclosporin, and gold)
reduce oral steroid requirements in patients with severe asthma (Hill, 1995;
Lynch & McCune, 1997).
1.10.5 New drug therapy for asthma
 Leukotriene modifiers consist of the lipoxygenase inhibitors such as
zileuton, and the leukotriene antagonists such as montelukast and zafirlukast.
The drugs are given orally and a single drug can therefore treat both rhinitis
and asthma. Both types of drug are effective in patients with mild or moderate
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asthma (Horwitz et al., 1998). Leukotriene antagonists cause some
bronchodilatation within an hour of administration (Reiss et al., 1997) and
results of long term studies (Horwitz et al., 1998; Barnes & Miller, 2000) have
shown a reduction in symptoms and exacerbations. Both drugs have shown
efficacy when added to an inhaled corticosteroid (Horwitz et al., 1998).
Montelukast was ineffective when added to other treatment in a pragmatic
study of patients with more severe asthma (Robinson et al., 2001).
Leukotriene antagonists should theoretically be useful in aspirin-induced
asthma, but their effectiveness in these patients has been limited (Dahlen et
al., 1998). Churg-Strauss syndrome has occurred in association with use of
the leukotriene antagonists, but whether it is due to a direct drug effect or
unmasking of the syndrome as inhaled or oral corticosteroids are reduced is
still uncertain (Stirling & Chung, 1999; Tuggey & Hosker, 2000).
1.11 Drugs that may be promising in near future
 The suggestion that the anti-inflammatory effects of corticosteroids are
due to gene silencing (transrepression), whereas the adverse effects are due
to gene activation (transactivation) (Newton, 2000) has led to interest in
dissociated steroids that have only transrepression properties and should
therefore have fewer adverse effects. Dissociated steroids produced
unwanted effects on bone in animals, however, suggesting that some of their
adverse effects are linked to transrepression (Belvisi et al., 2001).
 The role of glucocorticoid receptor polymorphisms in determining the
response to corticosteroids is also being investigated (Huizenga et al., 1998)
as is whether long-acting ?-agonists enhance the anti-inflammatory effects of
corticosteroids in vivo as shown in vitro (Knox et al., 2001). Increased
understanding of the role of various cytokines and chemokines and the
imbalance between Th1 and Th2 cells in asthma raises the possibility of
interventions at different sites in the inflammatory cascade (Stirling & Chung,
2000) (Table 1.4). Some improvements in asthma control have been seen in
early studies of soluble interleukin 4 receptors (Borish et al., 1999) and
selective Th2 cytokine inhibitors (Tamaoki et al., 2000).
 Clinical studies of humanised monoclonal antibodies to Ig E, CD4+
cells, and interleukins 4 and 5 are under way. Antibodies to Ig E caused a
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large reduction in circulating free Ig E without major safety problems (Milgrom
et al., 1999). The first large-scale clinical study (Milgrom et al., 1999) with an
Ig E monoclonal antibody, omalizumab, in selected patients showed some
clinical benefit and it enabled the dose of inhaled corticosteroid to be reduced.
The effects of antibodies to interleukin 5 (Leckie et al., 2001) and interleukin
12 (Bryan et al., 2000) on clinical features of asthma have been disappointing.
The need for regular injections to administer monoclonal antibodies is likely to
restrict their role to patients with troublesome asthma. The completion of the
human genome project is likely to fuel a new and important period of research
into asthma therapy.
1.12 Drawbacks of modern medicines in asthma treatment
Despite the availability of a wide range of drugs for the treatment of
asthma, the relief offered by them is mainly symptomatic. Moreover, the side
effects of these drugs are also quite disturbing. Hence, a continuous search is
on going to identify effective and safe remedies to treat bronchial asthma.
Therefore, it is necessary to look for new solutions to manage this health
problem. Although many drugs and interventions are available to manage
asthma, in most instances these are expensive for a developing country like
India and have several adverse effects. India is a country with a vast reserve
of natural resources and a rich history of traditional medicine (Grover & Vats,
2001).
 Although the contribution of modern synthetic medicine for elevating
the human sufferings cannot be under-estimated, equally true is the fact that
most of them leave unwanted harmful side/toxic effects on the human system
disturbing the basic physiology. During the last three decades or so, there has
been serious realization of these problems associated with synthetic drugs
and as a result the world has started exploring the herbs as agents of therapy
which, apart from being comparatively economical and easily available, are
relatively free from the hazardous side effects, toxicity and development of
resistance towards causative organisms. This does not mean that plants are
hundred percent safe but in-depth review of literature and scientific work is
still required in the field of medicinal plants regarding assessment of heavy
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metals and presence of toxins to call them safe Indian Medicinal Plants
(Prasad et al., 2009).
1.13 Ayurveda
 According to the World Health Organization (WHO), about three-
quarters of the world population relies upon traditional remedies (mainly
herbs) for the health care of its people. In fact, herbs/plants are the oldest
friends of mankind. They not only provided food and shelter but also served
the humanity to cure different ailments. The herbal medicine also sometime
called as, traditional or natural medicine existed in one way or another in
different cultures/civilizations, such as Egyptians, Western, Chinese, Kampo
(Japan), Ayurveda (India), and Greco-Arab or Unani/Tibb (South Asia) (Gilani
& Rahman, 2005).
Ayurveda is a great Indian tradition and have an important role in
discovery of new medicines. A considerable amount of research on
pharmacognosy, chemistry, pharmacology and clinical therapeutics has been
carried out on ayurvedic medicinal plants (Patwardhan et al., 2004).
Numerous molecules have come out of ayurvedic experiential base, including
Rauwolfia alkaloids for hypertension, psoralens for vitiligo, Holarrhena
alkaloids in amoebiasis, guggulsterons as hypolipidemic agents, Mucuna
pruriens for Parkinson’s disease, piperidines as bioavailability enhancers,
baccosides for mental retention, picrosides for hepatic protection, phyllanthins
as antivirals, curcumines for inflammation, withanolides and many other
steroidal lactones and their glycosides as immunomodulators (Patwardhan,
2000). Ayurveda (Ayur: Life; Veda: Science) means science of life in Sanskrit
and aims at holistic management of health and disease. It remains one of the
most ancient medical systems widely practiced in the Indian subcontinent and
has a sound philosophical, experiential and experimental basis. Charak
Samhita and Sushrut Samhita (100–500 B.C.) are main ayurvedic classics,
which describe over 700 plants along with their classification, pharmacological
and therapeutic properties. Rasayana therapy is one of the eight branches of
ayurveda and generally consists of nourishing and rejuvenating drugs with
multiple applications for longevity, memory enhancement, immunomodulation,
and adaptogenic activity. Many researchers have supposed the neuro-
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endocrine immune axis theory to explain Rasayana activity and they have
considered it to be an innovative source of immunodrugs (Patwardhan,
2005a, b). Better understanding of basic principles of ayurveda and
harmonization of various practices will need new algorithms and programs for
strengthening decisions with a system in practice (AyuSoft, 2004). The whole
person concept of ayurveda and the Prakriti relevance in therapeutics indicate
strong genetic connotation and can form basis of pharmacogenomics and
customized medicine (Patwardhan, 2005c).
 Globally, there is a positive trend in favor of traditional and integrative
health sciences both in research and practice. There are common approaches
to drug discovery including use of chemical biology, serendipity, chemical
synthesis, combinatorial chemistry and genomics. However, the innovative
approaches involve ethnopharmacology, reverse pharmacology, holistic,
systems biology and personalized medicine. Many recent studies suggest that
entry barriers have fallen over time for new drug introductions (Di Masi &
Paquette, 2004). The development histories of entrants to new drug classes
suggest that development races better characterize new drug than does a
model of post hoc imitation. To resolve this impasse, pharmaceutical
companies are now looking for true innovative approaches to drug discovery.
The WHO has newly established a Commission on Intellectual Property,
Innovation and Public Health to address these issues critically (Patwardhan,
2005c).
1.14 Significance of medicinal plants & traditional medicines
in the management of asthma
Medicinal plants, since time immemorial, have been used in virtually all
cultures as a source of medicine. It is assumed that a major part of traditional
therapy involves the use of plant extracts or their active principles
(Ignacimuthu et al., 2006). Due to lack of organized health care systems in
developing countries, people with chronic diseases like asthma are among the
worst suffers in their communities today. Hence, majority of the populations
still have limited access or no access, especially those in remote areas, to
modern medicines. Instead, they use traditional medicines for a range of
disease complications (Zibula & Ojewole, 2000). The active principles of many
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plant species are isolated for direct use as drugs, lead compounds or
pharmacological agents. Different species of medicinal plants are used in the
treatment of asthma.  There are many natural herbs and herbal supplements
that can be used for asthma treatment (Table 1.6). Natural Asthma treatment
incorporates vitamins, minerals and herbs to relieve symptoms and prevent
further attacks.
Table 1.6 List of some medicinal plants traditionally claimed to have
potential anti-asthmatic activity (Prasad et al., 2009)
Plant name Family Common Name
Acorus calamus Araceae Sweet Flag
Asystasia gangetica Acanthaceae Foxglove
Adhatoda vasica Acanthaceae Adusa
Aegle marmelos Rutaceae Golden apple/ Bael
Alstonia scholaris Apocynaceae Sitwan chaal/Milky pine
Andrographis paniculata Acanthaceae Creat, Kalmegh
Astercantha longifolia Acanthaceae Kulikhara, Kokilaksah
Allium cepa Lilliaceae Pyaaz, Onion
Acacia catechu Mimosaceae Black catechu/Khair
Albizia lebbeck Leguminosae Pit Shirish, Shirisha
Atropa belladonna Solanaceae Devils cherries
Acalypha indica Euphorbiaceae Kuppi
Boswellia serrata Bruseraceae Indian olibanum tree
Benincasa hispida Cucurbitaceae Ash gourd
Lumea lacera Compositeae Kukurmutta/Kukronda
Caesalpinia bonducella Caesalpiniaceae Fever nut/Bonduc nut
Cuminum cyminum Umbelliferae Jeera
Cinnamomum cassia Laureaceae Chinese cinnamon/Dalchini
Clerodendrum serratum Verbenaceae Bharnagi
Cissus quandrangularis Vitaceae Hajora/Asthisanhari
Curcuma longa Zingiberaceae Turmeric/Haldi
Camellia sinensis Theaceae Tea
Calotropis procera Asclepiadaceae
Madaar/Dead sea
Apple/Arka
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Cannabis sativa Cannabaceae Bhang
Callicarpa macrophylla Verbenaceae Beauty berry
Datura metel Solanaceae Thorn apple
Ephedra sinica Ephedraceae Ma Huang
Ganoderma lucidum Ganodermataceae Reishi
Glycyrrhiza glabra Fabaceae Liquorice
Grindelia camporum Asteracea Valley gum plant
Hedychium spicatum Zingiberaceae Kapur kachari
Inula racemosa Asteraceae Pushkarmoola
Lobelia inflate Campanulaceae Tobacco
Lafoensia pacari Lythraceae Didal
Morus alba Moraceae Mulberry fruit
Moringa oleifera Moringaceae Drumstick tree
Murraya koenigii Rutaceae Curry leaves
Nigella sativa Ranunculaceae Kalajira
Nardostachys jatamansi Valerianaceae Jatamansi
Oscimum sanctum Labiateae Tulsi
Picrorhiza kurroa Scrophulareaceae Kutki
Plantago major Plantaginaceae Plantain
Piper longum Piperaceae Pippali
Pimpinella anisum Umbelliferaceae
Anise, Anason, Anis,
Anasur, Anisu
Sida cordifolia Malvaceae Flannel weed
Solanum melongena Solanaceae Eggplant / Brinjal
Solanum xanthocarpum Solanaceae Yello berried night shade
Saussuria lappa Asteraceae Costus, Kut root
Scutellaria baicalensis Labiatae Baikal skullcap
Tamarindus indica Leguminosae Tamarind
Terminalia belerica Combretaceae Vibhitaki
Tragia involucrate Euphorbiaceae Bichuti
Tussilago farfara Asteraceae Clots Foot
Tinospora cordifolia Menispermaceae Guduchi
Ulmus rubra Ulmaceae Slippery elm
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Withania somnifera Solanaceae Indian Ginseng
Xanthoxylum nepalensis Berberidaceae Prickly ash, Toothache tree
Zingiber officinale Zingiberaceae Ginger
 Among many disease or disorders, asthma is a serious disorder
affecting large population of the world.  Although there is a significant increase
in the prevalence of number of patients suffering from asthma in every age
group during the last decade, the largest increase of 73 percent was reported
among children and young adults under the age group of 18 years. India has
documented an estimated approx 15-20 million asthmatic patients (Prasad et
al., 2009). Some of the Medically advanced countries like United States of
America have developed and maintained a national database of their citizens
along with the natural allergy (asthma) causing plants detail, this detail
includes the pollen releasing time, along with the main geographical
distribution to assist its citizens in selection of a living as well as working place
that may be free of trees responsible for causing asthma to particular
individual. This reflects the seriousness of any country towards the healthcare
needs of their citizens. The similar database or at least initiation of such type
of database in India is need of the hour. Herbs are highly esteemed for
millennia as a rich source of therapeutic agents for prevention and treatment
of asthma and its ailments.
 In the light of above background, the present study was aimed to
screen Indian medicinal plants and their combinations in the form of
polyherbal formulations for the potential anti-asthmatic activity and synergistic
effects of these combinations.
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2. Review of Literature
Among several respiratory diseases affecting man, bronchial asthma is the
most common disabling syndrome. Nearly 7–10% of the world population
suffers from bronchial asthma. Asthma is characterized by various airway
obstruction, airway eosinophilic inflammation and bronchial hyper
responsiveness (Djukanovic et al., 1990) and is a global health problem that
results from a complex interplay between genetic and environmental factors
(Philip, 2003). Despite the availability of a wide range of drugs, the relief
offered by them is mainly symptomatic and short lived. Moreover, the side
effects of these drugs are instigates scientists to identify effective and safe
remedies to treat bronchial asthma (Govindan et al., 1999).
Herbal medicines are being used by nearly about 80% of the world’s
population, largely in developing countries for primary health care (Goldberg,
1994). Assessing the current status of health care system in adequacies of
synthetic drugs is likely to be more glaring in the coming years. It has been
reported that there has been an alarming increase in number of diseases and
disorders caused by synthetic drugs, prompting a switch over to traditional
herbal medicines (Ghule & Patil, 2001). Alternative system of medicine is a
major component of health care globally and many healthcare providers and
organizations are being forced to consider integrating them into their practice
and treatment guideline (Muller & Clauson, 1997).
From time immemorial, man depends on plants as medicine. From a
historical perspective, it is evident that the fascination for plants is also as old
as mankind itself. The plant kingdom represents a rich storehouse of organic
compounds, many of which have been used for medicinal purposes and could
serve as lead for the development of novel agents having good efficacy in
various pathological disorders in the coming years. Conventional
antiasthmatic compounds such as sodium cromolyn and sodium cromoglycate
is one of the examples of the lead prepared from the analogs of the naturally
occurring furanchromone khellin (visammin), found in Ammi visnaga Lam
(Cox et al., 1970). Explanation of the chemical constituents of the plants and
pharmacological screening will thus provide us the basis for developing new
life saving drugs. Herbs have always been the principal form of medicine in
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India and presently they are becoming popular throughout the world, as
people strive to stay healthy in the face of chronic stress and pollution, and to
treat illness with medicines that work in count with the body’s own defense
(Perumalsamy et al., 1998). There is a widespread belief that green
medicines are healthier and more harmless or safer than synthetic ones.
Ayurveda is a traditional Indian Medicinal System practiced for
thousands of years. Considerable research on pharmacognosy, chemistry,
pharmacology and clinical therapeutics has been carried out on medicinal
plants. Natural products, including plants, animals and minerals have been
the basis of treatment of human diseases. The current accepted modern
medicine has gradually developed over the years by scientific and
observational efforts of scientists. However, the basis of its development
remains rooted in traditional medicine and therapies (Vishunakanta & Rana,
2008).
2.1 Solanum xanthocarpum
Selection of scientific and systematic approach for the biological evaluation of
plant products based on their use in the traditional systems of medicine forms
the basis for an ideal approach in the development of new drugs from plants.
One such plant is Solanum xanthocarpum (SX) Schrad. & Wendl. (Family:
Solanaceae) commonly known as the Indian night shade or Yellow berried
night shade (English) and kantakari (Sanskrit). It is a prickly diffuse, bright
green perennial herb, woody at the base, 2-3 m in height, and found
throughout India, mostly in dry places as a weed along the roadsides and
waste lands (Anonymous, 1989). SX has held a place of importance in the
Hindu Materia Medica, primarily as an expectorant and antipyretic (Chopra et
al., 1956). Various medicinal properties are attributed to this plant, particularly
in the treatment of asthma, chronic cough and catarrhal fever (Siddiqui et al.,
1983). It is one of the members of the dashamula (ten roots) of the Ayurveda
(Mohan et al., 2007).
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2.1.1 Taxonomic classification
Kingdom - Plantae
Subkingdom - Tracheobionta
Division - Magnoliophyta
Class - Magnoliopsida
Subclass - Asteridae
Order - Solanales
Family - Solanaceae
Genus – Solanum
Species- Solanum xanthocarpum
2.1.2 Botanical description (Kirtikar & Basu, 1993)
2.1.2.1 Synonyms
Latin: Solanum xanthocarpum, Solanum surattense
Sanskrit: Kantkari
Hindi:  Kateri, Kattay
Gujarati: Bhoringni
2.1.2.2 Geographical source
It occurs throughout India, in dry situations as a weed along the
roadsides, and wastelands. It is naturally propagated by seed in waste lands.
It is mainly distributed in Ceylon, Malaya, and Asian regions (Sheth, 2005).
2.1.2.3 Morphological characters
The plant is very prickly diffused bright green perennial herb (Figure
2.1A), somewhat woody at the base. The stem is somewhat zigzag and the
branches are numerous. The prickles are compressed, straight, yellow,
glabrous and shining, often exceeding 1.3 cm. Leaves are usually 10-15 in
numbers and 2.5-5.7 cm in length (Figure 2.1B); ovate or elliptic, sinuate or
sub-pinnatified; obtuse or sub-acute, stellately hairy on both sides; armed on
the midrib and often on the nerves with long yellow sharp prickles; base
usually rounded and unequal-sided; petiole 1.3-2.5 cm long and stellately
hairy. The flowers are purple in color (Figure 2.1C). The berries are green and
white strips when young (Figure 2.1D) but yellow (Figure 2.1E) when mature.
They are 1.3-2 cm in diameter, yellow, or white with green veins, surrounded
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by the enlarged calyx. Seeds are 2.5 mm in diameter and glabrous. Calyx is
nearly 1.3 cm long, densely hairy and prickly (Kirtikar & Basu, 2005).
Figure 2.1 Morphology of the plant Solanum xanthocarpum: (A) Whole plant,
(B) Leaf, (C) Flower, (D) Unripe fruits, (E) Ripe fruits.
2.1.3 Traditional uses
In the Ayurveda, plant is described as pungent, bitter, digestive, and
astringent. Stems, flowers, and fruits are bitter. Root decoction is used as
febrifuge, diuretic, and expectorant (Vadnere et al., 2008). Charaka and
Sushruta used the extract of entire plant and fruits in internal prescription for
bronchial asthma, tympanitis, misperistalsis, piles, and dysuria and for
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rejuvenation. Kantkari Ghrita of Charaka is specific for cough and asthma.
Lincture prepared from the stamens of flowers is prescribed for chronic cough
in children (Khare, 1995).
The whole plant is used traditionally for curing various ailments.
Decoction of the plant is used in gonorrhea; paste of leaves is applied to
relieve pains; seeds act as expectorant in cough and asthma; roots are
expectorant and diuretic, useful in the treatment of catarrhal fever, cough,
asthma and chest pain (Ghani, 1998). The plant is also known to have pest
repellent properties and used as a contact poison and mollusicide. Roots are
one of the constituents of well known Ayurvedic preparation “Dasmul Asava”
and used as an expectorant, cough, asthma, and chest pain in Ayurvedic
medicine (Khare, 1995).
Fruits are edible and used by the local people as folk medicines in
treating throat infections and other inflammatory problems (Sinha, 1996). The
stem, flowers and fruits are prescribed for relief in burning sensation in the
feet accompanied by vesicular eruptions (Chopra et al., 1956). The
antispasmodic, antitumor, cardiotonic, hypotensive, antianaphylactic, and
cytotoxic activities are also reported (Gupta et al., 1967). Fruit juice is useful
in sore throats and rheumatism (Ghani, 1996). A decoction of the fruits is
used by tribal and rural people of Orissa, India for the treatment of diabetes
(Nadkarni, 1954). The fruits are eaten as an anthelmintic and for indigestion.
The extensive survey of literature revealed that SX is an important
source of many pharmacologically and medicinally important chemicals,
especially solasodine and other chemicals like solasonine, campestrol,
campeferol, diosgenin, and various useful alkaloids. The solasodine is the
most studied chemical constituent of SX which has a role in the production of
sex hormones.
2.1.4 Phytochemical investigations
v Chemical examinations of berries of SX were initially done by Saiyed
and Kanga (1936), which led to the isolation of glycoalkaloid
solasonine
v The fruits are reported to contain several steroidal alkaloids like
solanacarpine (Gupta & Dutt, 1938) and solamargine (Siddique et al.,
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1983); constituents like caffeic acid (Siddique et al., 1983); coumarins
like aesculetin and aesculin (Tupkari et al., 1972); steroids carpesterol,
diosgenin, campesterol, daucosterol, and triterpenes like cycloartanol
(Sato & Latham, 1953).
v Friedman et al. (2003) showed estrogenic activity of solanidine in an in
vitro assay.
v Josekutty, (1998) showed that the fruits of SX contain alkaloid
saponins which can be extracted in alcohol and have a heart-
stimulating function.
v Different studies on this plant demonstrated the isolation of solasonine
and solasodine (Saiyad & Kangra, 1936), ß-sitosterol (Sato & Latham,
1953), and carpesterol (Heble et al., 1968).
v Gupta and Dutt, (1938) reported study of the fruits and showed that
fruits contained 20.71% of dry seeds, 4.62% of pericarp and 74.67
percent of moisture. The powdered seeds yielded 19% of greenish-
yellow oil which did not contain nitrogen or sulphur. The composition of
the oil was calculated as oleic acid, 42.93; linolic acid, 36.18; palmitic
acid, 5.37; steric acid, 9.77; arachidic acid, 0.35, and unsaponifiable
matter, 1.2 percent.
The berries are the main source of solasodine and diosgenin. Solasodine
is N-analogue of diosgenin and used as a steroidal precursor in the steroid
drug industry for the manufacture of corticosteroids, antifertility drugs,
anabolic steroids etc. It is present in the form of a glycoside in most of the
berries of the plant belonging to the genus solanum and the glycoalkaloids are
variously known as solasonine, solamargine etc. with the common spiro
aminoketal alkaloid or aglycon namely solasodine.
2.1.4.1 Solasodine
v SX has a high concentration of solasodine alkaloid, a spiroketal
alkaloid sapogenin with a heterocyclic nitrogen atom, which is the
starting material for the manufacture of cortisone and sex hormones
(Bector & Puri, 1971).
v The solasodine content of the berries of SX is reported to vary from
1.1% to 4.6% (Asolkar & Chadha, 1979) depending apparently on
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climatic and soil conditions. The solasodine content of the unripe
berries was 1.7% (on dry weight basis) as against 0.75% noted for the
ripe berries.
v Weissenberg et al. (1998) estimated content of solasodine from the
plant. Solasodine has been estimated by various methods by many
workers viz. gravimetric, non-aqueous, potentiometric,
chromatography, colorimetric, and even Radio Immuno Assay. A
number of analytical methods like high performance thin-layer
chromatography (HPTLC) (Weissenberg et al., 1998), and high-
performance liquid chromatography (HPLC) (Kadkade & Bhatnagar,
1975), capillary electrophoresis, gas chromatography (GC) (Laurila et
al., 1999), are available for determination of solasodine from its plant.
v Trivedi and Pundarikakshudu, (2007) showed that solasodine does not
have a conjugated double bond in its structure.
v Emmanuel et al. (2006) reported satisfactory content of solasodine
(0.84%) in the plant. Further, they reported that the control of
temperature, time of extraction and concentration of hydrochloric acid
has some influence on the percentage recovery of solasodine.  They
also mentioned that the temperature should be low throughout the
process of isolation of solasodine as overheating may affect actual
recovery of solasodine.
v Pure white crystals of solasodine could be obtained with 196-197°C
mp. Solasodine is a nitrogenous analogue of diosgenin which can be
converted to progesterone, a steroidal sex hormone used in the oral
contraceptive industry (Emmanuel et al., 2006).
v The studies of Emmanuel et al. (2006) revealed anti-inflammatory
activity of solasodine against carrageenan-induced paw edema in rats.
Solasodine showed significant reduction of the inflammatory reaction.
v Heble et al. (1968) reported the isolation and identification of ß-
sitosterol and diosgenin from callus tissues of SX. Chemical
examination of SX berries also resulted in the isolation of diosgenin.
They concluded that the tissue cultures of SX have yielded ß-sitosterol
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and diosgenin in quantities much higher than that obtained from the
growing plant.
2.1.4.2 Carpesterol
v Saiyed and Kanga, (1936) isolated the substance carpesterol along
with a steroidal alkaloid glycoside. Carpesterol was the first compound
isolated from the lipid fraction of plant and it was hoped that a structural
knowledge of carpesterol would shed some light on the biogenetic
pathway leading to solasodine, which is the major alkaloid
accompanying carpesterol in SX and commonly found among many
other solanum species.
v Subsequent investigations of extracts from SX confirmed the presence
of diosgenin (Sato & Latham, 1953), and ?-sitosterol (Beisler & Sato,
1971).
v Chungath and Nair, (1989) reported the variation in the solasodine
content, at different stages of fruit maturity viz. berries when green in
color and color changing from green to yellow. It was concluded that
the berries of SX in the initial stages of fruit development are very
small, green in color with white blotched stripes. On growing, it
develops yellow color which signifies the beginning of ripening. On
ripening it attains yellow color.  Berries on further standing in the plant
becomes deep yellow in color, at which stage the stalk through which
the berries are attached turns brown in color from the original green.
During fruit development or maturity, an associated change in the
steroidal glycoalkaloid content and therefore, in the steroidal alkaloid
content has been reported. They used colorimetric method for the
determination of the solasodine content. Solasodine forms yellow
colored complex with methyl orange and is extractable in chloroform
and gives maximum absorbance at 425 nm.  It was shown that, the
berries collected during various months from the same area differed in
the solasodine content. The greatest amount of solasodine was
present when berries were yellow in color (i.e. when the berries were
ripe).
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v From the fruit extract of SX, cycloartanol, sitosterol, stigmasterol,
campesterol, cholesterol, sitosteryl glucoside, stigmasteryl glucoside,
solamargine, and ?-solamargine were identified (Kusano & Takemoto,
1975).
2.1.5 Pharmacological actions
2.1.5.1 Anti-asthmatic properties
v A pilot study by Mohan et al. (2007) on the clinical efficacy of SX and
Solanum trilobatum in bronchial asthma proved the significant use of
herbs in treatment of asthma.
v Vadnere et al. (2008) studied effects of SX flower extract on some of
the parameters like smooth muscle relaxation, and antagonism of
asthma mediators such as histamine and eosinophils, which seemed to
be prominent in pathophysiology of asthma. Further, they showed that
ethanol extract of SX revealed a significant antihistaminic activity in
histamine-induced contraction in goat tracheal chain preparation. This
indicates that the SX flower has antihistaminic (H1-receptor antagonist)
action. Also, ethanolic extract of SX has been shown to reduce milk-
induced eiosinophilia.
v SX is widely used by practitioners of the Siddha system of medicine in
southern India to treat respiratory diseases. The powder of whole dried
plant or a decoction is used for this purpose (Nadkarni, 1954).
v Govindan et al. (1999) showed that treatment with SX improved the
pulmonary functions to a significant level in patients suffering from mild
to moderate asthma. Subjective relief from asthmatic symptoms was
reported by the patients an hour after administration of SX powder. The
effect lasted for about 6–8 hr; however, responses observed were
apparently less when compared to that of deriphilline or salbutamol
(Davies, 1990). The dose of SX was well tolerated and no untoward
effects were reported. It was suggested that relief from the symptoms
of bronchial asthma produced by SX may be due to: (a) a direct
bronchodilator effect, (b) reduction in the bronchial mucosal edema,
and/or (c) reduction in the secretions within the airway lumen.
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2.1.5.2 Hypoglycemic activity
v The Kondh tribes of Dhenkanal district of Orissa, India use the hot
aqueous extract of the matured fruits as a traditional medicine for the
treatment of diabetes mellitus (Kar et al., 1996).
v Kar et al. (1996) reported the hypoglycemic activity of the aqueous
extract of the fruits of SX.
v The aqueous extract showed significant hypoglycemic effect in both
normal and streptozotocin induced diabetic rats. The activity was
comparable to that of standard oral hypoglycemic agent glibenclamide.
The results indicated that SX exhibited a potent blood glucose lowering
property both in normal and streptozotocin induced diabetic rats. The
LD50 of the extract was found to be high indicating high margin of
safety (Gupta et al., 2005).
2.1.5.3 Hepatoprotective activity
v Jigrine is a polyherbal formulation containing aqueous extracts of 14
medicinal plants including SX and used for liver ailments (Gupta et al.,
2005).
v Najmi et al. (2005) investigated the DPPH-free radical scavenging,
hepatoprotective, and antioxidant activity of Jigrine against
galactosamine-induced hepatotoxicity in rats.
2.1.5.4 Cardiovascular effects
v Pasnani, (1988) postulated that Abana, a polyherbal formulation
containing SX, causes: (i) A direct sensitization of the atrium through
an increase in permeability to Ca2+ and (ii) down regulation of
adrenoceptors.
2.1.5.5 Antifilarial effect
v Mohan et al. (2006) reported the larvicidal potential of crude extracts of
SX and suggested its suitability as an ecofriendly, effective larvicide in
the management of mosquito populations and in limiting the outbreak
of various vector borne epidemics.
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2.1.5.6 Mosquito larvicidal effect
v The plant has been used in the various fields of pest management
(Singh & Bansal, 2003)
v The fruit extracts of SX revealed larvicidal activity against An.
stephensi and Cx. Quinquefasciatus and one culicine species Ae.
aegypti (Rajkumar & Jebanesan, 2005). Volatile oil obtained from SX
exhibited repellency against mosquito Cx. quinquefasciatus at a very
lower concentration. The root extract is also effective against
anopheline and culicine mosquito species, though at higher
concentrations in comparison to fruit extract (Mohan et al., 2006).
2.1.5.7 Miscellaneous activities
v Dixit and Gupta, (1982) reported antiandrogenic activity of solasodine .
v Further study showed antifertility effects of solasodine in male rats and
dogs (Dixit, 1986).
v Carpesterol and four steroidal glycosides isolated from methanol
extract of SX fruits exhibited inhibitory effects on the radial growth of
Aspergillus niger and Trichoderma viride. Methanolic extract from dried
fruits of SX showed antifungal activity against A. brassicae (Singh &
Kaushal, 2007).
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2.2 Aegle marmelos
As per Charaka (1500 BC), no drug has been longer or better known or
appreciated by the inhabitants of India than the Aegle marmelos (AM)
(CHEMEXCIL, 1992).
2.2.1 Botanical description (Kirtikar & Basu, 1993)
2.2.1.1 Geographical source
AM is a fruit-bearing tree indigenous to dry forest on hills and plains of
central and southern India, Sri Lanka, Myanmar, Pakistan, Bangladesh,
Nepal, Vietnam, Cambodia and Thailand. It belongs to the family Rutaceae,
related to citrus.
2.2.1.2 Synonyms
In English there are different names: Bengal quince, Golden apple,
Stone apple. It has many Indian names, depending on the geographical
region or the language, for example: Maredu (Andra Pradesh), Bel (Bengal),
Bili (Gujurat), Kumbala (Karnatak), Vilwam (Kerala), Bilwa (Sanskrit), Kuvalum
(Tamil nadu).
2.2.1.3 Taxonomic classification
Kingdom: Plantae
Division: Magnoliphyta
Class: Magnoliopsida
Subclass: Rosidae
Order: Sapindales
Family: Rutaceae
Genous : Aegle
Species: Aegle marmelos
2.2.2 Traditional uses
AM has been used as herbal medicine for the management of diabetes
mellitus in Ayurvedic, Unani and Siddha systems of medicine in India (Kar et
al., 2003). The main usage of the parts of this tree is for medicinal purposes
(Bhattacharya, 1986). The unripe dried fruits are astringent, digestive,
stomachic and used to cure diarrhea and dysentery (Shoba & Thomas, 2001).
Sweet drink prepared from the pulp of fruits produce a soothing effect on the
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patients who have just recovered from bacillary dysentery. The ripe fruit is a
good and simple cure for dyspepsia. The roots and the bark of the tree are
used in the treatment of fever by making a decoction of them. The leaves are
made into a poultice and used in the treatment of opthalmia. The leaves of the
plant have been claimed to be used for the treatment of inflammation, asthma,
hypoglycemia, febrifuge, hepatitis, and analgesic (Nadkarni, 2000). The
mucilage of the seed is a cementing material. The wood takes a fine polish
and is used in building houses, constructing carts, and agricultural
implements. A yellow dye is obtained from the rind of the unripe fruits. The
dried fruits, after their pulp separated from the rind are used as pill boxes for
keeping valuable medicines, sacred ashes and tobacco. In Homeopathic
treatments, it is largely used for conjunctivitis, rhinitis, and chronic dysentery.
Ayurveda also prescribes the fruit of the herb for heart, stomach, intestinal
tonic, chronic constipation, and dysentery; some forms of indigestion, typhoid,
debility, cholera, hemorrhoids, intermittent fever, and for heart palpitation
(Sharma & Bhagwan, 2000). The unripe fruit is medicinally better than the ripe
fruit.
2.2.3 Morphological characters
It is a medium sized tree (average 8.5 m tall) with spines on the
branches and very aromatic (Figure 2.2A). It matures in about 60 years.
Leaves are pulp green, trifoliate (Figure 2.2B). Flowers are greenish white,
sweetly scented. Fruits are 2.5 to 3.25 mm in diameter; globular or ovoid in
shape, grayish brown color, outside surface hard and nearly smooth (Figure
2.2C). Rind is adherent to a light red pulp, in which there are ten to fifteen
cells, each containing several woody seeds (Figure 2.2D). It has a faint
aromatic odor and mucilaginous taste.
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Figure 2.2 Morphology of the plant Aegle marmelos: (A) Whole plant, (B)
Trifoliate leaves, (C) Unripe fruit, (D) Portion of ripe fruits with seeds.
2.2.4 Phytochemical constituents
v Narendra et al. (2007) documented that leaves of AM contain an
alkaloidal-amide, Aegeline 2.
v Panda and Kar (2006) reported Scopoletine (7-Hydroxy-6-methoxy
coumarin) from the leaves of plant having antithyroid activity.
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v AM whole plant extract has been shown to contain a triterpinoid, lupeol
(Lambertini et al., 2005) which is capable of inhibiting cell proliferation.
v The leaves have been shown to contain inorganic trace elements such
as Cu, Ni, Zn, K, and Na (Narendhirakannan et al., 2005).
v A new 7-geranyloxy coumarin [7-(2,6-dihydroxy-7-methoxy-7-methyl-3-
octaenyloxy) coumarin] named marmenol has been isolated from the
leaves of methanolic extract of AM (Ali and Perrez, 2004).
v In addition to marmenol, several known compounds, praealtin D, trans-
cinnamic acid, valencic acid, 4-methoxy benzoic acid, betulinic acid, cis
and transcoumaroyltyramine, montanine, and rutaretin have also been
obtained from the extract (Ali & Perrez, 2004).
v Lampronti et al. (2003) identified three derivatives, butyl-ptolyl sulphide,
6-methoxy-4-chromanone, and butylated hydroxyanisole from the
extract exhibiting strong inhibitory activity on in vitro growth of human
k562 cells.
2.2.5 Phrmacological studies
2.2.5.1 Antibacterial
v Sudharameshwari and Radhika (2007) screened the crude petroleum
ether, chloroform, ethanolic and aqueous extract of AM for the
antibacterial activity. Petrolium ether extract of AM showed no activity
against B. cereus but exhibited effect against E. coli and S. aureus
respectively as compared to streptomycin. Chloroform extract of Bael
showed inhibition against E. coli but no activity was found to be against
P. aeruginosa and S. aureus. Ethanolic extract showed a zone of
inhibition against P. auriginosa and S. aureus (Prema, 2004).
Antibacterial activity of aqueous extract showed maximum zone of
inhibition against P. aeruginosa and P. vulgaris but no activity was
found against E. coli.
v Further, Mazumder et al., (2006) demonstrated that root extract treated
animals showed significant inhibitory activity against castor oil induced
diarrhea.
v Dhubey, (2003) evaluated antidiarrhoeal activity of unripe fruit extract
by studying influence on gastrointestinal transit as measured by a
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charcoal marker and on castor oil induced accumulation of intestinal
fluid in mice.
v In another study Shoba and Thomas, (2001) suggested that the
methanolic plant extract were more effective than aqueous plant
extract against castor oil induced diarrhea.
2.2.5.2 Antifungal activity
v The anti fungal activity of essential oils isolated from the leaves of Bael
has been demonstrated by Rana et al. (1997) using spore germination
assay.
2.2.5.3 Antiulcer activity
v Goel et al. (1997) reported luvangetin, a pyranocoumarine isolated
from the seeds of AM, showed significant protection against pylorus
ligated and aspirin induced gastric ulcer in rats & cold resistant stress
induced gastric ulcers in rats & guinea pigs.
2.2.5.4 Cardiovascular activity
v The effect of constituents isolated from methanolic extract of root bark
of Bael on spontaneous beating of cultured mouse myocardial cells
was examined by Kakiuchi et al. (1991). The extract inhibited the
beating rate by approximately 50%. Among the isolated constituents,
aurapten was the most potent inhibitor, which was comparable with
that of verapamil.
v Prinie and Rasaduarai, (2005) showed that aqueous leaf extract of AM
has preventive effect on isoprenaline (isoproterenol) induced
myocardial infarction in the rats pre-treated with plant extract for 35
days.
2.2.5.5 Anticancer activity
v Venkatesh et al. (2006) showed the cytoprotective activity of the extract
of AM in the Chinese hamster V79 cells in vitro. Pretreatment of cells
with AM reduced doxorubicine-induced cytotoxicity as evidenced by
increase in the cell survivals. Further, a bioactive component lupeol
was thought to be responsible for this activity (Lambertini et al., 2005)
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v Jagetia et al. (2005) showed antineoplastic action of hydroalcholic
extract of AM.
2.2.5.6 Antiviral activity
v Badam et al. (2002) showed in vitro antiviral activity of a series of
compounds in various parts of AM.
2.2.5.7 Anti-inflammatory, analgesic and antipyretic activity
v Arul et al. (2005) evaluated anti-inflammatory, antipyretic, and
analgesic activities of different extracts of the leaves of AM. The
extracts caused significant inhibition of the carragenin-induced paw
edema and cotton pellet granuloma in rats.
v The plant extract also produced marked analgesic activity by reducing
the early and late phases of paw licking in mice. A significant reduction
in hyperpyrexia and acetic acid-induced writhing testes were also
produced by the extracts (Shankarnath et al., 2007).
2.2.5.8 Antifertility activity
v Chauhan et al. (2007) evaluated effect of ethanolic extract of AM leaf
on the reproductive system of male albino rats for 60 days. There was
a marked reduction in motility and density of the sperm derived from
cauda epididymis of the treated animals. Serum testosteron levels also
decreased significantly in all the experimental groups, withdrawal of the
extract restored all the altered parameters including organ weights,
fertility, testosteron levels, and tissue biochemistry to control levels
after 120 days.
v Sur et al. (1999) showed that ethanolic extrct administered orally at a
dose of 25 mg/kg and 50 mg/kg body weight for 30 days had significant
antispermatogenic properties in albino rats.
2.2.5.9 Radioprotective effect
v Jagetia et al. (2004) studied radio protective effect of hydroalcoholic
extract of the fruit in mice exposed to different doses of gamma
radiations. A total of 20 mg/kg of AM extract for 5 consecutive days
before irradiation (gamma radiation) was found to afford maximum
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protection as evidenced by the highest number of survivors after 30
days post irradiation.
2.2.5.10 Antihyperglycemic activity
v Aegeline 2, an alkaloidal amide isolated from the leaves of AM, was
found to have antihyperglycemic activity (Narendra et al., 2007) as
evidenced by lowering the blood glucose levels in sucrose challenged
streptozotocin induced diabetic rats.
v Aqueous extract of AM seeds was reported to decrease blood glucose
level (Keshvi et al., 2006) in normal healthy rats after 6 h of
administration.
v Kamalakkanna and Prinie, (2006) reported that oral administration of
fruit extract to diabetic rats for a period of 30 days resulted significant
increase in body weight, weight of the pancreas, and insulin levels
associated with a significant decrease in fasting blood glucose level.
v On contrary, Gholaps and Kar, (2004) suggested that AM may
potentially regulate corticosteroid induced diabetes mellitus.
v Sabu and Kuttan (2004) studied and concluded that continuous
administration of the methanolic extract of plant resulted in reduction of
blood sugar.
v In the study of Kamalakkanna et al. (2003), rats were rendered diabetic
by streptozotocin (45 mg/kg) administered intraperitonially. Aqueous
extract of AM fruits (250 mg/kg) was given twice daily for one month.
Blood glucose, plasma insulin, glycosylated hemoglobin, liver glycogen
and change in body weight were determined. Treatment with aqueous
extract reversed the effect on diabetes on those biochemical
parameters to near normal levels. The effect of the extract was more
effective than glibenclamide in restoring the values of these
parameters.
v Sachdeva et. al. (2001) suggested that alcoholic leaf extract for seven
consecutive days lowered average blood glucose level by 67% in
glucose-induced hyperglycemic rats.
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2.2.5.11 Antidyslipidemic activity
v Keshvi et al. (2006) showed that aqueous seed extract had
hypolipidmic effect in diabetic rat.
v Aegeline 2, an alkaloidal amide, isolated from the leaves of AM
significantly decreased the plasma triglyceride levels by 55%, total
cholesterol by 24% and free fatty acids by 24%.
2.2.5.12 Anti-thyroid activity
v Panda and Kar, (2006) showed that scopoletin (7-Hydroxy -6- methoxy
coumarin) isolated from the leaves of AM at a dose of 1 mg/kg,
administered daily for 7 days to levo thyroxin treated animals
decreased the level of serum thyroid hormone.
2.2.5.13 Antioxidant activity
v Sabu and Kuttan (2004) showed that the oxidative stress produced by
alloxan was found to be significantly lowered by the administration of
methanolic extract of the plant.
v Kamalakkannan et al. (2003) evaluated the anti lipid perioxdative
activity of aqueous extract of fruit in streptozotocin diabetic rats in heart
and pancreas. Oral administration of the extract for 30 days (125 and
250 mg/kg body weight twice daily) produced a significant decrease in
the elevated level of the peroxidation product and hydroperoxidase in
the tissues.
2.2.5.14 Miscellaneous activities
v Bioassay-directed fractionation of the ethylacetate extract of the stem
bark of AM revealed presence of skimmiarepin C along with
skimmiarepin A (senecioate ester analogue), which exhibited moderate
insecticidal activity against phaedon cochleariae and Musca domestica
(Samavasekeva et al., 2004).
v Alcoholic extract at a dose of 1 mg/ml and 2 mg/ml produces a positive
relaxant effect in isolated guinea pig ileum and tracheal chain, which
confirmed the traditional use of AM in asthmatic complaints (Arul et al.,
2004).
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v Extract of AM exhibited a dose-dependent nitric oxide scavenging
activity (Jagetia & Baliga, 2004).
2.2.5.15 Toxicity study
v Rana et al. (1997) studied toxic effects of total alcoholic, total aqueous,
whole aqueous and methanolic extracts isolated from leaves of AM in
experimental rats. Following the chronic administration of extract of
AM, 50 mg/kg intraperitonially for 14 days, the histopathological studies
of heart, liver, kidney, testis, spleen and brain showed no remarkable
changes. The LD50 value showed a broad therapeutic window and high
therapeutic value for AM extract.
v Intraperitonial administration of the extract of leaves of AM at doses of
50, 70, 90 and 100 mg/kg body weight for 14 consecutive days to male
and female Wistar rats did not induce any short term toxicity.
Consecutively, the data demonstrated that the extract of leaves of AM
have a high margin of drug safety (Rana et al., 1997).
v Goel et al. (1997) reported that the aqueous extract of AM does not
adversely affect the male body and testicular weight as well as cauda
epididymal sperm counts. No notable changes in sperm morphology
and mortility were observed.
v Jagetia et al. (2005) demonstrated the acute toxicity study of AM. They
showed that drug was non-toxic up to a dose of 1750 mg/kg body
weight. The LD50 was found to be 2250 mg/kg, i.p.
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2.3 Murraya koenigii
2.3.1 Botanical Description (Kirtikar & Basu, 1993)
2.3.1.1 Geographical source
Murraya koenigii (L.) (MK) is an aromatic more or less deciduous shrub
or a small tree up to 6 m in height, found throughout India up to an altitude of
1,500 m, more commonly in forest often as gregarious under-growths. It is
cultivated for its aromatic leaves (Anonymous, 1998). The plant grow best in
tropical and sub-tropical climates in sunny to semi-shaded locations, though
they can sustain in other climates by moving pots to warm protected areas in
winter and maintaining humid conditions in areas where summers are hot and
dry. They are very frost sensitive. Soil needs to be enriched with lots of
organic material and be well drained. Seeds germinate readily (Prajapati et
al., 2003). Almost every part of this plant has a strong characteristic odor.
2.3.1.2 Taxonomical classification
Kingdom: Plantae
Division: Magnoliophyta
Class: Magnoliopsida
Order: Sapindales
Family: Rutaceae
Genus: Murraya
Species: Murraya koenigii
2.3.1.3 Synonyms
English: Curry leaves
Sanskrit : Krishna nimba
Hindi : Kathnim, Mitha neem, Curry patta
Gujarati : Goranimb, Kadhilimbdo
Bengali : Barsanga, Kariphulli
Assamese: Narsinghs, Bisharhari
Malayalam : Karriveppilei
Marathi : Karhinimb, Poospala, Gandla,
Telugu: Karepaku
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2.3.1.4 Morphological characters
The plant is a spreading shrub or small tree (Figure 2.3A). The main stem is
dark green to brownish, with numerous dots on it. The bark can be peeled off
longitudinally, exposing the white wood underneath. The girth of the main
stem is 16 cm. Leaves, exstipulate, bipinnately compound, 30 cm long, each
bearing 24 leaflets, having reticulate venation; leaflets, lanceolate, 4.9 cm
long, 1.8 cm broad, having 0.5-cm long petiole (Roy, 1977). Fruits, round to
oblong, 1.4 to 1.6 cm long, 1 to 1.2 cm in diameter (Figure 2.3B); fully ripe
fruits, black with a very shining surface. Seed, one in each fruit, 11 mm long, 8
mm in diameter, color spinach green. Flowering and fruiting occurs between
December to July. Flowers are bisexual, white, funnel-shaped, sweetly
scented, stalked, complete, ebracteate, regular, actinomorphic, pentamerous,
and hypogynous. The average diameter of a fully opened flower is 1.12 cm.
Inflorescence bears 60 to 90 flowers with calyx 5-lobed, persistent, inferior,
green; corolla, white, polypetalous, inferior, with 5 petals, lanceolate, length, 5
mm; androecium, polyandrous, inferior, with 10 stamens, arranged into circles
of five each; smaller stamens, 4 mm. long whereas the longer ones, 5 to 6
mm; gynoecium, 5 to 6 mm long; stigma, bright, sticky; style, short; ovary,
superior (Khosa & Prasad, 1972) (Figures 2.3C and 2.3D). This plant can
grow to a tree up to 6 m tall in warm, humid climates, but it can also be grown
very successfully in a pot as a much smaller plant. It will also generally be
smaller if grown out of its normal climate zone. The pungently- flavoured
pinnate leaves are borne on opposite slender branchlets and have an unusual
pendant habit. The leaves themselves are smooth and shiny with paler
undersides. Blackish berries follow white, perfumed flowers in summer (Khosa
& Prasad, 1974).
2.3.2 Traditional uses
The leaves of this plant are used as a spice in different curry preparations in
India. The plant has been used in traditional Indian medicine for a range of
ailments. The whole plant is considered to be a tonic and stomachic. Roots
and bark are stimulant and are applied externally for skin eruptions and
poisonous bites. Green leaves are febrifuge and used in dysentery
(Anonymous, 1987).
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Figure 2.3 Morphology of the plant Murraya koenigii: (A) Whole plant, (B)
Fruits, (C) Flowers, (D) Leaves.
2.3.3 Phytochemical investigations
v Narsimhan et al. (1975) have shown that MK contains carbazole
alkaloids namely murrayanine, mahanimbine, girinimbine, murrayacine,
isomurrayazoline, mahanine, koenine, koenigine, koenidine,
koenimbine, 8, 8’-biskoenigine. Other alkaloids are O-
methylmurrayamine, O-methylmahanine, isomahanine, bismahanine,
and bispyrayafoline.
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v It is reported that the leaves are fair sources of vitamin A. They are
also a rich source of calcium, but due to presence of oxalic acid in high
concentration its nutritional availability is affected. The free amino acids
present in leaves are asparagine, glycine, serine, aspartic acid,
glutamic acid, threonine, alanine, proline, tyrosine, and tryptophan. It
contains 0.8% potash. The major constituents of curry leaf are
monoterpenes (70%); seed cotyledons (86%), constituting-pinene
(52%) and cis-ß-ocimene (34%) (Anonymous, 1987).
v Narsimhan et al. (1975) reported that the leaves of MK yield number of
alkaloids viz., mahanine, koenine, koenigine, and koenidine.
v Narsimhan et al. (1976) showed that the hexane extract of the plant
yielded mahanimbine, girinimbine, isomahanimbine and koenimbidine.
v Sharma et al. (1980) confirmed the structures of mahanine, koenine,
koenimbine, isomahanimbine, and koenigicine by synthetic studies.
v The other constituents isolated from the leaves were a coumarin
glucoside (Gupta & Nigam, 1970), scopolin and murrayanine (Ganguly
et al., 1970).
v Gopalan et al. (1984) showed that the leaves contain calcium,
phosphorus, iron, thiamine, riboflavin, niacin, vitamin C, carotene and
oxalic acid. The essential oil from leaves yielded d-?-phellandrene, d-
sabinene, d-?- pinene, dipentene, d-?-terpinol, and caryophyllene.
v It has been reported that the stem barks of MK on extraction with
petroleum were reported to yield a number of carbazole alkaloid viz.,
girinimbine (Chakraborty et al., 1964), murrayanine (Chakraborty et al.,
1965) and mahanimbine.
v Optically inactive mahanimbine was also isolated from the extract
(Chakraborty et al., 1974).
v Murrayacine, another alkaloid, have been isolated from the plant
(Chakraborty et al., 1971).
v Bhattacharya and Chakraborty, (1984) have documented
spectroscopic, degradative and synthetic evidences for girinimbine,
cyclomahanimbine, mahanimbidine, mahanimbinine, murrayanine,
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mahanimbicine, murrayacine, murrayacinine, mahanimboline, and
mukanol.
v Dutta et al. (1969) have isolated some carbazole alkaloids from the
stem bark as: murrayazolidine, murrayacinine, cyclomahanimbine,
murrayazoline, murrayazolinine, isomurrayazoline, curryanin, and
curryangin.
v Eventually curryangin, murrayazoline and mahanimbidine were
reported to have the same structure. The alcoholic extract of the MK
stem yielded mukoenic acid i.e., 1-methoxy-carbazole-3-carboxylic acid
(Bhattacharya & Chakraborty, 1984).
v The methyl ester of mukoenic acid–mukonine was isolated from the
petrol extract of the stem bark (Chakraborty et al., 1978).
v The roots of MK, on extraction with light petroleum, yielded a carbazole
alkaloid, mahanimboline. The hexane extract of roots yielded
girinimbine. The benzene extract yielded two alkaloids mukoline and
mukolinidine and assigned the structures 6- hydroxymethyl-1-methoxy
carbazole and 6-formyl-1-methoxy carbazole respectively (Roy et al.,
1982).
v The MK fruits yielded an alkaloid namely koenimbine, murrayazoline,
murrafoline, and pyrayaquinone-A (Roy et al., 1982).
2.3.4 Pharmacological actions
2.3.4.1 Antibacterial activity
v Goutam and Purohit, (1974) reported the antibacterial activity of the
plant. The essential oil from MK leaves showed antibacterial effect
against B. subtilis, Staph. aureus, C. pyogenes, P. vulgaris, and
Pasteurella multicida. The pure oil was active against the first three
organisms even at a dilution of 1:500.
2.3.4.2 Antifungal activity
v The essential oil from leaves of MK has been shown to possess
antifungal activity against C. albicans, C. tropicalis, A. niger, A.
fumigates, and Microsporum gypseum. It was effective against C.
albicans even at a dilution of 1:500. The ethanolic extract of the leaves
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showed fungitoxicity against Colletotrichum falcatum and Rhizoctonia
solani (Kishor et al., 1982).
v On contrary, Singh and Sharma (1978) reported that the ethanolic
extract of the roots and also the whole plant excluding roots of MK, did
not show any antifungal activity against Cryptococcus neoformans,
Trichophyton mentagrophytes, and Microsporum canis.
2.3.4.3 Antiprotozoal activity
v In the study of Bhakuni et al. (1969), ethanolic extracts of MK whole
plant excluding roots (extract A) and roots alone (extract B) were
screened for their pharmacological actions. Extract A showed
antiprotozoal action against E. histolytica and antispasmodic effect on
isolated guinea pig ileum, whereas extract B showed antiprotozoal
activity against E. histolytica as well as hypertensive activity in cat/dog.
2.3.4.4 Hypoglycaemic activity
v Yadav et al. (2002) have shown a significant hypoglycaemic action of
MK. Feeding of diet containing various doses of curry leaves (5, 10 and
15%) to normal rats for 7 days as well as mild and moderate diabetic
rats for 5 weeks showed varying hypoglycemic and anti-hyperglycemic
effect. In normal rats, reduction in blood glucose was almost negligible
(approximately 4% with 10 and 15% diet). In mild and moderate
diabetic rats, feeding of 5, 10 and 15% diet caused a maximal
reduction in blood sugar by 13.1, 16.3 and 21.4% and 3.2, 5.58, 8.21%
respectively.
v Another study reported that MK showed antihyperglycemic activity in
STZ-induced diabetic rats. Oral administration of ethanolic extract of
MK at a dose of 200 mg/kg/ b.w./day for a period of 30 days
significantly decreased the levels of blood glucose, glycosylated
hemoglobin, urea, uric acid and creatinine in diabetic treated group of
animals. Determination of plasma insulin level revealed the insulin
stimulatory effect of the extract. The results suggested that MK
possesses statistically significant hypoglycemic potential in STZ-
induced diabetic rats. The MK extract appeared to be more effective
than glibenclamide, a known antidiabetic drug (Arulselvon et al., 2006).
Review of Literature
Dept. of Pharm. Sci., Saurashtra University, Rajkot, Gujarat, India
56
v The study of Vinuthan et al. (2004) postulated the effect of daily oral
administration of aqueous extract (600 mg/kg b.wt.) and methanol
extract (200 mg/kg b.wt.) of MK leaves for a period of eight weeks on
blood glucose and plasma insulin level in alloxan-induced diabetic rats.
Blood glucose levels of diabetic rats treated with aqueous and
methanol extracts of MK showed significant reduction as compared to
diabetic control groups. Plasma insulin levels were significantly high on
43rd and 58th days of treatment in aqueous and methanol extracts of
MK treated groups. This suggests that the hypoglycemic effect may be
mediated through stimulating insulin synthesis and/or secretion from
the beta cells of pancreatic Islets of Langerhans.
v The findings also suggested that the aqueous extract of MK leaves
showed hypoglycemic activity in normal and alloxan-induced diabetic
rabbits. The scientific evaluation of its hypoglycemic activity was
explored and compared with the effect of a standard hypoglycemic
drug, tolbutamide. A single oral administration of variable dose levels
(200, 300, and 400 mg/kg) of aqueous extract led to lowering of blood
glucose level in normal as well as in diabetic rabbits (Kesari et al.,
2005).
2.3.4.5 Antioxidant activity
v The literature review also revealed the antioxidative properties of the
extract of MK leaves. The activity was evaluated on the basis of oil
stability index together with their radical scavenging ability against 1-1-
diphenyl-2-picrylhydrazyl (DPPH). The methylene chloride (CH2Cl2)
extract and the ethyl acetate (EtOAc) soluble fraction of the 70%
acetone extract prolonged the OSI values significantly compared to
those of tocopherol. Five carbazole alkaloids were isolated from the
CH2Cl2 extract and their structures were identified to be euchrestine,
bismurrayafoline, mahanine, mahanimbicine and mahanimbine based
on 1H and 13C NMR and mass (MS) spectral data (Yukari et al., 2001).
v Baliga et al. (2003) examined the plant extract of MK for its possible
regulatory effect on nitric oxide (NO) levels using sodium nitroprusside
as a NO donor in vitro. The extract had shown direct scavenging of NO
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and exhibited significant activity. The result showed that MK might be
potent and novel therapeutic agents for scavenging of NO, the
regulation of pathological conditions caused by excessive generation of
NO and its oxidation product, peroxynitrite.
v In another study, the antioxidant potential of curry leaves in rats,
treated with a known chemical carcinogen-dimethylhydrazine
hydrochloride (DMH), was investigated. Vitamin A content in the liver
was significantly increased whereas glutathione (GSH) content was not
altered. The results indicated that curry leaves have high potential as
reducer of the toxicity of DMH (Khan et al., 1996).
2.3.4.6 Haematological studies
v Khan et al. (1995) screened the curry leaves for haematological
studies. In this study the rats were fed at doses equal to normal human
intake. It did not cause any adverse effect on food efficiency ratio
(FER), red blood cell count (RBC), white blood cells (WBC), total count,
differential counts or on the levels of blood constituents, like serum
electrolytes, blood urea, haemoglobin, total serum protein, albumin-
globulin ratio, fibrin level, glycosylated haemoglobin and the activity of
glutamic oxaloacetic transaminase (GOT), glutamic pyruvic
transaminase (GPT) and alkaline phosphatase in serum. No
histopathological changes were observed in the liver of rats
administered curry leaf.
2.3.4.7 Hypolipidemic activity
v Khan et al. (1996) reported biochemical responses in rats by
supplementation of MK leaves to the diet. Albino rats were fed for 90
days on a standard laboratory rat diet plus 20% coconut oil either with
the addition of 10 % curry leaf. Feed was offered at a level of 10 %
body weight. The spice resulted in the reduction in total serum
cholesterol and LDL + VLDL, an increase in the HDL, lower release of
lipoproteins into the circulation and an increase in the LCAT (Lecithin
Cholesterol Acyl Transferase) activity.
v Studies on the effect of curry leaves supplementation on lipid profile,
glycated proteins and amino acids were also done in non-insulin
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diabetic patients. The results indicated a transient reduction in fasting
and post-prandial blood sugar levels at 15-days period with no
appreciable changes in serum glycosylated protein levels, glycosylated
low density lipoprotein cholesterol fraction, serum lipids, and lipoprotein
cholesterol levels (Iyer & Mani, 1990).
2.3.4.8 Anti-lipid peroxidative activity
v The status of lipid peroxidation was investigated by Khan et al. (1996)
in rats fed with MK. The concentration of melondialdehyde showed a
significant decrease, while hydroperoxides and conjugated dienes were
significantly increased in liver and heart. Glutathione levels in liver,
heart and kidney were lowered in rats administered these spices.
Glutathione reductase, Glutathione peroxidase and Glutathione-S-
Transferase, SOD and catalase activity showed a sharp increase.
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2.4 Caesalpinia bonducella
Caesalpinia bonducella (CB), also known as Caesalpinia crista, is an
important medicinal herb reported in Ayurveda belonging to family
Caesalpiniaceae. It is found throughout India and tropical countries of the
World (Kirtikar & Basu, 1993). Species like C. nuga and C. jayoba are also
sometimes wrongly designated as synonyms for C. bonducella. In fact, C.
jayoba is an adulterant of C. bonducella (Ram et al., 1991). “Bonducella” the
name of the species is derived from the Arabic word “Bonduce” meaning a
“little ball” which indicated the globular shape of the seed (Handa & Kaul,
1996).
2.4.1 Botanical description (Kirtikar & Basu, 1993)
2.4.1.1 Geographical source
The plant is up to 15 m in height, found up to an altitude of 1,000 m in
Himalaya and wild throughout the plains of India. Also, found particularly
along the seacoast, and throughout the hotter parts of India, Burma and Sri
Lanka (Kirtikar & Basu, 1993).
2.4.1.2 Synonyms
Sanskrit: Kakachika, Karanja and Latakaranja
Gujarati: Kanchka, Kakachiyo
Hindi: Kathkaranj
English: Fever nut
Bengali: Nata
Tamil: Avil
Urdu: Akitmakit
Marathi: Gajaga
2.4.1.3 Morphological characters
The plant is climber; branches finely grey, armed with hooked and straight
hard yellow prickles (Figure 2.4A). Seed coat is hard, glossy, and greenish to
ash grey in color; Seeds 1-2, oblong, lead-colored, 1.3 cm. long (Figure 2.4B).
In dry seed, kernel gets detached from the testa. Testa is about 1-1.25 mm in
thickness and is composed of three distinct layers, the outermost - thin and
brittle, the middle one-broad, fibrous and dark – brown and the innermost –
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white and papery layer. The kernel surface is hard, pale yellowish–white,
circular to oval, flattened and about 1.23- 1.75 cm. in diameter (Kirtikar and
Basu, 1993). Leaves are with large, leafy, branched, basal appendages; 30-
60 cm. long; petioles prickly; stipules a pair of reduced pinnae at the base of
the leaf and pointed; Leaflets 6-9 pairs, 2-3.8 by 1.3-2.2 cm in size (Figure
2.4C). Flowers are usually 15-25 cm. long; Calyx 6-8 mm. long, hairy; lobes
obovate-oblong, obtuse (Figure 2.4D).
2.4.2 Taxonomical classification
Kingdom: Plantae
Division: Magnoliophyta
Class: Magnoliopsida
Order: Fabales
Family: Fabaceae
Genus: Caesalpinia
Species: Caesalpinia bonducella
2.4.3 Phytochemical investigation
The alkaloids have been isolated from the leaves, stem, twig, and fruits of the
plant (Willaman & Li, 1970)
2.4.3.1 Alkaloids
v There is controversial reports exist regarding the presence of alkaloids
in C. bonducella. Some research workers detected an alkaloid “Natin”
in the plant but others could not confirm the presence of the same
(Ghatak, 1934).
v The presence of alkaloid in the seed and twigs (Iyengar & Pendse,
1965) and its absence in stem and leaf was indicated in later reports
(Puri, 1980).
2.4.3.2 Glycosides
v First non-alkaloidal bitter principle isolated from the seed of C.
bonducella was Bonducin (Bonducellin) (Dymock & Whooper, 1890).
v The structural formula of Bonducin (a homoisoflavone) has been well
established (Purshotaman et al., 1982).
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v Number of enzymes like protease, urease, amylase, peroxidase,
catalase and oxidase has been reported in the seed (Vinayak et al.,
1929).
v Puri, (1980) have reported steroidal saponins in the twigs of the plants.
2.4.3.3 Terpenoids and other isolated constituents
v Caesalpin (C24H32O8) (1-ketone 6, 7-diacetylcassane), and ?-caesalpin
(C20H28O6) (1-ketone 5, 6, 7, 14-tetrahydroxy voucapanone) were the
first isolated bitter cassane/voucapane diterpenoids from the seeds of
C. bonducella (Oudarti et al., 1890).
v Three more Caesalpins–E caesalpin, F caesalpin and Y caesalpin
have also been isolated from kernels of C. bonducella. ?-caesalpin, a
minor constituent, is closely related to ?–caesalpin (Purushotaman et
al., 1981)
v F caesalpin is shown to be closely related to E caesalpin (Balman et
al., 1980).
v The kernals contains fatty oil (20-24%); starch, sucrose, two
phytosterols, one of them was identified as sitosterol, and a
hydrocarbon (mp 58-590C) identified as heptocosane (Tummin, 1930).
v A cassane furanoditerpene, caesalpinin have been isolated from the
roots of CB (Peter & Tinto, 1997).
v Two other cassane diterpenes, named caesaldekarins F and G, were
isolated and identified from the roots of CB. The caesaldekarin C was
also isolated from the roots of this plant (Peter et al., 1998).
v Bonducellpins A, B, C and D were also reported from the roots of the
plant (Peter et al., 1997).
v Diosgenin (steroidal saponin) was also reported from the root (Jain et
al., 1991).
v Ethanolic extract of bark of CB have been shown to yield two
homoisoflavonoids, 6-O-methylcaesalpinianone and caesalpinianone
from bark of the plant (Athar et al., 2009).
v The leaves were shown to contain pinitol (4.1%), glucose and minerals
like calcium (2%) and phosphorous (0.3%). Brazillin and bonducin have
been isolated from leaf (Watt & Breyer-Brandwijk, 1962).
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v A waxy material and an amorphous bitter principle (C20H32O8, m.p.
119.12, yield 0.35%) have also been isolated from the leaves (Khuda
et al., 1961).
Figure 2.4 Morphology of the plant Caesalpinia bonducella: (A) Whole
plant, (B) Fruit containing seeds, (C) Leaves, (D) Flowers.
2.4.4 Traditional uses (Kirtikar & Basu, 1993)
v The seed is claimed to be styptic, purgative and anthelmintic and cures
inflammations; useful in colic, malaria, hydrocele, skin diseases and
leprosy in the Unani system. In Madras, an ointment is made from the
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powdered seeds with castor oil and applied externally in hydrocele and
orchitis. The seeds are considered tonic, ferifuge, anthelmintic,
antiblennorrhagic, and specific in the treatment of hydrocele. The oil
from the seeds is used in convulsions and paralysis. In Guinea, the
pounded seeds are considered vesicant. The powdered seeds were
mixed with equal part of pepper powder to malaria patients and were
found to possess feeble antiperiodic properties. The seeds are ground
in water and given internally in snake-bite. Seed and long pepper
powders taken with honey gives good expectorant effect. Burnt seeds
with alum and burnt areca nut are a good dentifrice useful in spongy
gums, gum boils, etc. In West Indies, the roasted seeds are used as
anti diabetic. The kernel of the seed is very useful and valuable in all
ordinary cases of simple, continued and intermittent fevers. The kernel
powder mixed with equal parts of black pepper is taken thrice a day in
a dose of 15-30 grains by adults and 3-4 grains by children. It is said to
produce lots of perspiration, leading to the reduction of fever. Kernel
powder with sugar and goat milk gives good results in liver disorder.
Decoction of roasted kernels is used in asthma. Children unable to
digest mother’s milk were given the extract of the kernel or its powder
along with ginger, salt and honey to get good stomachic effect. Paste
prepared from kernel gives relief from boils and other such swellings. A
cake made of 30 grains of powdered kernels, fried in ghee taken twice
a day is a valuable remedy in cases of acute ovaritis.
v The roots are considered febrifuge and anthelmintic, they are much
used as an astringent in leucorrhoea. In Guinea, a decoction of the root
is prescribed in fever. The root-bark is good for tumours and for
removing the placenta. Bark of root possesses number of properties
like febrifuge and anthelmintic etc. In Jamaica, it is used as rubifacient
and as a local application for sores. The bark powder with honey is
taken in cases of hernia. In Himachal Pradesh, the roots are used in
intermittent fever and diabetes.
v The juice of leaves is anthelmintic; good in elephantiasis and small
pox; destroys the bad odour due to perspiration. In disorders of liver,
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the leaves are considered very efficacious. The oil extracted from
leaves is given in convulsions, palsy and similar complaints. The young
leaves are used in intermittent fevers, and for expelling intestinal
worms. In Ceylon, they are applied for toothache, and they are also
given for worms in children. In Guinea, the boiled leaves are used as a
gargle for sore throat. Leaves ground with onion, if applied on boils
gives good relief. Finely powdered leaves are prescribed as a uterine
tonic after child birth. The leaf extract with asafoetida is prescribed in
cases of indigestion.
v The flower is bitter and cures Kapha and Vata. The ash is used in
ascites.
v Aphrodisiac, anthelmintic; cures urinary discharges, piles, and wounds.
The oil from fruit is good for indolent ulcers as per the Ayurveda.
Roasted fruits are used in eye diseases, hyperacidity and as fish
poison. In Hawaii islands, the pulp of the pod is used for purifying the
blood, in congestion and as a laxative. In Philippines, fresh fruit powder
with garlic and mixed with lukewarm water is rubbed on the body to
mitigate fever.
v The stem is used in eye diseases and as a fish poison. In Sri Lanka,
the plant is used for the treatment of skeletal fractures.
2.4.5 Pharmacological actions
2.4.5.1 Anti diarrheal activity
v Significant anti diarrheal activity in mice was shown by the nuts of CB
(Iyengar & Pendse, 1965).
2.4.5.2 Antiviral activity
v The alcoholic extracts of roots and stem showed antiviral activity
against vaccinia virus (Dhar et al., 1968).
2.4.5.3 Anti-fertility activity
v Anti-fertility action of seeds was noted in rats and mice (Bhinde et al.,
1970).
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2.4.5.4 Antibacterial activity
v Four triterpenoids and methanol extract from the seeds of CB have
been shown to possess a wide range of inhibiting activity against both
gram-positive and gram-negative bacteria (Saeed & Sabir, 2001).
2.4.5.5 Anti diabetic activity
v The seed kernel powder was reported to have hypoglycaemic activity
in experimental animals. Four extracts (petroleum ether, ether, ethyl
acetate, and aqueous) were prepared from the seed kernels and tested
for their hypoglycaemic potentials in normal as well as alloxan-induced
diabetic rats. In normal rats, only ethyl acetate and aqueous extracts
showed a minimum significant hypoglycaemic effect, compared to that
of glibenclamide. In diabetic rats, the non-polar extracts i.e. the ether
extract showed a marginal anti-diabetic activity, while the petroleum
ether extract failed to show significant hypoglycaemic effect, besides,
reversing the diabetes induced changes in lipid and liver glycogen
levels. However, both the polar extracts (ethyl acetate and aqueous) as
well as glibenclamide, showed the hypoglycemic effect. Since both the
polar extracts were, chemically, found to contain triterpenoidal
glycosides, it was postulated that they might be the active principles
contributing to the anti diabetic actions of the plant (Parameshwar et
al., 2002).
2.4.5.6 Hypoglycaemic effect
v CB is used by the tribal people of India for controlling blood sugar.
Chakrabarty et al. (2003) showed significant blood sugar lowering
effect of CB in type 2 diabetic model (Chakrabarty et al., 2003).
2.4.5.7 Antitumor and antioxidant activity
v The study of Gupta et al. (2004) established anti-tumour effect of the
methanol extract of CB leaves (MECB) in the Ehrlich ascites carcinoma
(EAC)-bearing Swiss albino mice. The extract was administered at the
doses of 50, 100, and 200 mg/kg body weight per day for 14 days after
24h of tumor inoculation. The study dealt with the effect of MECB on
the growth of transplantable tumor, life span of EAC-bearing hosts,
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haematological profile, and biochemical parameters such as lipid
peroxidation (LPO), glutathione content (GSH), superoxide dismutase
(SOD), and catalase (CAT) activities. MECB caused significant (P <
0.01) decrease in tumor volume, packed cell volume, and viable cell
count; and it prolonged the life span of EAC-tumor bearing mice.
MECB significantly (P < 0.05) decreased the levels of lipid peroxidation
and significantly (P < 0.05) increased the levels of GSH, SOD, and
CAT. The MECB was found to be devoid of conspicuous short-term
toxicity in the mice when administered daily (i.p.) for 14 days at the
doses of 50, 100, 200, and 300 mg/kg. The treated mice showed
conspicuous toxic symptoms only at 300 mg/kg. The results indicated
significant antitumor and antioxidant activity of MECB in EAC-bearing
mice.
2.4.5.8 Antipyretic and analgesic activities
v Archna et al. (2005) subjected ethanolic extract (70%) of CB seed
kernel for its antipyretic and antinociceptive activities in adult albino
rats or mice of either sex at 30, 100, and 300 mg/kg orally. The extract
demonstrated marked antipyretic activity against Brewer’s yeast-
induced pyrexia in rats. The extract showed significant central
analgesic activity in hot plate and tail flick methods.
v Archna et al. (2005) established analgesic effect of the plant in both
acetic acid-induced writhing test in mice and Randall-Selitto assay in
rats. It was also shown that plant significantly inhibited the formalin-
induced hind paw licking in mice.
2.4.5.9 Anti filarial activity
v Gaur et al. (2008) showed that the crude extract of the plant produced
fall in microfilaria (mf) count in L. sigmodontis-cotton rat model.
2.4.5.10 Anxiolytic activity
v Venkat et al. (2008) showed the anxiolytic activities of seed extract of
CB in experimental animals.
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2.4.5.11 Anti-inflammatory action
v Shukla et al. (2008) established anti-inflammatory activity of the plant.
Various concentrations of the seed oil of CB (100, 200, and 400 mg/kg
orally) were tested in carrageenan-induced rat paw edema, brewer’s
yeast induced pyrexia, acetic acid-induced writhing and hot plate
reaction time in experimental rats to assess the anti-inflammatory,
antipyretic and analgesic activities. The paw volumes, pyrexia and
writhes in experimental rats were reduced significantly (P < 0.05) as
compared to that of control, and hot plate test showed significant
licking effect in rats.
2.4.5.12 Antioxidant activity
v Ethanolic extract of CB seeds have been shown to possess antioxidant
activity in the DPPH-radical scavenging assay (Shukla et al., 2009).
2.4.5.13 Immunomodulatory activity
v Shukla et al. (2009) reported immunomodulatory activity of the seeds
of the plant. Oral administration of ethanolic seed extract of CB (200-
500 mg/kg) evoked a signicant increase in percent neutrophil adhesion
to nylon fibers as well as a dose dependent increase in antibody titre
values, and potentiated the delayed type hypersensitivity reaction
induced by sheep red blood cells. Also, it prevented myelosuppression
in cyclophosphamide drug treated rats and showed good response
towards phagocytosis in carbon clearance assay. These results
indicated that CB possesses potential Immunomodulatory activity and
has therapeutic potential for the prevention of autoimmune diseases.
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The presence of synergistic and/or side-effects neutralizing combinations
in medicinal plants is an old concept put forth by the Hippocrates and
strengthened by Ibn Sina and others. The plants in their crude form show
interesting combination of activities and there is a huge potential of medicinal
plants not only as a source of new drugs but also their use in the form of
botanicals both in developing countries and the industrialized world (Gilani &
Rahman, 2005).
There are clear trends to show that the mainstream in pharmaceutical
research is moving away from single molecule or single target approach to
combinations and multiple target approaches (Wermuth, 2004).
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3. Objectives
Asthma is characterized by bronchoconstriction and inflammation, with
infiltration and activation of inflammatory cells such as eosinophils and mast
cells, and subsequent release of inflammatory mediators. Much of the therapy
directed at the treatment of asthma is either to provide symptomatic relief
through bronchodilation or to reduce inflammation to prevent or delay airway
remodelling. The current drug therapy is only symptomatic and do not limit
disease progress. Additionally, besides the high cost, the prolonged use of
many of these drugs is associated with severe adverse reactions and toxicity.
As a result, alternative treatments based on natural plant products and herbal
mixtures in the form of polyherbal formulations are becoming increasingly
popular in the India, US and other countries.
In India, the ancient literatures like ‘Charak Samhita’ and ‘Sushruta
Samhita’ describe use of plants and polyherbal formulations for health care
(Mukherjee & Wahile, 2006). The trend in pharmaceutical research is moving
away from single molecule or single target approach to combinations and
multiple target approaches (Wermuth, 2004). There is growing evidence to
show that medicinal plants contain synergistic and/or side-effects neutralizing
combinations (Gilani & Rahman, 2005). Considering this fact, we aimed for
the synergistic action of four medicinal plants in the form of polyherbal
formulation.
From the literature review, it was found that no work has been reported
on antiasthmatic effects of the plants SX, AM, MK and CB and their
combination as polyherbal formulation. Keeping this in view, the present study
has been undertaken to validate traditional claims for anti-asthmatic activity of
these plants and to find out underlying mechanisms.
In the light of above background, an attempt has been made to
evaluate effect of four medicinal plants and their combination in form of
polyherbal formulation for the antihistaminic, anticholinergic, and mast cell
stabilising activities. The study was also aimed to evaluate anti-inflammatory
effects in experimental animals to find the probable mechanism of action of
these plants/polyherbal formulations. The phytochemical study and acute
toxicity was determined.
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The objectives of the study are
Ø To study the extraction and standardization of crude drugs
Ø  To study the phytochemical investigation of crude extracts
Ø  To study the development of polyherbal formulation, evaluation and
assessment of anti-asthmatic activity
Ø To study the evaluation of extracts for anti-asthmatic activity
Ø To study the synergistic action of four medicinal plants in the form of
polyherbal formulation
Ø To study the acute toxicity of the all extracts of the plants and
polyherbal formulations
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4. Materials and methods
4.1 Collection, identification and authentication of plant
materials
The leaves of different plants (Solanum xanthocarpum, Murraya koenigii,
Aegle marmelos and Caesalpinia bonducella) were collected from the outfield
of Junagadh city, Gujarat, India in February-March 2007. The plant materials
were identified and authenticated by Dr. Pranjeevan Parmar, Botanical Survey
of India, Jodhpur, Rajasthan, India and also by Dr. M. M. Jani, Head,
Department of Botany, Bahauddin Science College, Junagadh, Gujarat, India.
The voucher specimens (SU/DPS/Herb/19-22) of the collected plant samples
were deposited in the Department of Pharmaceutical Sciences, Saurashtra
University, Rajkot, India for future reference (Figure 4.1 to 4.4).
4.2 Drugs and Chemicals
Compound 48/80, disodium chromoglycate (DSCG), histamine
dihydrochloride, acetylcholine chloride, atropine sulfate, mepyramine meleate,
carrageenan, acetylsalicylic acid (ASA), and toluidine blue were purchased
from Sigma (St. Louis, MO, USA). Histamine solution was freshly prepared in
normal saline (NaCl, 8.5 g/l). All the other drugs were of analytical grade and
they were dissolved in distilled water and desired concentration was prepared.
Prednisolone was generously gifted by Inga Laboratories Ltd., Mumbai, India.
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Figure 4.1 The authenticated herbarium specimen of the plant Solanum
xanthocarpum
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Figure 4.2 The authenticated herbarium specimen of the plant Aegle
marmelos
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Figure 4.3 The authenticated herbarium specimen of the plant Caesalpinia
bonducella
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Figure 4.4 The authenticated herbarium specimen of the plant Murraya
koenigii
Materials and methods
Dept. of Pharm. Sci., Saurashtra University, Rajkot, Gujarat, India76
4.3 Extraction
Leaves of different plants were washed with distilled water to remove dirt and
soil, and shade dried. Routine pharmacognostic studies including organoleptic
tests, macroscopic, and microscopic observations were carried out to confirm
the identity of the materials. The dried material of each plant was coarsely
powdered (500 g) and defatted with petroleum ether (60-800C), and then
extracted separately with ethanol (95% v/v) in Soxhlet apparatus (Figure 4.5).
The extracts were filtered, and concentrated by distilling off the solvents and
evaporated to dryness using water bath to get crude ethanol extract. The yield
values for ethanolic extract of SX (EESX), ethanolic extract of AM (EEAM),
ethanolic extract of CB (EECB) and ethanolic extract of MK (EEMK) were
20.48%, 11.45%, 9.48%, and 6.96% w/w, respectively. Different extracts were
subjected to phytochemical screening and screened for possible
pharmacological actions. For the pharmacological tests, the extracts were
suspended in double distilled water containing carboxy methyl cellulose
(CMC, 0.5% w/v).
Figure 4.5 Soxhlet apparatus for the extraction of different plant
extracts
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4.4 Macroscopic observations
The powdered drug was subjected to macroscopic studies which
comprised of characters like shape, size, surface characteristics, texture,
fracture characteristics and appearance of cut surface, color, odor,
appearance, taste, smell, etc.  These characters were examined for
identity and purity of material.
4.5 Experimental animals
Antihistaminic and anticholinergic studies were conducted on guinea pigs
(350-500 g) of either sex fed on commercial pellet diet (Amrut, Pranav Agro
Industries Ltd, India). They were group housed in polypropylene cages (640 x 410
x 250 mm high) under standard conditions of temperature (22 ± 20C), relative
humidity (60 ± 5%) and 12:12 light/dark cycle, where lights on at 0700 and off
at 1900 h. They were divided in groups of ten animals each. The saline fed
group served as control and one group was treated with a standard drug.
Before experimentation, the animals were kept on fast for 24 h but water was
given ad libitum, Animals receiving different doses of plant extracts were also
observed for any alteration in their general behavior.
For anti-inflammatory paradigms, Wistar albino rats weighing 140–160
g of either sex were used. Five animals were group housed in polypropylene
cages (640 x 410 x 250 mm high) and kept at departmental animal house in
well cross ventilated room at the same experimental condition explained
above. They were provided with standard rodent pellet diet (Amrut, Pranav
Agro Industries Ltd, Baroda, Gujarat, India) and tap water ad libitum except
the food was withdrawn 18–24 h before the experiment. All the experimental
protocols were approved by the Institutional Animal Ethics Committee (IAEC),
N. R. Vekaria Institute of Pharmacy and Research Centre, Junagadh, Gujarat,
India (approved number-NRVCP/IAEC/08-2k7/01). All the experiments and
the care of the laboratory animals were according to current ethical guidelines
by the Committee for the Purpose of Control and Supervision on Experiments
on Animals (CPCSEA), Ministry of Environment and Forests, Government of
India, New Delhi.
Materials and methods
Dept. of Pharm. Sci., Saurashtra University, Rajkot, Gujarat, India78
4.6 Habituation to animals
Rats and guinea pigs were habituated to handling by holding them and
injecting vehicle through oral/i.p. routes to minimize non-specific stress and to
simulate the actual protocol conditions. Handling also consisted of weighing
and restraining animals on platform for 1 min, and gently massaging on dorsal
site as was done in the actual protocols. The same platform was used during
drug administration.  Moreover, the animals were familiarized with the diet in
their home cage-environment and laboratory environments before subjecting
them to the tests. All the experiments commenced 24 hours following the final
habituation and were conducted according to the protocols mentioned below.
4.7 Acute toxicity test (Determination of LD50)
The acute toxicity tests (LD50) for the different plant extracts were determined
according to the procedure described by Lorke (1983). The crude ethanolic
extracts were used for the test. Albino mice (20–25 g) of either sex were used.
This method involved an initial dose finding procedure, in which the animals
were divided into three groups of three animals per group. Doses of 10, 100,
and 1000 mg/kg were administered orally, one dose for each group. The
treated animals were monitored for 24 h for mortality and general behavior.
From the result of the above step, four different doses of 200, 400, 800,
and 1600 mg/kg were chosen and administered (p.o.) respectively to four
groups of one mouse per group. The treated animals were again monitored
for 24 h. The LD50 was then calculated as the geometric mean of the lowest
dose showing death and the highest dose showing no death.
4.8 Preparation of polyherbal formulations
Polyherbal formulations are prepared by mixing fixed quantities of dried
extracts of different plants (Figure 4.6A, B) as follows:
Ø The polyherbal formulation-I was composed of 25 mg of EESX +
25 mg of EEAM + 50 mg of EECB + 50 mg of EEMK (Mixture of
the 50% of least effective dose of each plant)
Ø The polyherbal formulation-II was composed of 50 mg of EESX +
50 mg of EEAM + 100 mg of EECB + 100 mg of EEMK (Mixture
of the least effective dose of each plant)
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Figure 4.6 Polyherbal formulations (PHF) A and B
4.9 Preparation of the test extracts
Different extracts were suspended in 0.5% CMC in distilled water to prepare
different doses (PHF: 150, and 300; EESX and EEAM: 50, 100, 200, and 300;
EEMK and EECB: 100, 200, 300, and 400 mg/kg body weight) and
administered orally. The same doses were employed for different protocols
except specified in some experiments. The control animals were given an
equivalent volume of CMC vehicle. In each protocol, one of the groups is
reference standard group in which various standard anti-asthmatics were
injected to animals.
4.10 Screening for antiasthmatic activity
4.10.1 Histamine-induced bronchospasm in guinea pigs
(Armitage et al., 1961)
The guinea pigs fasted for 24 h were exposed to an atomised fine mist of 2%
histamine dihydrochloride aerosol (dissolved in normal saline) using nebulizer
at a pressure of 300 mm Hg in the histamine chamber (24 x 14 x 24 cm, made
of perplex glass) (Figure 4.7). Guinea pigs exposed to histamine aerosol
showed progressive signs of difficulty in breathing leading to convulsions,
asphyxia, and death. The time until signs of convulsion appeared is called
pre-convulsion time (PCT/PCD). By observation experience was gained so
that the preconvulsion time can be judged accurately. As soon as PCD
commenced, animals were removed from the chamber and placed in fresh air
to recover. In the present experiments the criterion used was time for onset of
dysponea and percent protection was calculated. Those animals which
developed typical histamine asthma within 3 min were selected out three days
A B
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prior to the experiment and were given habituation practice to restrain them in
the histamine chamber. They were divided in groups of ten animals each.
Mepyramine 8.0 mg/kg, i.p., and different doses of plant extracts or polyherbal
formulations intraperitonially were administered 30 min prior to exposure.
Animals, which did not develop typical asthma within 6 min, were taken as
protected.
Figure 4.7 Histamine chamber for screening of anti-histamine and anti-
cholinergic properties of drugs.
4.10.2 Acetylcholine-induced bronchospasm in guinea pigs
(Kumar & Ramu, 2002)
Similar procedure was repeated by exposure of aerosol of 0.5% acetylcholine
in another set of animals (each group having ten animals) using atropine
sulphate (2 mg/kg) as a standard.
4.10.3 Mast cell degranulation by compound 48/80
(Kaley & Weiner, 1971)
This was carried out as per the method described by Kaley and Weiner (1971)
with little modification. Male albino rats were sacrificed by cervical dislocation.
The animals were immediately injected with 15 ml of pre-warmed (37°C)
buffered salt solution (BSS; NaCl 137 mM; KCl 2.7 mM; MgCl2 1.0 mM; CaCl2
0.5 mM; NaH2PO4 0.4 mM; Glucose 5.6 mM; HEPES 10 mM) into the
peritoneal cavity, and massaged gently in this region for 90 s, to facilitate cell
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recovery. A midline incision was made and the peritoneum was exposed
(Figures 4.8 and 4.9). The pale fluid was aspirated using a blunted plastic
Pasteur pipette, and collected in a plastic centrifuge tube. The fluid was then
centrifuged at 1000 rpm for 5 min, and the supernatant discarded to reveal a
pale cell pellet. The cell pellets were re-suspended in fresh buffer and re-
centrifuged. Aliquots of the cell suspension were incubated with different
doses of the test compounds or disodium cromoglycate, before challenge with
compound 48/80. The aliquots were carefully spread over glass slides, and
the mast cells were stained with 1% toluidine blue, and counterstained with
0.1% light green. The slides were dried in air and the mast cells counted from
randomly selected high power objective fields (X450). The effect of different
plant extracts on mast cells was studied by incubating the mast cells for 10
min with the above compounds in a concentration of 1, 10 or 100 µg/ml. In
another set of experiments the mast cells which were pre-incubated with
different plant extracts or polyherbal formulations were exposed to the mast
cell degranulator, compound 48:80 (10 µg/ml), and the incubation continued
for a further 10 min. Then, the mast cells were carefully spread over glass
slides. The percent degranulation of the mast cells in each treatment was
calculated. DSCG 20 µg/ml was also included in the study for comparison.
4.10.4 Histamine-induced hind paw edema in rats
(Horakova & Moratova, 1964)
The method of Horakova and Moratova (1964) was followed. Oedema in one
of the hind paws of the rat was induced by the subplantar injection of 0.1 ml
freshly prepared 0.1% (w/v) histamine (a phlogistic agent) (Sigma Chemical
Co., St. Louis, MO, USA) in normal saline. The pedal volume was measured
just before (0 h) and 3 h after the phlogistic challenge. Mepyramine (10
mg/kg) per os (p.o.) was employed as reference standard in the experiment.
Different plant extracts or polyherbal formulation treatments were given 1 h
before the phlogistic challenge. ASA (30 mg/kg, p.o.) was used as reference
standard drug. Percent inhibition of edema volume between treated and
control group was calculated as: Percent inhibition = 1 – VT/VC × 100
Where, VC,  and  VT represent the mean increase in paw volume in
control and treated groups, respectively.
Materials and methods
Dept. of Pharm. Sci., Saurashtra University, Rajkot, Gujarat, India82
Figure 4.8 Opened rat abdominal cavity for the isolation of peritoneal mast
cells
Figure 4.9 Opened rat peritoneal cavity showing mesentries (which contains
peritoneal mast cells) attached along intestinal portion.
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4.10.5 Carrageenin-induced hind paw edema in rats
(Acute inflammation model) (Winter et al., 1962)
The acute hind paw edema was produced by injecting 0.1 ml of carrageenan
(freshly prepared as 1% suspension in 1% CMC) locally into the plantar
aponeurosis of the right hind paw of rats (Winter et al., 1962) (Figure 4.10).
EESX (50, 100, 200, and 400 mg/kg, p.o.) was administered to four different
groups while the other two groups served as negative, and positive controls,
and received vehicle (1 ml/kg, p.o.), and standard drug, acetylsalicylic acid
(ASA, 300 mg/kg, p.o.), respectively. For each treatment group six animals
were used. Different doses of the test compounds, and ASA were
administered 1 h prior to the injection of carrageenan. A mark was made at
the ankle joint of the paw of rat and pedal volume up to this point was
measured using plethysmometer at 0 h (just before) and 1-, 2- and, 3-h post-
carrageenan injections. Increase in the paw edema volume was considered
as the difference between 0 and 1-, 2-, or 3-h. Percent inhibition of edema
volume between treated and control groups was calculated as follows:
Percent inhibition = 1 – VT/VC × 100
Where, VC,  and  VT represent the mean increase in paw volume in
control and treated groups, respectively.
All the animals were fasted for 12 h and deprived of water only during
the experiment. The deprivation of water was to ensure uniform hydration and
to minimize variability in oedematous response.
4.10.6 Dextran-induced oedema in rats
(Sub-acute inflammation model)
Sub-acute oedema (Winter, 1964) in one of the hind paws of the rat was
induced by the subplantar injection of 0.1 ml freshly prepared 6% (w/v)
dextran (a phlogistic agent) (Sigma Chemical Co., St. Louis, MO) in normal
saline. The paw volume was measured before, and 3 h after the phlogistic
injection. Different doses of the test and reference drug dissolved/suspended
in normal saline was given p.o. 1 h before the dextran injection. Percent
inhibition of edema volume between treated and control groups were
calculated as follows:
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Percent inhibition = 1 – VT/VC × 100
Where, VC,  and  VT represent the mean increase in paw volume in
control and treated groups, respectively.
4.10.7 Formaldehyde-induced hind paw volume
 (Sub-acute inflammation model)
The test was performed according to the technique developed by Brownlee
(1950). Pedal inflammation was induced by injecting 0.1 ml of 4%
formaldehyde solution below the plantar aponeurosis of the right hind paw of
the rats. The paw volume was recorded immediately prior to compound
administration (0 h), and then at 1.5 h, and 24 h after formaldehyde injection.
Vehicle (1 ml/kg, p.o.), different doses of the test compounds, and standard
drug, ASA (300 mg/kg, p.o.) were administered 1 h prior to formaldehyde
injection. Percent inhibition of edema volume between treated, and control
groups were calculated as follows:
Percent inhibition = 1 – VT/VC × 100
Where, VC,  and  VT represent the mean increase in paw volume in
control and treated groups, respectively.
4.10.8 Cotton pellet granuloma in rats
 (Chronic inflammation model)
The effect of test drugs at different concentration on chronic or proliferative
phase of inflammation was assessed in cotton pellet granuloma rat model as
described by Winter and Porter, (1957). Autoclaved cotton pellets weighing 10
± 1 mg each were implanted subcutaneously through small incision made
along the axilla region of the rats anesthetized with thiopental sodium (45
mg/kg, i.p.). The different groups of rats were administered with different
doses of the test compounds, and prednisolone (10 mg/kg, p.o.) once daily for
7 consecutive days from the day of cotton pellet insertion. The control group
received vehicle (1 ml/kg, p.o.). On the eighth day, all the rats were
anaesthetized and the cotton pellets covered by the granulomatous tissue
were excised and dried in hot air oven at 600C till a constant weight was
achieved. Granuloma weight was obtained by subtracting the weight of dry
cotton pellet on 0 day (before start of experiment) from the weight of the dry
Materials and methods
Dept. of Pharm. Sci., Saurashtra University, Rajkot, Gujarat, India85
cotton pellet on eighth day. Percent inhibition of granuloma formation between
treated, and control group was calculated using following formula:
Percent inhibition = 1 – VT/VC × 100
Where, VC, and VT represent the mean increase in granuloma
formation in control and treated groups, respectively.
4.11 Data analysis
The data are presented as mean ± S.E.M.  Statistical significance was
determined using One-way Analysis of Variance (ANOVA) followed by
Dunnett’s t-test or Chi-square test with Yate’s correction factor. Differences
were considered significant at P < 0.05.
4.12 Phytochemical screening of ethanolic extracts of
different plants (Khandelwal, 2000; Handa & Kapoor, 2005; Harborne,
2006)
Ethanolic extracts were chemically tested to know the presence of different
primary, and secondary metabolites present in them as per the following
scheme:
4.12.1 Tests for sterol/steroids
4.12.1.1 Salkowaski test
Few mg of the sample was taken in 2 ml of chloroform and 2 ml of
concentrated sulphuric acid and shaken. The development of red color in the
chloroform layer indicates the presence of sterols/steroids.
4.12.2 Test for terpenoids
4.12.2.1 Liebermann–Burchard test
Few mg of the sample was dissolved in 1 ml of chloroform and few drops of
acetic anhydride. Concentrated sulphuric acid was added by the side of the
test tube. Production of purple color indicates the presence of triterpenoids
and blue–green color indicates the presence of sterols.
4.12.3 Test for alkaloids
Few mg of the sample was taken in 5 ml of 1.5% v/v hydrochloric acid and
filtered.  The filtrate was then tested using following reagents:
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4.12.3.1 Dragendorff’s reagent
It is a solution of potassium bismuth iodide. It was prepared by dissolving
bismuth nitrate (8 gm) in nitric acid (20 ml), and separately dissolving
potassium iodide (27.2 gm) in water (50 ml), mixing the two solutions, and
making up the volume to 100 ml. Above Dragendorff’s reagent was sprayed
on Whatman No. 1 filter paper then the paper was dried. The test filtrate after
basification with dilute ammonia was extracted with chloroform and the
chloroform extract was applied on the filter paper, impregnated with
Dragendorff’s reagent, with the help of a capillary tube.  Development of an
orange red color on the paper indicated the presence of alkaloids.
4.12.3.2 Mayer’s Reagent
1.36 gm of mercuric chloride, and 3 gm of potassium iodide were dissolved in
water to make 100 ml. To a little of each extract taken in dilute hydrochloric
acid in a watch glass, few drops of the reagent was added, formation of cream
colored  precipitate shows  the presence of alkaloid.
4.12.3.3 Hager’s reagent
It is a saturated solution of picric acid in water. When the test filtrate was
treated with this reagent, yellow precipitate was obtained indicating the
presence of alkaloids.
4.12.3.4 Wagner’s Reagent
It is a solution of potassium triiodide in water which was prepared by
dissolving 1.3 gm iodine in a solution of potassium iodide (2 gm) in water to
make 100 ml. Formation of brown precipitate after addition of this reagent in
extract indicates the presence of alkaloids.
4.12.4 Test for tannins
Sample was taken separately in water, warmed, and filtered.  Tests were
carried out with the filtrate using following reagents:
4.12.4.1 Ferric chloride test
A 5% w/v solution of ferric chloride in 90% alcohol was prepared.  Few drops
of this solution were added to a little of the above filtrate. Dark green or deep
blue color shows the presence of tannins.
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4.12.4.2 Lead acetate test
A 10% w/v solution of basic lead acetate in distilled water was added to the
test filtrate.  Precipitate indicates the presence of tannins.
4.12.5 Test for flavonoids
4.12.5.1 Shinoda test
To the sample, 5 ml of 95% ethanol, few drops of HCl, and few magnesium
turnings were added. The pink color shows the presence of flavonoids.
4.12.6 Test for carbohydrates
4.12.6.1 Molisch's test
About 0.1 gm of the sample was dissolved in 2 ml of water, and added 2-3
drops of 1% ethanolic solution of alpha naphthol, and then carefully poured 2
ml of concentrated sulphuric acid down the side of the test tube so that it
forms a heavy layer at the bottom. A deep violet color is produced if
carbohydrates are present.
4.12.6.2 Fehling‘s test
1 ml of Fehling’s A and 1 ml of Fehling’s B solutions were mixed and boiled
for 1 minute. Equal volume of sample was then added, heated in boiling water
bath for 5-10 minutes. First a yellow then brick red color shows the presence
of carbohydrates.
4.12.6.3 Benedict’s test
Equal volumes of the reagent, and sample were added. Mixture was then
boiled for five minutes. Depending on the reducing sugar present a range of
colors develops.
 4.12.7 Test for proteins
4.12.7.1 Biuret test
To the sample 4% NaOH, and few drops of 1% CuSO4 were added. Violet or
pink color indicates the presence of proteins.
4.12.7.2 Xanthoproteic test
Sample was mixed with 1 ml of concentrated sulphuric acid, formation of
precipitate shows positive test.
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4.12.7.3 Millon‘s test
3 ml of sample was mixed with Millon‘s reagent, formation of precipitate
indicates the presence of proteins.
4.12.8 Test for saponins
4.12.8.1 Foam test
A few mg of the sample was shaken vigorously with water. Honeycomb like
foam indicates the presence of saponins.
4.12.8.2 Heamolytic test
Sample was added to one drop of blood placed on glass slide. Hemolytic
zone indicated the presence of saponins.
4.12.9 Test for anthraquinone glycosides
4.12.9.1 Borntrager’s test
To 3 ml of the sample, dilute sulphuric acid was added, boiled, and flittered.
To the filtrate equal volume of chloroform was added, and shaken. After
separating the organic layer, ammonia was added. Turning pink of ammonical
layer indicates the presence of said glycosides.
4.12.10 Test for cardiac glycosides
4.12.10.1 Keller-Kiliani test
The sample was dissolved in acetic acid containing trace amounts of ferric
chloride. It was then transferred to the surface of concentrated sulphuric acid.
A reddish brown ring will be formed at the junction, and the color slowly
changes to blue.
4.12.10.2 Legal’s test
A few drops of pyridine, and sodium nitroprusside were added to the sample,
and made alkaline. A pink or red color is obtained.
4.13 Thin layer chromatography (TLC)
 TLC studies were carried out for different ethanolic plant extracts. The
different solvent systems of different polarities were prepared, and TLC studies
were carried out to select the solvent system capable of showing better
resolution.
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4.13.1 TLC procedure (Wagner, 1996)
Preparation of extracts: 100 mg of ethanolic extract of different plants
were separately dissolved in 10 ml ethanol.
Adsorbent    : Silica gel G (activated)
Plate size   : 5 x 15 cm
Thickness   : 0.4 mm
Activation temperature   :  110°C for 10 min
Solvent system  : For alkaloids:
     Toluene:Ethyl acetate (85:15) or
Tolune:ethyl acetate (93:7)
     For Flavonoids:
Ethyl acetate:formic acid:glacial acetic
acid:water (10:1.1:1.1:2.6)
For saponins:
Chloroform:glacial acetic acid:methanol:water
(64:32:12:08)
4.13.2. Chromatography chambers, conditions of saturation
and the development of TLC plates
Rectangular glass chambers were used for chromatography. To avoid
insufficient chamber saturation, and undesirable edge effect, a smooth sheet
of filter paper was placed (in U shape) in TLC chamber, and was allowed to
be in the developing solvent. Having been moistened, the paper was then
pressed against the walls of the chamber, so that it adhered to the walls. A
number of developing solvent systems were tried during the study. Each time
the plate was treated with one of the following reagents: sprayed with
Dragendorff reagent; or sprayed with anisaldehyde-sulphuric acid and heated
at 1100C for 5 minutes; or treated with 1% AlCl3 in methanol and observed
under UV light; or sprayed with Lieberman Burchard reagent and heated at
1000C for 5 minutes. Number of spots, color, and Rf values were recorded.
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5. Results
5.1 Extraction
Dried leaf powders of different collected plants (500 gm) were defatted with
petroleum ether (60-800C), and then extracted with ethanol (95% w/v) to get
concentrated ethanol extract. The yields of different plant extracts were as
follows: EESX (20.48% w/w), EEAM (11.45% w/w), EECB (9.48% w/w),
EEMK (6.96% w/w). Summary of different extracts, their consistency and yield
values are given in Table 5.1.
Table 5.1
Ethanolic extracts of various plants with their appearance and yield (in
gm)
S. No. Extracts Color and consistency of dried
extracts
Yield (% w/w)
1 EESX Dark brownish green, oily 20.48
2 EEAM Dark brown, sticky 11.45
3 EECB Dark greenish, oily 9.48
4 EEMK Dark brownish green, sticky 6.96
5.2 Acute toxicity test (Determination of LD50)
The results of acute toxicity study (LD50) are shown in Table 5.2. The LD50 of
the EESX, EEAM, and polyherbal formulations I and II was calculated to be
2262.7 mg/kg, whereas, LD50 of the EECB and EEMK was calculated to be
1131.4 by oral route. During the acute toxicity study, animals were observed
for gross behavioral and morphological changes (respiratory distress,
immobility, convulsion, loss of righting reflex etc.). Based on the results of
acute study, doses were then selected. The plant extracts did not produce any
significant changes in the normal behavior of the animals, and no toxic
symptoms were seen at the dose levels studied.
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Table 5.2
Acute toxicity tests of ethanolic extracts of S. xanthocarpum, A. marmelos, C.
bonducella, M. koenigii, and polyherbal formulations I and II
Dose
(mg/kg)
Death pattern at 24 h after treatment
EESX EEAM EECB EEMK
Polyherbal
formulation I
Polyherbal
formulation II
Stage I
10 0/3 0/3 0/3 0/3 0/3 0/3
100 0/3 0/3 0/3 0/3 0/3 0/3
1000 0/3 0/3 0/3 0/3 0/3 0/3
Stage II
200 0/1 0/1 0/1 0/1 0/1 0/1
400 0/1 0/1 0/1 0/1 0/1 0/1
800 0/1 0/1 0/1 0/1 0/1 0/1
1600 0/1 0/1 1/1 1/1 0/1 0/1
3200 1/1 1/1 ---- --- 1/1 1/1
Determination of LD50 for EESX, EEAM, and polyherbal formulation I and II
LD50 = (1600 × 3200)1/2 = 2262.7 mg/kg, p.o.
Determination of LD50 for EECB, EEMK
 LD50 = (800 × 1600)1/2 = 1131.4 mg/kg, p.o.
Results
Dept. of Pharm. Sci., Saurashtra University, Rajkot, Gujarat, India92
5.3 Effect of different plant extracts, and polyherbal
formulations on compound 48/80-induced in vitro mast cell
degranulation in rats
In the control study, 33% of mast cells were degranulated. Addition of DSCG
(20 µg/ml), EESX (10-100 µg/ml), EEMK (100 µg/ml) or the polyherbal
formulations I and II (100 µg/ml) reduced the percentage of degranulation (P <
0.01) compared to the control group. Compound 48/80 (10 µg/ml) produced
about 76% degranulation of mast cells. Pretreatment with DSCG (20 µg/ml),
EESX (10-100 µg/ml), EEAM (100 µg/ml), EEMK (1, 10, and 100 µg/ml) or the
polyherbal formulations I (10-100 µg/ml), and II (1, 10, and 100 µg/ml)
significantly reduced (P < 0.01) degranulation of mast cells as compared to
compound 48/80-treated control group (Figure 5.1). The protection given by
them at higher concentrations was comparable to that of DSCG, a potent
mast cell stabilising agent. Interestingly, EECB failed to produce any
significant effect where as higher dose of EEMK produced significant effect on
mast cell degranulation induced by compound 48/80 (Table 5.3 and Figures
5.2, 5.3).
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Figure 5.1 Effect of various treatments on compound 48/80-induced
peritoneal mast cell degranulation in rats. The figure shows more numbers
of degranulated mast cells in (A) positive control (vehicle treated) group, and
(B) negative control (compound 48/80 treated) group.  The treatments with (C)
disodium cromoglycate (20 µg/ml), EtOH extract of (D) S. xanthocarpum (10,
100 µg/ml), (F) A. marmelos (100 µg/ml), and (G) M. koenigii (1, 10, and 100
µg/ml), (H) polyherbal formulation I (10, 100 µg/ml) and (I) polyherbal
formulation II (1, 10, 100 µg/ml) significantly protected mast cells (P < 0.01) as
compared to compound 48/80-treated group. EtOH extract of C. bonducella
(E) was devoid of protective effect. (The pointed arrow indicates degranulated
rat peritoneal mast cells; magnification for all photo plates: 450X).
A C
D F
HG I
B
450X
E
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Table 5.3
Effect of ethanolic extracts of S. xanthocarpum, A. marmelos, C. bonducella,
and M. koenigii and polyherbal formulations I and II on mast cell
degranulationa
Pre-treatment (µg/ml) Degranulation after treatment (%)
Vehicle
Compound 48/80
(10 µg/ml)
Vehicle 33.4 ± 0.93 75.8 ± 1.36b
DSCG (20) 12.8 ± 3.07** 20 ± 1.79##
EESX (1) 24 ± 2.91ns 68.4 ± 2.42ns
EESX (10) 20.6 ± 2.64* 32.8 ± 1.96##
EESX (100) 17.8 ± 1.59** 41.6 ± 3.33##
EEAM (1) 25.6 ± 2.23ns 71.6 ± 3.12ns
EEAM (10) 26.8 ± 1.88ns 68 ± 2.37ns
EEAM (100) 25.8 ± 4.32ns 53.6 ± 2.68##
EECB (1) 24.4 ± 2.4ns 76.8 ± 3.97ns
EECB (10) 23.6 ± 3.16ns 70.4 ± 2.93ns
EECB (100) 25.6 ± 2.62ns 66.8 ± 3.23ns
EEMK (1) 26.4 ± 3.12ns 38.4 ± 2.54##
EEMK (10) 24.8 ± 3.15ns 32.8 ± 1.56##
EEMK (100) 17.4 ±1.03** 23.4 ± 1.97##
Polyherbal formulation-I (1) 27.6 ± 2.44ns 72.4 ± 1.54ns
Polyherbal formulation-I (10) 26.8 ± 4.08ns 63.8 ± 2.27#
Polyherbal formulation-I (100) 15.6 ± 2.29** 54.6 ± 3.80##
Polyherbal formulation-II (1) 27.4 ± 2.16ns 57.4 ± 2.32##
Polyherbal formulation-II (10) 25.8 ± 2.18ns 45.8 ± 2.31##
Polyherbal formulation-II (100) 17.6 ± 1.94** 30.4 ± 0.81##
aEach value represents the mean ± S.E.M. of five observations; nsNot
significant, bP < 0.01 vs vehicle control group; *P < 0.05, **P < 0.01 vs. control
(vehicle treated), One-way ANOVA followed by Dunnett’s t-test; #P < 0.05, ##P
< 0.01 vs. control (Compound 48/80 treated), One-way ANOVA followed by
Dunnett’s t-test.
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Figure 5.2 Effect of ethanolic extracts of S. xanthocarpum, A. marmelos, C. bonducella, M. koenigii leaves, and
polyherbal formulation-I, and II on mast cell degranulation (before compound 48/80 treatment)
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Each value represents the mean ± S.E.M. of five observations; *P < 0.05, **P < 0.01 vs. control (vehicle treated); One-
way ANOVA followed by Dunnett’s t-test. C-Control group, DSCG-Disodium chromoglycate; EESX-EtOH extract of
S. xanthocarpum; EEAM-EtOH extract of A. marmelos; EECB-EtOH extract of C. bonducella; EEMK-EtOH extract of
M. koenigii; PHF-Polyherbal formulation.
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Figure 5.3 Effect of ethanolic extracts of S. xanthocarpum, A. marmelos, C. bonducella, M. koenigii leaves, and
polyherbal formulation-I, and II on mast cell degranulation (After compound 48/80 treatment)
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Data represents mean ± S.E.M. of five observations; *P < 0.05, **P < 0.01 vs. control (Compound 48/80 treated); One-
way ANOVA followed by Dunnett’s t-test. C-Control group, DSCG-Disodium chromoglycate; EESX-EtOH extract of
S. xanthocarpum; EEAM-EtOH extract of A. marmelos; EECB-EtOH extract of C. bonducella; EEMK-EtOH extract of
M. koenigii; PHF-Polyherbal formulation.
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5.4 Histamine-induced bronchospasm in guinea pigs
The results are summarised in Tables 5.4, 5.5, and Figure 5.4. Histamine
aerosol produced bronchoconstriction in all control group animals. All control
animals showed convulsion during the first 3 min of the experiment.
The polyherbal formulations I (150 mg/kg, i.p.), and II (300 mg/kg, i.p.)
significantly protected animals (P < 0.01) from histamine-induced
bronchoconstriction.
Prior treatment of EESX (200, and 300 mg/kg, i.p.) offered significant
protection to guinea-pigs against histamine aerosol-induced bronchospasm (P
< 0.01). EEAM at the doses 200, and 300 mg/kg, i.p. significantly protected
guinea-pigs against histamine aerosol-induced bronchospasm (P < 0.01).
EECB showed protective effect at the doses 300, and 400 mg/kg, i.p.
Pretreatment with EEMK at the dose 300 mg/kg (P < 0.05), and 400 mg/kg (P
< 0.01) protected guinea-pigs from bronchospasm. Mepyramine (a standard
anti-histaminic drug, 8 mg/kg, i.p.) significantly protected 90% of animals from
asphyxia (P < 0.001).
However, prior treatment with EESX (50, and 100 mg/kg), EEAM (50,
and 100 mg/kg), EECB (100, and 200 mg/kg) and EEMK (100, and 200
mg/kg) could not offer protection from the development of asphyxia produced
by histamine aerosol.
Table 5.4
Effect of polyherbal formulations I and II on histamine-aerosol in guinea pigsa
Treatment Dose (mg/kg, i.p.) Protection (%)
Control (saline, 1 ml/kg, p.o.) - 0
Mepyramine 8 90***
Polyherbal-1 150 70**
Polyherbal-2 300 80**
an = 10 in each group; **P < 0.01, ***P < 0.001 vs. control; (?2 with Yate’s
correction)
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Table 5.5
Effect of ethanolic extracts of S. xanthocarpum, A. marmelos, C. bonducella,
and M. koenigii leaves on histamine-aerosol in guinea pigsa
Treatment Dose (mg/kg, i.p.) Protection (%)
Control saline, 1 ml/kg 0
Mepyramine 8 90***
EESX 50 10
100 30
200 80**
300 70**
EEAM 50 10
100 40
200 80**
300 80**
EECB 100 0
200 30
300 70**
400 80**
EEMK 100 0
200 40
300 60*
400 70**
an = 10 in each group; *P < 0.05, **P < 0.01, ***P < 0.001 vs. control; (?2 with
Yate?s correction)
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Figure 5.4 Effect of ethanolic extracts of S. xanthocarpum, A. marmelos, C. bonducella, M. koenigii leaves, and
polyherbal formulation-I, and II on histamine-induced bronchospasm in guinea pigs.
*P < 0.05, **P < 0.01, ***P < 0.001 vs. control; n = 10 for each group; ?2 test with Yate?s correction. C-Control group,
Mep-Mepyramine; EESX-EtOH extract of S. xanthocarpum; EEAM-EtOH extract of A. marmelos; EECB-EtOH extract
of C. bonducella; EEMK-EtOH extract of M. koenigii; PHF-Polyherbal formulation.
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5.5 Acetylcholine-induced bronchospasm in guinea pigs
The results are summarised in Tables 5.6, 5.7, and Figure 5.5. Acetylcholine-
aerosol produced bronchoconstriction in all animals of control group.
The polyherbal formulations I (150 mg/kg, i.p.), and II (300 mg/kg, i.p.)
significantly protected animals (P < 0.01) from acetylcholine-induced
bronchoconstriction.
Prior treatment of EESX (50, 100, 200, and 300 mg/kg, i.p.), and EECB
(100, 200, 300, and 400 mg/kg, i.p.) could not offered significant protection to
guinea-pigs against acetylcholine aerosol-induced bronchospasm.
EEAM at the doses 100, 200, and 300 mg/kg, i.p. significantly
protected guinea-pigs (P < 0.01) against acetylcholine aerosol-induced
bronchospasm. Pretreatment with EEMK (200, 300, and 400 mg/kg, i.p.)
significantly protected (P < 0.01) guinea-pigs from acetylcholine-induced
bronchospasm.
However, prior treatment with, EEAM (50 mg/kg, i.p.), and EEMK (100
mg/kg, i.p.) could not offer protection from the development of asphyxia
produced by acetylcholine aerosol.
Atropine sulfate (a standard anti-muscarinic drug, 2 mg/kg, i.p.)
significantly prolonged pre-convulsion time to 460 ± 4.33 sec (P < 0.01) and
protected animals from asphyxia.
Table 5.6
Effect of polyherbal formulations I and II on acetylcholine-aerosol-induced
bronchospasm in guinea pigsa
Treatment
Dose (mg/kg,
i.p.)
Preconvulsion time
(sec)
Protection
(%)
Control saline, 1.0 ml/kg 128 ± 2.72 -
Atropine 2 460 ± 4.33 72.17**
Polyherbal formulation-1 150 210 ± 3.18 39.04**
Polyherbal formulation-2 300 285 ± 3.70 55.08**
aValues are mean ± S.E.M. (n = 5); **P < 0.01 vs. control; Dunnett’s t-test
after One-way ANOVA.
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Table 5.7
Effect of ethanolic extracts of S. xanthocarpum, A. marmelos, C. bonducella,
and M. koenigii leaves on acetylcholine-aerosol-induced bronchospasm in
guinea pigsa
Treatment
Dose
(mg/kg, i.p.)
Preconvulsion time
(sec)
Protection (%)
Control saline, 1 ml/kg 128 ± 2.72 -
Atropine 2 460 ± 4.33 72.17**
EESX 50 130 ± 1.38 1.53ns
100 135 ± 2.98 5.18ns
200 133 ± 2.32 3.76ns
300 130 ± 2.02 1.53ns
EEAM 50 131 ± 3.58 2.30ns
100 193 ± 4.14 33.67**
200 287 ± 3.56 55.4**
300 280 ± 5.98 54.28**
EECB 100 129 ± 3.43 0.01ns
200 133 ± 3.67 3.76ns
300 131 ± 3.86 2.29ns
400 135 ± 4.53 5.18ns
EEMK 100 141 ± 4.15 9.21ns
200 203 ± 3.74 36.94**
300 298 ± 5.03 57.04**
400 295 ± 5.05 56.61**
aValues are mean ± S.E.M. (n = 5); nsNot significant, **P < 0.01 vs. control;
Dunnett’s t-test after One-way ANOVA.
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Figure 5.5 Effect of ethanolic extracts of S. xanthocarpum, A. marmelos, C. bonducella, and M.
koenigii leaves and polyherbal formulation-I, and II on acetylcholine-aerosol-induced bronchospasm
in guinea pigsa
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Data are presented as mean ± S.E.M. (n = 5); **P < 0.01 vs. control; One-way ANOVA followed by Dunnett’s
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formulation.
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5.6 Carrageenan-induced rat paw edema
The Tables 5.8, 5.9, and Figures 5.7, 5.8, and 5.9 show results of the effect of
various plant extracts and polyherbal formulations on carrageenan-induced rat
paw edema.
The injection of carrageenan into hind paw of rat provoked
inflammatory reactions marked by edema in the paw (Figure 5.6). The
polyherbal formulations I (150 mg/kg, p.o.), and formulation II (300 mg/kg,
p.o.) reduced the paw edema to 0.50 ± 0.03 ml, and 0.45 ± 0.03 ml,
respectively (percentage inhibition of edema was 30.55%, and 37.50%,
respectively) at 1 h, which was highly significant (P < 0.01), when compared
to the control group of animals. The polyherbal formulations I (150 mg/kg,
p.o.), and formulation II (300 mg/kg, p.o.) reduced the inflammatory increase
in paw volume to 0.45 ± 0.03 ml, and 0.40 ± 0.03 ml at 2 h, respectively
(percentage inhibition of edema was 47.67%, and 53.48%, respectively),
which was highly significant (P < 0.01), when compared to control animals.
The polyherbal formulations I (150 mg/kg, p.o.), and formulation II (300 mg/kg,
p.o.) significantly reduced edema to 0.60 ± 0.03 ml, and 0.50 ± 0.03 ml,
respectively at 3 h (percentage inhibition of edema was 36.84%, and 47.36%,
respectively), which was highly significant (P < 0.01), when compared to the
control group of animals.
The EESX at the doses of 100, 200, and 300 mg/kg, p.o. reduced the
paw edema to 0.55 ± 0.03 ml, 0.35 ± 0.03, and 0.33 ± 0.03 ml, respectively
(percentage inhibition of edema was 23.61%, 51.38%, and 54.16%,
respectively) at 1 h, which was highly significant (P < 0.01), when compared
to the control group of animals. The EESX at the dose of 100, 200, and 300
mg/kg reduced the inflammatory increase in paw volume to 0.58 ± 0.02 ml,
0.39 ± 0.02 ml, and 0.41 ± 0.02 ml at 2 h, respectively (percentage inhibition
of edema was 32.55%, 54.65%, and 52.32%, respectively), which was highly
significant (P < 0.01), when compared to control animals. Also at the doses
100 mg, 200 mg, and 300 mg, EESX significantly reduced edema to 0.65 ±
0.02 ml, 0.51 ± 0.02 ml, 0.52 ± 0.03 ml, respectively at 3 h (percentage
inhibition of edema was 31.57%, 46.31%, and 45.26%, respectively), which
was highly significant (P < 0.01), when compared to the control group of
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animals. Interestingly, EESX at the dose of 50 mg/kg failed to produce any
significant reduction in the inflammatory increase in paw volume at any point
of time measurement (1 h, 2 h or 3 h).
The EEAM at the doses of 100, 200, and 300 mg/kg, p.o. reduced the
paw edema to 0.62 ± 0.04 ml, 0.38 ± 0.02, and 0.41 ± 0.02 ml, respectively
(percentage inhibition of edema was 15.06% (P < 0.05), 47.22%, and 43.05%,
respectively) at 1 h, which was highly significant (P < 0.01), when compared
to the control group of animals. The EEAM at the dose of 100, 200, and 300
mg/kg reduced the inflammatory increase in paw volume to 0.64 ± 0.03 ml,
0.45 ± 0.04 ml, and 0.47 ± 0.02 ml at 2 h respectively (percentage inhibition of
edema was 25.58%, 47.67%, and 45.34% respectively), which was highly
significant (P < 0.01), when compared to control animals. Interestingly, EEAM
at 100, 200, and 300 mg/kg doses did not produce significant reduction in
edema at 3 h. EEAM (50 mg/kg) failed to produce any significant reduction in
the inflammatory increase in paw volume at any point of time measurement (1
h, 2 h or 3 h).
The EECB (200, 300, and 400 mg/kg, p.o.) was devoid of any inhibitory
action on paw edema at 1 h, and 2 h when compared to the control group of
animals. However at 3 h, EECB (200, 300, and 400 mg/kg, p.o.) significantly
reduced the inflammatory increase in paw volume to 0.71 ± 0.03 ml, 0.58 ±
0.02 ml, and 0.60 ± 0.03 ml, respectively (percentage inhibition of edema was
25.26%, 38.94%, and 36.84%, respectively), which was highly significant (P <
0.01), when compared to control animals. EECB at the dose of 100 mg/kg
failed to produce any significant reduction in the inflammatory increase in paw
volume at any point of time measurement (1 h, 2 h or 3 h).
The EEMK at the doses of 300, and 400 mg/kg, p.o. reduced the paw
edema to 0.45 ± 0.03 ml, and 0.47 ± 0.04 ml, respectively (percentage
inhibition of edema was 37.5%, and 34.72%, respectively) at 1 h, which was
highly significant (P < 0.01), when compared to the control group of animals.
The EEMK at the dose of 200, 300, and 400 mg/kg reduced the inflammatory
increase in paw volume to 0.68 ± 0.02 ml, 0.56 ± 0.02 ml, and 0.57 ± 0.04 ml
at  2  h, respectively (percentage inhibition of edema was 20.93%, 34.88%,
and 33.72%, respectively), which was highly significant (P < 0.01), when
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compared to control animals. Also, at the doses 100 mg, 200 mg, 300 mg,
and 400 mg, EEMK significantly reduced edema to 0.83 ± 0.03 ml (P < 0.05),
0.78 ± 0.04 ml, 0.61 ± 0.02 ml, 0.62 ± 0.04 ml, respectively at 3 h (percentage
inhibition of edema was 12.63%, 17.89%, 35.78%, and 34.73%, respectively)
which was highly significant (P < 0.01), when compared to the control group of
animals. Interestingly, EEMK at the dose of 100 mg/kg failed to produce any
significant reduction in the inflammatory increase in paw volume at 1 h, and 2
h.
ASA (a standard anti-inflammatory drug, 300 mg/kg, p.o.) was devoid
of any inhibitory action on reduction of paw edema volume up to 2 h, which
had very less effect than that of the various plant extracts for the same time
points. However at 3 h time point, ASA markedly reduced the inflammatory
increase in paw volume to 0.46 ± 0.02 ml. The percentage inhibition of edema
was 51.57% (P < 0.01). The inhibition was more than any of the plant extracts
at 3 h.
Figure 5.6 Carrageenan-induced rat paw edema.  The figure shows (A)
normal paw of rat and (B) swelling (edema) at 3 h after carrageenan (0.1 ml of
1% solution) injected by subplanter route (The arrow indicates swelling in hind
paw of rat).
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Table 5.8
Effect of polyherbal formulations I, and II on carrageenan-induced rat paw
edemaa
Treatment
Dose
(mg/kg, p.o.)
Paw edema volume (ml) (% Inhibition)
1 h 2 h 3 h
Control saline,1 ml/kg 0.72 ± 0.02 0.86 ± 0.01 0.95 ± 0.01
ASA 300
0.69 ± 0.04
(4.17ns)
0.78 ± 0.03
(9.3ns)
0.46 ± 0.02
(51.57**)
Polyherbal
formulation-1
150
0.50 ± 0.03
(30.55**)
0.45 ± 0.03
(47.67**)
0.60 ± 0.03
(36.84**)
Polyherbal
formulation-2
300
0.45 ± 0.03
(37.50**)
0.40 ± 0.03
(53.48**)
0.50 ± 0.03
(47.36**)
aValues are mean ± S.E.M. (n = 6); nsNot significant, **P < 0.01 vs. control;
Dunnett’s t- test after One-way ANOVA.
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Table 5.9
Effect of ethanolic extracts of S. xanthocarpum, A. marmelos, C. bonducella,
and M. koenigii leaves on carrageenan-induced rat paw edemaa
Treatment
Dose
(mg/kg,
 p.o.)
Paw edema volume (ml)
(% Inhibition)
1 h 2 h 3 h
Control
saline,
1 ml/kg
0.72 ± 0.02 0.86 ± 0.01 0.95 ± 0.01
ASA 300
0.69 ± 0.04
(4.16ns)
0.78 ± 0.03
(9.3ns)
0.46 ± 0.02
(51.57**)
EESX 50
0.70 ± 0.04
(2.77ns)
0.82 ± 0.03
(4.65ns)
0.94 ± 0.03
(1.05ns)
100
0.55 ± 0.03
(23.61**)
0.58 ± 0.02
(32.55**)
0.65 ± 0.02
(31.57**)
200
0.35 ± 0.03
(51.38**)
0.39 ± 0.02
(54.65**)
0.51 ± 0.02
(46.31**)
300
0.33 ± 0.03
(54.16**)
0.41 ± 0.02
(52.32**)
0.52 ± 0.03
(45.26**)
EEAM 50
0.72 ± 0.02
(0.0ns)
0.79 ± 0.03
(8.13ns)
0.94 ± 0.05
(1.05ns)
100
0.62 ± 0.04
(15.06*)
0.64 ± 0.03
(25.58**)
0.93 ± 0.01
(2.10ns)
200
0.38 ± 0.02
(47.22**)
0.45 ± 0.04
(47.67**)
0.93 ± 0.03
(2.10ns)
300
0.41 ± 0.02
(43.05**)
0.47 ± 0.02
(45.34**)
0.94 ± 0.05
(1.05ns)
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EECB 100
0.70 ± 0.02
(2.77ns)
0.85 ± 0.02
(1.16ns)
0.90 ± 0.03
(5.26 ns)
200
0.65 ± 0.02
(9.72ns)
0.85 ± 0.05
(1.16ns)
0.71 ± 0.03
(25.26**)
300
0.65 ± 0.04
(9.72ns)
0.80 ± 0.04
(6.97ns)
0.58 ± 0.02
(38.94**)
400
0.70 ± 0.04
(2.77ns)
0.80 ± 0.04
(6.97ns)
0.6 ± 0.03
(36.84**)
EEMK 100
0.70 ± 0.02
(2.77ns)
0.8 ± 0.01
(6.97ns)
0.83 ± 0.03
(12.63*)
200
0.66 ± 0.04
(8.33ns)
0.68 ± 0.02
(20.93**)
0.78 ± 0.04
(17.89**)
300
0.45 ± 0.03
(37.5**)
0.56 ± 0.02
(34.88**)
0.61 ± 0.02
(35.78**)
400
0.47 ± 0.03
(34.72**)
0.57 ± 0.04
(33.72**)
0.62 ± 0.04
(34.73**)
aValues are mean ± S.E.M. (n = 6); nsNot significant, *P < 0.05, **P < 0.01 vs.
control; Dunnett’s t-test after One-way ANOVA.
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Figure 5.7 Effect of ethanolic extracts of S. xanthocarpum, A. marmelos, C. bonducella, M. koenigii leaves, and
polyherbal formulation-I, and II on carrageenan-induced rat paw edema (at 1 h)
Data are presented as mean ± S.E.M. (n = 6); *P < 0.05; **P < 0.01 vs. control; One-way ANOVA followed by
Dunnett’s t-test. C-Control group, ASA-Aspirin; EESX-EtOH extract of S. xanthocarpum; EEAM-EtOH extract of A.
marmelos; EECB-EtOH extract of C. bonducella; EEMK-EtOH extract of M. koenigii; PHF-Polyherbal formulation.
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Figure 5.8 Effect of ethanolic extracts of S. xanthocarpum, A. marmelos, C. bonducella, M. koenigii leaves, and
polyherbal formulation-I, and II on carrageenan-induced rat paw edema (at 2 h)
Data are presented as mean ± S.E.M. (n = 6); **P < 0.01 vs. control; One-way ANOVA followed by Dunnett’s t-test.
C-Control group, ASA-Aspirin; EESX-EtOH extract of S. xanthocarpum; EEAM-EtOH extract of A. marmelos; EECB-
EtOH extract of C. bonducella; EEMK-EtOH extract of M. koenigii; PHF-Polyherbal formulation.
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Figure 5.9 Effect of ethanolic extracts of S. xanthocarpum, A. marmelos, C. bonducella, M. koenigii leaves, and
polyherbal formulation-I, and II on carrageenan-induced rat paw edema (at 3 h)
Data are presented as mean ± S.E.M. (n = 6); *P < 0.05; **P < 0.01 vs. control; One-way ANOVA followed by
Dunnett’s t-test. C-Control group, ASA-Aspirin; EESX-EtOH extract of S. xanthocarpum; EEAM-EtOH extract of A.
marmelos; EECB-EtOH extract of C. bonducella; EEMK-EtOH extract of M. koenigii; PHF-Polyherbal formulation.
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5.7 Dextran-induced rat paw edema
The Tables 5.10, 5.11, and Figure 5.10 show results of the effect of various
plant extracts, and polyherbal formulations on dextran-induced rat paw
edema.
The polyherbal formulation I (150 mg/kg, p.o.), and formulation II (300
mg/kg, p.o.) reduced the paw edema to 0.50 ± 0.03 ml, and 0.40 ± 0.03,
respectively at 3 h (percentage inhibition of edema was 47.36%, and 57.89%,
respectively) which was highly significant (P < 0.01) when compared to the
control group of animals.
The EESX at the doses 100, 200, and 300 mg/kg, p.o. significantly
reduced the paw edema to 0.65 ± 0.01 ml, 0.45 ± 0.01 ml, and 0.41 ± 0.01 ml,
respectively at 3 h (percentage inhibition of edema was 31.57%, 52.63%, and
56.84%, respectively) which was highly significant (P < 0.01), when compared
to the control group of animals.
The EEAM at the dose of 100, 200, and 300 mg/kg, p.o. reduced the
inflammatory increase in paw volume to 0.67 ± 0.02 ml, 0.49 ± 0.01 ml, and
0.40 ± 0.02 ml, respectively at  3  h (percentage inhibition of edema was
29.47%, 48.42%, and 57.89%, respectively), which was highly significant (P <
0.01) when compared to control animals.
Also EECB at the doses 200 mg, 300 mg, and 400 mg, p.o.
significantly reduced edema to 0.76 ± 0.01 ml, 0.57 ± 0.03 ml, and 0.56 ± 0.02
ml, respectively at 3 h (percentage inhibition of edema was 20.0%, 40.0%,
and 41.05%, respectively), which was highly significant (P < 0.01) when
compared to the control group of animals.
EEMK at the doses 200 mg, 300 mg, and 400 mg, p.o. significantly
reduced edema to 0.74 ± 0.01 ml, 0.57 ± 0.02 ml, and 0.58 ± 0.02 ml,
respectively at 3 h (percentage inhibition of edema was 22.10%, 40.0%, and
38.94%, respectively), which was highly significant (P < 0.01) when compared
to the control group of animals.
Interestingly, EESX (50 mg/kg, p.o.), EEAM (50 mg/kg, p.o.), EECB
(100 mg/kg, p.o.), and EEMK (100 mg/kg, p.o.) failed to produce any
significant reduction in the inflammatory increase in paw volume at 3 h post
dextran injection.
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ASA (a standard anti-inflammatory drug, 300 mg/kg, p.o.), at 3 h post
dextran injection, reduced edema volume to 0.25 ± 0.02 ml. The percentage
inhibition of edema was 73.68% (P < 0.01) which was highest edema
reduction than any of the plant extracts at 3 h.
Table 5.10
Effect of polyherbal formulations I, and II on dextran-induced paw edema in
ratsa
Treatment Dose (mg/kg, p.o.) Paw edema volume (ml) Inhibition (%)
Control saline, 1 ml/kg 0.95 ± 0.02 -
ASA 300 0.25 ± 0.02 73.68**
Polyherbal
formulation-I
150 0.50 ± 0.03 47.36**
Polyherbal
formulation-II
300 0.40 ± 0.03 57.89**
aValues are mean ± S.E.M. (n = 6); nsNot significant, **P < 0.01 vs. control;
Dunnett’s t-test after One-way ANOVA.
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Table 5.11
Effect of ethanolic extracts of S. xanthocarpum, A. marmelos, C. bonducella,
and M. koenigii leaves on dextran-induced rat paw edemaa
Treatment Dose (mg/kg, p.o.) Paw edema volume (ml) Inhibition (%)
Control saline, 1 ml/kg 0.95 ± 0.02 -
ASA 300 0.25 ± 0.02 73.68**
EESX 50 0.93 ± 0.03 2.1ns
100 0.65 ± 0.01 31.57**
200 0.45 ± 0.01 52.63**
300 0.41 ± 0.01 56.84**
EEAM 50 0.95 ± 0.02 0ns
100 0.67 ± 0.02 29.47**
200 0.49 ± 0.01 48.42**
300 0.4 ± 0.02 57.89**
EECB 100 0.94 ± 0.04 1.05ns
200 0.76 ± 0.01 20**
300 0.57 ± 0.03 40**
400 0.56 ± 0.02 41.05**
EEMK 100 0.93 ± 0.02 2.1ns
200 0.74 ± 0.01 22.10**
300 0.57 ± 0.02 40**
400 0.58 ± 0.02 38.94**
aValues are mean ± S.E.M. (n = 6); nsNot significant, **P < 0.01 vs. control;
Dunnett’s t-test after One-way ANOVA.
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Figure 5.10 Effect of ethanolic extracts of S. xanthocarpum, A. marmelos, C. bonducella, M. koenigii leaves, and
polyherbal formulation-I, and II on dextran-induced rat paw edema
Data are presented as mean ± S.E.M. (n = 6); **P < 0.01 vs. control; One-way ANOVA followed by Dunnett’s t-test. C-
Control group, ASA-Aspirin; EESX-EtOH extract of S. xanthocarpum; EEAM-EtOH extract of A. marmelos; EECB-
EtOH extract of C. bonducella; EEMK-EtOH extract of M. koenigii; PHF-Polyherbal formulation.
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5. 8 Cotton pellet granuloma
Tables 5.12, 5.13, and Figure 5.11 show results of the effect of various plant
extracts, and polyherbal formulations on cotton pellet granuloma test in rats.
The polyherbal formulation I (150 mg/kg, p.o.) and, formulation II (300
mg/kg, p.o.) reduced granuloma formation to 90.0 ± 1.70 mg, and 60.10 ±
2.32 mg, respectively (percentage inhibition of granuloma formation was
18.25%, and 45.41%, respectively) which was highly significant (P < 0.01)
when compared to the control group of animals.
The EESX at the doses 100, 200, and 300 mg/kg, p.o. significantly
reduced the granuloma formation to 65.7 ± 1.93 mg, 55.8 ± 1.51 mg, and 55.4
± 1.32 mg, respectively (percentage inhibition of granuloma formation was
40.32%, 49.31%, and 49.68%, respectively) which was highly significant (P <
0.01), when compared to the control group of animals.
The EEAM at the doses 100, 200, and 300 mg/kg, p.o. significantly
reduced the granuloma formation to 95.6 ± 1.13 mg, 92.4 ± 1.86 mg, and 92.3
± 1.41 mg, respectively (percentage inhibition of granuloma formation was
13.16%, 16.07%, and 16.16%, respectively) which was significant (P < 0.01),
when compared to the control group of animals.
The EECB at the doses 200, 300, and 400 mg/kg, p.o. significantly
reduced the granuloma formation to 96.1 ± 3.36 mg, 93.1 ± 1.86 mg, and 93.0
± 1.64 mg, respectively (percentage inhibition of granuloma formation was
12.71%, 15.44%, and 15.53%, respectively) which was highly significant (P <
0.01), when compared to the control group of animals.
The EEMK at the doses 200, 300, and 400 mg/kg, p.o. significantly
reduced the granuloma formation to 94.4 ± 1.12 mg, 91.1 ± 1.0 mg, and 90.1
± 1.28 mg, respectively (percentage inhibition of granuloma formation was
14.25%, 17.25%, and 18.16%, respectively) which was significant (P < 0.01),
when compared to the control group of animals.
Interestingly, EESX (50 mg/kg, p.o.), EEAM (50 mg/kg, p.o.), EECB
(100 mg/kg, p.o.), and EEMK (100 mg/kg, p.o.) failed to produce any
significant reduction in the granuloma formation.
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Prednisolone (a standard chronic anti-inflammatory drug, 10 mg/kg,
p.o.), reduced granuloma formation to 63.4 ± 1.16 mg. The percentage
inhibition of granuloma formation was 42.41% (P < 0.01).
Table 5.12
Effect of polyherbal formulations I, and II on cotton pellet-induced granuloma
in ratsa
Treatment
Dose
(mg/kg, p.o.)
Weight of granuloma (mg) Inhibition (%)
Control saline, 1 ml/kg 110.1 ± 2.20 -
Prednisolone 10 63.4 ± 1.16 42.41**
Polyherbal-1 150 90.0 ± 1.70 18.25**
Polyherbal-2 300 60.1 ± 2.32 45.41**
aValues are mean ± S.E.M. (n = 6); nsNot significant, **P < 0.01 vs. control;
Dunnett’s t-test after One-way ANOVA.
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Table 5.13
Effect of ethanolic extracts of S. xanthocarpum, A. marmelos, C. bonducella,
and M. koenigii leaves on cotton pellet-induced granuloma in ratsa
Treatment
Dose
(mg/kg, p.o.)
Weight of granuloma
(mg)
Inhibition
(%)
Control saline, 1 ml/kg 110.1 ± 2.20 -
Prednisolone 10 63.4 ± 1.16 42.41**
EESX 50 108.5 ± 1.83 1.45ns
100 65.7 ± 1.93 40.32**
200 55.8 ± 1.51 49.31**
300 55.4 ± 1.32 49.68**
EEAM 50 105 ± 1.46  4.63ns
100 95.6 ± 1.13 13.16**
200 92.4 ± 1.86 16.07**
300 92.3 ± 1.41 16.16**
EECB 100 104.3 ± 2.28 5.26ns
200 96.1 ± 3.36 12.71**
300 93.1 ± 1.86 15.44**
400 93 ± 1.64 15.53**
EEMK 100 107.1 ± 1.55 2.72ns
200 94.4 ± 1.12 14.25**
300 91.1 ± 1.00 17.25**
400 90.1 ± 1.28 18.16**
aValues are mean ± S.E.M. (n = 6); nsNot significant, **P < 0.01 vs. control;
Dunnett’s t-test after One-way ANOVA.
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Figure 5.11 Effect of ethanolic extracts of S. xanthocarpum, A. marmelos, C. bonducella, M. koenigii leaves, and
polyherbal formulation-I, and II on cotton pellet granuloma in rats.
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Data are presented as mean ± S.E.M. (n = 6); **P < 0.01 vs. control; One-way ANOVA followed by Dunnett’s t-test. C-
Control group, Pred-Prednisolone; EESX-EtOH extract of S. xanthocarpum; EEAM-EtOH extract of A. marmelos;
EECB-EtOH extract of C. bonducella; EEMK-EtOH extract of M. koenigii; PHF-Polyherbal formulation.
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5. 9 Histamine-induced rat paw edema
The Tables 5.14, 5.15, and Figure 5.12 show the results of the effect of
various plant extracts and polyherbal formulations on histamine-induced rat
paw edema.
The polyherbal formulations I (150 mg/kg, p.o.), and formulation II (300
mg/kg, p.o.) reduced the paw edema to 0.25 ± 0.03 ml, and 0.20 ± 0.02,
respectively at 3 h (percentage inhibition of edema was 30.55%, and 44.44%,
respectively) which was highly significant (P < 0.01) when compared to the
control group of animals.
The EESX at the doses 100, 200, and 300 mg/kg, p.o. significantly
reduced the paw edema to 0.26 ± 0.01 ml, 0.17 ± 0.02 ml, and 0.14 ± 0.01 ml,
respectively at 3 h (percentage inhibition of edema was 27.77%, 52.77%, and
61.11%, respectively) which was highly significant (P < 0.01), when compared
to the control group of animals.
The EEAM at the dose of 100, 200, and 300 mg/kg, p.o. reduced the
inflammatory increase in paw volume to 0.26 ± 0.02 ml, 0.20 ± 0.02 ml, and
0.18 ± 0.02 ml, respectively at  3  h (percentage inhibition of edema was
27.77%, 44.44%, and 50.0%, respectively), which was highly significant (P <
0.01) when compared to control animals.
EECB (100, 200, 300, and 400 mg/kg, p.o.) was devoid of any reducing
effect on edema at  3  h (P > 0.05) when compared to the control group of
animals.
EEMK at the doses 200 mg, 300 mg, and 400 mg, p.o. significantly
reduced edema to 0.20 ± 0.02 ml, 0.18 ± 0.01 ml, and 0.22 ± 0.02 ml,
respectively at 3 h (percentage inhibition of edema was 44.44%, 50.0%, and
38.88%, respectively), which was highly significant (P < 0.01) when compared
to the control group of animals.
EESX (50 mg/kg, p.o.), EEAM (50 mg/kg, p.o.), and EEMK (100 mg/kg,
p.o.) failed to produce any significant reduction in the inflammatory increase in
paw volume at 3 h post histamine injection.
Mepyramine (a standard anti-histaminic drug, 10 mg/kg, p.o.), at 3 h
post histamine injection, reduced edema volume to 0.12 ± 0.01 ml. The
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percentage inhibition of edema was 66.66% (P < 0.01) which was highest
edema reduction than any of the plant extracts at 3 h.
Table 5.14
Effect of polyherbal formulations I, and II on histamine-induced rat paw
edemaa
Treatment
Dose
(mg/kg, p.o.)
Paw edema volume
(ml)
Inhibition (%)
Control saline, 1 ml/kg 0.36 ± 0.02 -
Mepyramine 10 0.12 ± 0.01 66.66**
Polyherbal formulation-1 150 0.25 ± 0.03 30.55**
Polyherbal formulation-2 300 0.20 ± 0.02 44.44**
aValues are mean ± S.E.M. (n = 6); **P < 0.01 vs. control; Dunnett’s t-test
after One-way ANOVA.
Results
Dept. of Pharm. Sci., Saurashtra University, Rajkot, Gujarat, India122
Table 5.15
Effect of ethanolic extracts of S. xanthocarpum, A. marmelos, C. bonducella,
and M. koenigii leaves on histamine-induced rat paw edemaa
Treatment
Dose
(mg/kg, p.o.)
Paw edema volume
(ml)
Inhibition
(%)
Control saline, 1 ml/kg 0.36 ± 0.02 -
Mepyramine 10 0.12 ± 0.01 66.66**
EESX 50 0.31 ± 0.01 13.88ns
100 0.26 ± 0.01 27.77**
200 0.17 ± 0.02 52.77**
300 0.14 ± 0.01 61.11**
EEAM 50 0.34 ± 0.03 5.55ns
100 0.26 ± 0.02 27.77**
200 0.2 ± 0.02 44.44**
300 0.18 ± 0.02 50**
EECB 100 0.31 ± 0.02 13.88ns
200 0.35 ± 0.02 2.77ns
300 0.30 ± 0.03 16.66ns
400 0.30 ± 0.01 16.66ns
EEMK 100 0.34 ± 0.02 5.55ns
200 0.20 ± 0.02 44.44**
300 0.18 ± 0.01 50**
400 0.22 ± 0.02 38.88**
aValues are mean ± S.E.M. (n = 6); nsNot significant, **P < 0.01 vs. control;
Dunnett’s t-test after One-way ANOVA.
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Figure 5.12 Effect of ethanolic extracts of S. xanthocarpum, A. marmelos, C. bonducella, M. koenigii leaves, and
polyherbal formulation-I, and II on histamine-induced rat paw edema
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Data are presented as mean ± S.E.M. (n = 6); **P < 0.01 vs. control; One-way ANOVA followed by Dunnett’s t-test. C-
Control group, Mep-Mepyramine; EESX-EtOH extract of S. xanthocarpum; EEAM-EtOH extract of A. marmelos;
EECB-EtOH extract of C. bonducella; EEMK-EtOH extract of M. koenigii; PHF-Polyherbal formulation.
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5. 10 Formaldehyde-induced rat paw edema
The Tables 5.16, 5.17, and Figures 5.13, 5.14 show the results of the effect of
various plant extracts, and polyherbal formulations on formaldehyde-induced
rat paw edema.
The polyherbal formulations I (150 mg/kg, p.o.), and formulation II (300
mg/kg, p.o.) reduced the paw edema to 0.50 ± 0.02 ml, and 0.40 ± 0.02 ml,
respectively (percentage inhibition of edema was 31.50%, and 45.20%,
respectively) at 1.5 h, which was highly significant (P < 0.01), when compared
to the control group of animals. The polyherbal formulations I (150 mg/kg,
p.o.), and formulation II (300 mg/kg, p.o.) reduced the inflammatory increase
in paw volume to 0.65 ± 0.03 ml, and 0.60 ± 0.03 ml at 24 h, respectively
(percentage inhibition of edema was 32.98%, and 38.14%, respectively),
which was highly significant (P < 0.01), when compared to control animals.
The EESX (50, 100, 200, and 300 mg/kg, p.o.) failed to reduce the paw
edema at 1.5 h. However, at 24 h, EESX at the dose of 100, 200, and 300
mg/kg, p.o. reduced the inflammatory increase in paw volume to 0.80 ± 0.02
ml, 0.61 ± 0.03 ml, and 0.53 ± 0.01 ml, respectively (percentage inhibition of
edema was 17.52%, 37.11%, and 45.36%, respectively), which was highly
significant (P < 0.01), when compared to control animals.
The EEAM (50, 100, 200, and 300 mg/kg, p.o.) was completely devoid
of reducing effect on the paw edema at 1.5, and 24 h post formaldehyde
injection as compared to the control group of animals.
The EECB at the doses of 200, 300, and 400 mg/kg, p.o. reduced the
paw edema to 0.54 ± 0.03 ml, 0.40 ± 0.03 ml, and 0.38 ± 0.02 ml, respectively
(percentage inhibition of edema was 26.02%, 45.2%, and 47.94%,
respectively) at 1.5 h, which was highly significant (P < 0.01), when compared
to the control group of animals. The EECB at the doses of 200, 300, and 400
mg/kg, p.o. reduced the inflammatory increase in paw volume to 0.87 ± 0.03
ml (P < 0.05), 0.69 ± 0.02 ml, and 0.68 ± 0.03 ml at  24  h, respectively
(percentage inhibition of edema was 10.3%, 28.86%, and 29.89%,
respectively), which was highly significant (P < 0.01), when compared to
control animals.
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The EEMK (100, 200, 300, and 400 mg/kg, p.o.) at 1.5 h and the doses
100, and 200 mg/kg, p.o. at 24 h did not reduce the paw edema as compared
to the control group of animals. However, EEMK (300, and 400 mg/kg, p.o.)
significantly reduced the inflammatory increase in paw volume to 0.60 ± 0.02
ml, and 0.65 ± 0.02 ml at 24 h, respectively (percentage inhibition of edema
was 38.14%, and 32.98%, respectively), which was highly significant (P <
0.01), when compared to control animals.
ASA (a standard anti-inflammatory drug), at 300 mg/kg, p.o. dose, was
devoid of any significant action on reduction of paw edema volume up to 1.5
h. However at 24 h time point, ASA reduced the inflammatory increase in paw
volume to 0.86 ± 0.02 ml (percentage inhibition of edema was 31.95%; P <
0.5).
Table 5.16
Effect of polyherbal formulations I, and II on formaldehyde-induced paw
edema in ratsa
Treatment
Dose
(mg/kg, p.o.)
Paw edema volume (ml) Inhibition (%)
1.5 h 24 h 1.5 h 24 h
Control saline, 1 ml/kg 0.73 ± 0.03 0.97 ± 0.02 -- --
ASA 300 0.65 ± 0.02 0.86 ± 0.02 10.95ns 31.95**
Polyherbal
formulation-I
150 0.50 ± 0.02 0.65 ± 0.03 31.50** 32.98**
Polyherbal
formulation-II
300 0.40 ± 0.02 0.60 ± 0.03 45.20** 38.14**
aValues are mean ± S.E.M. (n = 6); nsNot significant, **P < 0.01 vs. control;
Dunnett’s t-test after One-way ANOVA.
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Table 5.17
Effect of ethanolic extracts of S. xanthocarpum, A. marmelos, C. bonducella,
and M. koenigii leaves on formaldehyde-induced rat paw edemaa
Treatment
Dose
(mg/kg, p.o.)
Paw edema volume (ml) Inhibition (%)
1.5 h 24 h 1.5 h 24 h
Control saline, 1 ml/kg 0.73 ± 0.03 0.97 ± 0.02 -- --
ASA 300 0.65 ± 0.02 0.86 ± 0.02 10.95ns 31.95**
EESX 50 0.65 ± 0.03 0.95 ± 0.04 10.95ns 2.08ns
100 0.65 ± 0.02 0.8 ± 0.02 10.95ns 17.52**
200 0.65 ± 0.02 0.61 ± 0.03 10.95ns 37.11**
300 0.66 ± 0.01 0.53 ± 0.01 9.58ns 45.36**
EEAM 50 0.69 ± 0.03 0.92 ± 0.04 5.47 ns 5.15 ns
100 0.70 ± 0.02 0.95 ± 0.01 4.10ns 2.06ns
200 0.70 ± 0.03 0.95 ± 0.04 4.10ns 2.06ns
300 0.70 ± 0.03 0.90 ± 0.02 4.10ns 7.21ns
EECB 100 0.68 ± 0.03 0.93 ± 0.03 6.84 ns 4.12 ns
200 0.54 ± 0.03 0.87 ± 0.03 26.02** 10.3*
300 0.4 ± 0.03 0.69 ± 0.02 45.2** 28.86**
400 0.38 ± 0.02 0.68 ± 0.03 47.94** 29.89**
EEMK 100 0.71 ± 0.02 0.91 ± 0.02 2.73 ns 6.18ns
200 0.71 ± 0.03  0.89 ± 0.03 2.73 ns 8.24ns
300 0.70 ± 0.01  0.6 ± 0.02 4.10ns 38.14**
400 0.70 ± 0.01 0.65 ± 0.02 4.10ns 32.98**
aValues are mean ± S.E.M. (n = 6); nsNot significant, **P < 0.01 vs. control;
Dunnett’s t-test after One-way ANOVA.
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Figure 5.13 Effect of ethanolic extracts of S. xanthocarpum, A. marmelos, C. bonducella, M. koenigii leaves, and
polyherbal formulation-I, and II on formaldehyde-induced rat paw edema (at 1.5 h)
Data are presented as mean ± S.E.M. (n = 6); **P < 0.01 vs. control; One-way ANOVA followed by Dunnett’s t-test. C-
Control group, ASA-Aspirin; EESX-EtOH extract of S. xanthocarpum; EEAM-EtOH extract of A. marmelos; EECB-
EtOH extract of C. bonducella; EEMK-EtOH extract of M. koenigii; PHF-Polyherbal formulation.
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Figure 5.14 Effect of ethanolic extracts of S. xanthocarpum, A. marmelos, C. bonducella, M. koenigii leaves, and
polyherbal formulation-I, and II on formaldehyde-induced rat paw edema (at 24 h)
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Data are presented as mean ± S.E.M. (n = 6); *P < 0.05, **P < 0.01 vs. control; One-way ANOVA followed by
Dunnett’s t-test. C-Control group, ASA-Aspirin; EESX-EtOH extract of S. xanthocarpum; EEAM-EtOH extract of A.
marmelos; EECB-EtOH extract of C. bonducella; EEMK-EtOH extract of M. koenigii; PHF-Polyherbal formulation.
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5.11 Phytochemical screening of different plant extracts
Table 5.18 depicts results of screening of different plant extracts
for various phytochemical constituents. EESX showed the presence of
alkaloids, proteins, anthraquinone glycosides, flavonoids, saponins,
sterols, tannins, and carbohydrates. EEAM was found to contain
alkaloids, flavonoids, saponins, steroids, and tannins. EECB showed
presence of alkaloids, proteins, flavonoids, saponins, sterols, tannins,
and carbohydrates. EEMK contained alkaloids, flavonoids, saponins,
sterols. The results of the TLC study are mentioned in the Table 5.19-
5.22 and Figures 5.15-5.18.
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Table 5.18 Phytoconstituents present in different plant extracts
Plant
constituents Tests/Reagents EESX EEAM EECB EEAM
Sterols/
terpenoids/
steroids
Salkowaski test + + + +
Liebermann-
Burchard reagent
+ + + +
Alkaloids Dragendorff’s
reagent
+ + + +
Mayer’s reagent + + + +
Hager’s reagent + - + +
Wagner’s reagent + + + +
Tannins Ferric chloride
solution
+ + + -
Lead acetate
solution
+ + + -
Flavonoids Shinoda test + + + +
Lead acetate
solution
+ + + +
Carbohydrates Molisch’s test + - + -
Fehling’s reagent + - + -
Benedict reagent  + - + -
Proteins Biuret test + - + -
Xanthoproteic test + - - -
Millon’s reagent + - + -
Saponins Foam test + + + +
Hemolytic test + + + +
Anthraquinone
glycosides
Borntrager’s test + - - -
Cardiac
glycosides
Legal test - - - -
Keller-Kiliani test - - - -
+ Found to be present; - Found to be absent.
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5.12 TLC profiles of different plant extracts
TLC study has shown the presence of different components in the
ethanolic extracts of different plants in specific solvent system.
Table 5.19 Thin layer chromatography of ethanolic extract of Solanum
xanthocarpum
Phytoconsti
tuent
Solvent system Detecting
reagent
Numbers, color
and  Rf values of
spots
Alkaloids Tolune:ethyl
acetate:
(85:15)
Dragendorff
reagent
Six spots of varied
colors with Rf
values; 0.25,
0.375, 0.438, 0.6,
0.65, 0.938 were
seen.
Flavonoids Ethyl
acetate:formic
acid:glacial
acetic
acid:water
(10:1.1:1.1:2.6)
Sprayed with
anisaldehyde
sulphuric acid and
heated at 1100C for
5 minutes.
Sprayed with 1%
AlCl3 in methanol
and observed
under UV light
Six spots (Four
light brown, one
pinkish and one
greenish) with Rf
values; 0.314,
0.386, 0.50, 0.571,
0.728, and 0.90
were seen.
No spots were
observed
Saponins Chloroform:gla
cial acetic
acid:methanol:
water
(64:32:12:08)
Sprayed with
Lieberman
Burchard reagent
and heated at
1000C for 5
minutes.
Three light brown
spots with Rf
values; 0.333,
0.480, and 0.613
were seen.
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Figure 5.15. TLC plates showing presence of (A) Alkaloids, (B)
Flavonoids, and (C) Saponins spots of ethanolic extract of
Solanum xanthocarpum (S.F. = Solvent Front).
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Table 5.20 Thin layer chromatography of ethanolic extract of
Aegel marmelos
Phytoconstit
uent
Solvent system Detecting reagent Numbers, color
and  Rf values
of spots
Alkaloids Tolune:ethyl
acetate: (85:15)
Dragendorff
reagent
Three light
orange-brown
spots with Rf
values; 0.235,
0.558, and
0.682 were
seen
Flavonoids Ethyl acetate:formic
acid:glacial acetic
acid:water
(10:1.1:1.1:2.6)
Sprayed with
anisaldehyde
sulphuric acid and
heated at 1100C
for 5 minutes.
Sprayed with 1%
AlCl3 in methanol
and observed
under UV light
Five light
brown spots
with Rf values;
0.160, 0.293,
0.440, 0.640,
and 0.866 were
seen.
No spots were
observed
Saponins Chloroform:glacial
acetic
acid:methanol:water
(64:32:12:08)
Sprayed with
Lieberman
Burchard reagent
and heated at
1000C for 5
minutes.
Five light brown
spots with Rf
values; 0.259,
0.454, 0.558,
0.688, and 0.831
were seen.
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Figure 5.16. TLC plates showing presence of (A) Alkaloids, (B)
Flavonoids, and (C) Saponins spots in ethanolic extract of Aegel
marmelos (S.F. = Solvent Front).
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Table 5.21 Thin layer chromatography of ethanolic extract of
Murraya koenigii
Phytoconstit
uent
Solvent system Detecting reagent Numbers,
color and
Rf values of
spots
Alkaloids Tolune:ethyl
acetate: (85:15)
Dragendorff
reagent
Three orange-
brown spots
with Rf values;
0.30, 0.437, and
0.587 were
seen
Flavonoids Ethyl
acetate:formic
acid:glacial acetic
acid:water
(10:1.1:1.1:2.6)
Sprayed with
anisaldehyde
sulphuric acid and
heated at 1100C
for 5 minutes.
Sprayed with 1%
AlCl3 in methanol
and observed
under UV light
Seven light
brown spots
with Rf values;
0.09, 0.260,
0.346, 0.466,
0.560, 0.693,
and 0.853 were
seen.
No spots were
observed
Saponins Chloroform:glacial
acetic
acid:methanol:wat
er (64:32:12:08)
Sprayed with
Lieberman
Burchard reagent
and heated at
1000C for 5
minutes.
Four light brown
spots with Rf
values 0.320,
0.474, 0.551,
and 0.666 were
seen.
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Figure 5.17. TLC plates showing presence of (A) Alkaloids, (B)
Flavonoids, and (C) Saponins spots in ethanolic extract of Murraya
koenigii (S.F. = Solvent Front).
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Table 5.22 Thin layer chromatography of ethanolic extract of
Caesalpinia bonducella
Phytoconstituent Solvent system Detecting
reagent
Numbers, color
and  Rf values
of spots
Alkaloids Tolune:ethyl
acetate (93:7)
Dragendorff
reagent
Four light brown
spots with Rf
values; 0.093,
0.466, 0.733,
and 0.906 were
seen.
Flavonoids Ethyl
acetate:formic
acid:glacial acetic
acid:water
(10:1.1:1.1:2.6)
Sprayed with
anisaldehyde
sulphuric acid
and heated at
1100C for 5
minutes.
Sprayed with
1% AlCl3 in
methanol
and
observed
under UV
light
Four light brown
spots with Rf
values; 0.333,
0.493, 0.626,
and 0.733 were
seen.
No spots were
observed
Saponins Chloroform:glacial
acetic
acid:methanol:water
(64:32:12:08)
Sprayed with
Lieberman
Burchard
reagent and
heated at
1000C for 5
minutes.
Four light brown
spots with Rf
values; 0.357,
0.485, 0.60, and
0.714 were
seen.
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Figure 5.18. TLC plates showing presence of (A) Alkaloids, (B)
Flavonoids, and (C) Saponins spots in ethanolic extract of Caesalpinia
bonducella (S.F. = Solvent Front).
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6. Discussion
In this study, an attempt has been made to evaluate antiasthmatic activity of
polyherbal formulations in the experimental animals. The results of the study
indicated the synergistic antiasthmatic effect by combination of different plant
extracts in rodents.
The acute toxicity was determined by the method of Lorke (1983),
which utilizes less number of mice and provides a 24-h LD50 value, which is
adequate for most practical purposes. The LD50 values for polyherbal
formulations I and II were found to be 2262.7 mg/kg, p.o. The LD50 values of
ethanolic extract of C. bonducella and M. koenigii were 1131.4 mg/kg, p.o.
and that of S. xanthocarpum and A. marmelos were 2262.7 mg/kg, p.o. These
LD50 values fall within the practically non-toxic range (Loomis, 1978). Based
on these results, doses of 50, 100, 200, 300 or 400 mg/kg of different plant
extracts were selected for various animal models. The synergistic
antiasthmatic action was evaluated by combining sub-effective doses of
different plant extracts.
Histamine and acetylcholine antagonists can be conveniently
recognized and assayed by their ability to protect guinea pigs against lethal
effects of bronchospasm induced by histamine and acetylcholine, respectively
(Broadbent & Bain, 1964). The results of the present study showed that prior
treatment of polyherbal formulations protected the animals to a significant
extent from the development of asphyxia produced by both the spasmogens.
This is indicative of antihistaminic and anticholinergic activities of the
polyherbal formulations. Interestingly, the effect was significantly higher than
any of the plant extracts used in the formulation suggesting the synergistic
action.
 In the present study, guinea pigs were used because of the extreme
sensitivity of their airways to the primary mediators of bronchoconstriction,
including histamine and leukotrienes, and their ability to be sensitized to
foreign proteins. Moreover, the resemblance of pulmonary responses and
anaphylactic sensitization to histamine challenge in both guinea pigs and
humans made this species the model of choice. Although there is no perfect
model of asthma which simulates asthmatic patients, guinea pig airways react
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to histamine, acetylcholine, leukotrienes, and other bronchoconstrictors in a
manner similar to that seen in humans (Popa et al., 1973; Agrawal et al.,
1991). Another similarity between the guinea pig model and asthmatic
patients is that enhanced bronchoconstriction occurs in both species following
sensitization, in response to ?-adrenergic antagonists (Matsumoto et al.,
1994). Thus, the guinea pig model resembles the human allergic pathology in
several aspects, especially in terms of mediator release.
The role of histamine and acetylcholine in asthma is well established
(Nelson, 2003). In the early stage of asthma, release of inflammatory
mediators like histamine, tryptase, acetylcholine, leukotrienes, and
prostaglandins are triggered by exposure to allergens, irritants, cold air or
exercise (Bosquet et al., 2000). Some of these mediators directly cause acute
bronchoconstriction. Spasmolytic drugs like ?-adrenergic agonists, xanthine
derivatives, and anticholinergics are used as quick relief medications in such
acute asthmatic attacks (Horwitz & Busse, 1995). In the present study, we
have used histamine and acetylcholine as spasmogens in the form of
aerosols to cause immediate bronchoconstriction in guinea pigs. Mepyramine
(8 mg/kg, i.p.) and atropine sulphate (2 mg/kg, i.p.) were used as reference
standard against histamine and acetylcholine-induced bronchospasm
respectively (Shah & Parmar, 2003). The polyherbal formulations have shown
significant bronchoprotection against both the types of spasmogens as
compared to control. EESX, EEAM, EECB, and EEMK also showed
significantly protection from histamine-induced bronchoconstriction. Moreover,
EEMK and EEAM showed anticholinergic action in the acetylcholine-induced
bronchoconstriction. Ayurveda has recommended a number of plants for the
treatment of asthma and other allergic disorders and has been successful in
controlling the disease as well (Zhimmet & Tashkin, 2000). Large numbers of
medicinal plant preparations have been reported to possess bronchodilatory
effects; some of these include Adhatoda vasica (Amin & Mehta, 1959),
Benincasa hispida (Kumar & Ramu, 2002), Albizzia lebbeck (Tripathi & Das,
1977), Cissampelos sympodialis (Thomas et al., 1997), and Sarcostemma
brevistigma (Saraf & Patwardhan, 1988). Phytoconstituents like alkaloids and
flavonoids are attributed to possess bronchodilatory activity (Amin & Mehta,
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1959; Saraf & Patwardhan, 1988). Qualitative phytochemical investigation of
ethanolic extracts which are present as ingredients in the polyherbal
formulations, have shown presence of these constituents. Therefore, the
results of present investigation suggested that, different plant extracts have
significant bronchodilatory activity.
Since polyherbal formulations showed significant inhibition of
histamine-induced bronchospasm, this instigated us to evaluate the
polyherbal formulations against another model for antihistaminic activity.
Histamine is known to increase vascular permeability mainly by acting
on postcapillary venules where the opening of endothelial gaps leads to
increased extravasation of plasma proteins (Grega et al., 1981). In addition to
its vascular effects, histamine excites small diameter afferent neurons and
evokes the release of vasoactive mediators from local nerve endings (Saria et
al., 1988). Therefore, histamine-induced edema formation may be the
consequence of vascular as well as of neuronal actions of histamine.
In histamine-induced inflammation model, polyherbal formulations,
EESX, EECB, and  EEMK exhibited significant inhibitory action, which
indicated anti-inflammatory action by means of inhibiting the synthesis,
release or action of histamine involved in inflammation (Rao et al., 2003).
In an attempt to further analyze the possible mode of action of
polyherbal formulations and different plant extracts, these drugs were studied
for their effect on mast cell degranulation. Addition of polyherbal formulations,
EESX, and EEMK to the mast cell suspension significantly reduced
degranulation of mast cells. Further, the degranulation induced by compound
48/80, a potent mast cell degranulator, was also prevented by polyherbal
formulations, EESX, EEAM, and EEMK in dose dependent manner. Histamine
together with platelet activating factor (PAF) is contained in the granules of
mast cells. Histamine is liberated in acute inflammation and is important
during the early phase in initiating allergic responses. PAF causes
vasodilatation, increased vascular permeability and is chemotactic to white
blood cells (Water & Talbot, 1996). These mediators from mast cells can be
released by injury, various histamine-releasing agents, interleukin-1, factors
derived from neutrophils that release histamine, macrophages, and platelets
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(Water & Talbot, 1996). The protective effect of polyherbal formulations
against mast cell degranulation indicates that this action may be responsible
for the observed anti-inflammatory effect. However, the effect of polyherbal
formulations on other inflammatory mediators cannot be excluded as mast cell
degranulation is only one of the complex mechanisms in the pathogenesis of
asthma.
The present study reports the effect of different plant extracts and their
combination as polyherbal formulation which produced the most potent anti-
inflammatory property. Different plant extracts found to be acting by different
mechanisms in the inflammatory conditions and hence enhanced anti-
inflammatory action was seen in the combination of these plant as polyherbal
formulations.
The administration of carrageenan produced a significant edema in the
rat paw, which was more intense in the control animals. The two main
mediators of inflammation are prostaglandins and PAF in carrageenan-
induced paw edema model. It has been established that the carrageenan-
induced edema is expressed in two phases (Vinegar et al., 1969). When the
first 3-h segment of the curve is analyzed, a biphasic response has been seen
(Figure 1). A rapid rise in foot volume occurs immediately after subplantar
injection of carrageenan. Subsequently, a diminution of foot volume occurs at
the end of 1 h, which has been designed as the first phase or early phase
edema. A second period of edema formation begins to develop at a slow rate
from the end of 1 h. Around 90 min, a strong acceleration of edema formation
occurs which tapers off after 3 h. The edema volume present at 3 h minus the
edema at 1 h represents the second phase or late phase edema volume
(Matyas Kottai et al., 1991).
The carrageenan-induced paw edema model in rats is known to be
sensitive to cycloxygenase (COX) inhibitors and has been used to evaluate
the effect of non-steroidal anti-inflammatory agents (Rao et al., 2005). The
edema (inflammation) induced by carrageenan is shown to be mediated by
histamine and 5-HT during first 1 h, after which increased vascular
permeability is maintained by the release of kinins up to 1.30 h and from 1.30
to 3 h, the mediators appear to be prostaglandins, the release of which is
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closely associated with migration of leucocytes into the inflamed site (Di-Rosa
et al., 1971). In the present study, polyherbal formulations significantly
reduced edema formation at 1, 2, and 3 h time points (both the phases of
inflammation). The possible mechanism could be action on early phase
mainly by inhibiting the mediator of inflammation, most probably by inhibiting
the histamine and serotonin, which are present in the proinflammatory cells
like neutrophils and mast cells. EESX and EEAM diminished edema in both
the phases of inflammation where as, EEAM reduced inflammation up to 2 h
only. These suggest that EESX and EEAM possess antihistaminic activity and
inhibition of prostaglandins where as, EEAM is devoid of action on
prostaglandin pathway but possess antihistaminic action. These data
confirmed the findings from the earlier animal models of antihistaminic activity
(histamine-aerosol in guinea pigs and histamine-induced paw edema in rats).
It is well known fact that the ASA, standard anti-inflammatory drug, act by
inhibiting the prostaglandins synthesis at late phase. In the present study,
ASA inhibited only second phase of inflammation which is in accordance with
earlier studies (Rao et al., 2005).
Figure 6.1 Phases of carrageenan-induced paw edema in rats. The
first or earlier phase is due to release of histamine and serotonin where
as, second phase is due to synthesis of prostaglandin.
1 h 2 h 3 h
0.1
0.2
0.6
0.8
1.2
1.4
First or Early phase (due to
release of histamine and 5-HT)
Second or late phase (Due to
synthesis of prostaglandins)
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In order to further explore mechanism of different plant extracts and
polyherbal formulations, dextran and formaldehyde-induced rat paw edema
models were selected. It has been reported that dextran induces fluid
accumulation, which contains little protein, and few neutrophils where as,
carrageenan induces protein rich exudation containing large number of
neutrophils (Kumar & Robbin, 1995). The edema induced by dextran involves
the participation of histamine and serotonin, which are discharged by the
mastocytes (Rowley & Benditt, 1959). In the dextran-induced inflammation
model, polyherbal formulations, EESX, EEAM, EECB, and EEMK significantly
reduced edema which indicated antihistaminic and anti-serotonin effects.
Inflammation induced by formaldehyde is biphasic, an early neurogenic
component is mediated by substance P and bradykinin followed by a tissue
mediated response where histamine, 5-HT, prostaglandins, and bradykinin
are known to be involved (Wheeler-Aceto & Cowan, 1991). In the
formaldehyde-induced inflammation, polyherbal formulations demonstrated
significant anti-inflammatory activity that lasted up to 24 h in contrast to ASA,
which was effective only at 1.5 h, suggesting its long duration of action. This
indicated that polyherbal formulations may have anti-inflammatory actions
through inhibition of histamine, serotonine, and other inflammatory mediators.
Further, EESX and EECB were effective only on the second phase
suggesting inhibitory action on histamine, serotonine, and other inflammatory
mediators and not through substance P or bradykinin. This data are in
accordance with the findings from the earlier animal models.
In order to assess efficacy of polyherbal formulations and different
plant extracts against proliferative phase of inflammation in which tissue
degeneration and fibrosis occur, the widely used cotton pellet granuloma test
was employed. During the repair process of inflammation, there is proliferation
of macrophages, neutrophils, fibroblasts and multiplication of small blood
vessels, which are the basic sources of forming a highly vascularised reddish
mass termed granulation tissue (Swingle, 1974; Bhattacharya et al., 1992).
Efficacy of anti-inflammatory agents in chronic inflammatory states is
indicated by their ability to inhibit the increase in the number of fibroblasts and
synthesis of collagen and mucopolysaccharides during granuloma tissue
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formation (Recio et al., 1995) In the present study, polyherbal formulations
significantly reduced the granuloma formation. The effect was comparable
with the standard drug prednisolone. This indicated that polyherbal
formulations can be good candidate for the chronic inflammatory diseases like
asthma. EESX, EEAM, EECB, and EEMK also significantly inhibited the
chronic inflammation.
From the results of the studies, it is obvious that polyherbal
formulations and different plant extracts possess antihistaminic,
anticholinergic, and mast cell stabilizing action. Further, they had potent
acute, sub-acute, and chronic anti-inflammatory activity, thereby indicating the
possibility of developing the cheaper, safer and potent agent for the treatment
of asthma. These findings scientifically validated the traditional use of these
plants for treating inflammatory disorders like asthma in the folk medicine.

Summary and conclusion
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 7. Summary and conclusion
Among several respiratory diseases affecting man, bronchial asthma is the
most common disabling syndrome. The therapy of asthma usually employs
steroids or disease modifying drugs. The long-term use of these, however,
may not limit the disease progression. All of these drugs have side effects and
the search for a novel anti-asthmatic drug continues. There is a dire need to
identify effective and safe remedies to treat bronchial asthma (Govindan et al.,
1999). If the herbal medicines are combined with each other or with one of the
currently available antiasthmatic agents, the combination might prove to be
the most potent for the treatment of asthma and the side effects of the
allopathic treatment can be reduced. For this purpose, polyherbal formulations
have been used successfully in ayurvedic medicine for centuries to cure
asthma and other disease.
The present study demonstrates the potent mast cell stabilizing activity,
anti-histaminic activity, anti-cholinergic activity, and anti-inflammatory activity
(acute: carrageenin-, dextran-, and histamine-induced rat paw edema; sub-
acute: formaldehyde-induced edema, and chronic proliferative inflammation:
cotton pellet granuloma) of polyherbal formulations and four medicinal plants
in different models of asthma and inflammation, thereby indicating the
possibility of developing a polyherbal formulation as the cheaper, safer and
potent anti-asthmatic and anti-inflammatory therapeutic agent.
The combination of SX, AM, CB, and MK produced synergistic action.
The selected plant species have been used in the traditional systems of
medicine for treating various ailments including asthma. Importantly, there
was no scientific evidence for the anti-asthmatic activity of these plants. The
present study validates traditional claims of these plants.
Although the results from this study are quite promising for the use of
polyherbal formulations as a medicinal agent for asthma, several limitations
exist in the current literature. Further studies are suggested to establish the
antiasthmatic activity by conducting clinical trials and also to isolate and
characterize the active principle/s responsible for the action.
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Summary 
Asthma is a chronic disease that affects approximately 300 million people 
worldwide. Although wide range of drug is available, the relief is mainly 
symptomatic and short lived. Solanum xanthocarpum Schrad. (Solanaceae), also 
known as yellow berried nightshade (English), is traditionally used to treat 
asthma. However, the scientific data on anti-asthmatic and anti-inflammatory 
actions of this plant has got little attention. An attempt has been made to evaluate 
anti-asthmatic, anti-inflammatory and mast cell stabilizing activities of ethanolic 
extract of Solanum xanthocarpum leaves (EESX) using acetylcholine (Ach) and 
histamine-induced airway constriction in guinea pigs and carrageenan-, dextran-, 
and histamine-induced paw oedemas, and cotton pellet-induced granuloma tests in 
rats. EESX showed significant bronchodilator activity on histamine-induced 
airway constriction and reversed the allergen-induced bronchospasm. 
Interestingly, EESX protected mast cells from compound 48/80-provoked 
degranulation and inhibited acute, sub-acute and chronic inflammation in different 
animal models. The LD50 of EESX was 2262.7 mg/kg, i.p. The present study for 
the first time indicates anti-asthmatic, anti-inflammatory and mast cell stabilizing 
activities of EESX, confirming its traditional claims. 
Key Words: Anti-asthmatic, Antihistaminic, Antiinflammatory, Compound  
48/80, Mast cell stabilization, Solanum Xanthocarpum. 
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Introduction 
Bronchial asthma is an inflammatory disorder of the airways characterized by 
airway obstruction, inflammation and bronchial hyper-responsiveness and is a 
global health problem that results from a complex interplay between genetic and 
environmental factors. Among several respiratory diseases affecting man, 
bronchial asthma is the most common disabling syndrome. Nearly 7–10% of the 
world population suffers from bronchial asthma (1). A wide range of drug is 
available for the treatment of asthma. However, the relief offered by these drugs 
is mainly symptomatic, short lived and results into complex side effects. It has 
been reported that there has been an alarming increase in number of diseases and 
disorders caused by synthetic drugs prompting a switch over to traditional herbal 
medicine (2). The modern medicine or allopathy has gradually developed over the 
years by scientific and observational efforts of scientists. However, the basis of its 
development remains rooted in traditional medicine and therapies (3). Assessing 
the current status of health care system in adequacies of synthetic drugs is likely 
to be more glaring in the coming years. In the developing countries, herbal 
medicines are being used by nearly about 80% of the world population (4, 5). 
Ayurveda is a traditional Indian medicinal system practiced for thousands of 
years. 
Selection of scientific and systematic approach for the biological evaluation of 
plant products based on their use in the traditional systems of medicine forms the 
basis for an ideal approach in the development of new drugs from plants. One 
such plant is Solanum xanthocarpum (SX) Schrad. (Family: Solanaceae) 
commonly known as yellow berried night shade (English). It is a prickly diffuse, 
bright green perennial herb found throughout hotter parts of India (6, 7). SX has 
held a place of some importance in the Hindu Materia Medica, primarily as an 
expectorant and antipyretic (7, 8). Various medicinal properties are attributed to 
it, particularly in the treatment of asthma, chronic cough and catarrhal fever (9). It 
is one of the members of the dashamula (ten roots) of the Ayurveda (10). A body 
of evidence suggests that SX is an important source of many pharmacologically 
and medicinally important chemicals, especially solasodine and related steroidal 
hormones. The plant is extensively studied for the various pharmacological 
activities like hepatoprotective, cardiovascular, hypoglycemic and mosquito 
repellent properties. The plant is traditionally prescribed for immunomodulation, 
hypolipidemic, antibacterial, sexual behaviour, tolerance and dependence. SX is 
widely used by practitioners of the Siddha system of medicine in southern India to 
treat respiratory diseases (11). Recently, it is suggested that treatment with SX 
improved the pulmonary functions to a significant level in patients suffering from 
mild to moderate asthma (2).  
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This study revealed that dose of SX was well tolerated and no untoward effects 
were observed. SX is a safe medicine in the traditional system and has been used 
by mankind over many centuries. Further, it was suggested that relief from the 
symptoms of bronchial asthma produced by SX may be due to: (a) a 
bronchodilator effect, (b) reduction in the bronchial mucosal edema, and/or (c) 
reduction in the secretions within the airway lumen. In the light of above 
background, the present study was aimed at evaluation of anti-asthmatic activity 
of ethanolic extract of Solanum Xanthocarpum (EESX) on experimental animals 
using different pharmacological protocols and identifying phytoconstituents 
present in the plant extract.  
Materials and methods 
Plant materials 
The leaves of Solanum xanthocarpum were collected from the outfield of 
Junagadh city, Gujarat, India in Feb-March. The plant materials were identified 
and authenticated by Dr. P.J. Parmar, Botanical Survey of India, Jodhpur, 
Rajasthan, India. A voucher specimen (SU/DPS/Herb/19) of the collected sample 
was deposited in the Department of Pharmaceutical Sciences, Saurashtra 
University, Rajkot for future reference. 
 
Drugs and Chemicals 
Compound 48/80, disodium chromoglycate (DSCG), histamine dihydrochloride, 
acetylcholine chloride, atropine sulfate, mepyramine meleate, carrageenan, 
acetylsalicylic acid (ASA) and toluidine blue were purchased from Sigma 
Chemical Co., St. Louis, MO. Histamine solution was freshly prepared in normal 
saline (NaCl, 8.5 g/l). All the other drugs were of analytical grade and they were 
dissolved in distilled water and desired concentration was prepared. Prednisolone 
was gifted by Inga Laboratories Ltd., Mumbai, India.   
 
Extraction 
Leaves of SX were washed with distilled water to remove dirt and soil, and shade 
dried. Routine pharmacognostic studies including organoleptic tests, macroscopic 
and microscopic observations were carried out to confirm the identity of the 
material. The dried material was powdered and passed through a 10-mesh sieve. 
The coarsely powdered material (500 g) of SX was extracted with ethanol (95%, 
v/v) in Soxhlet apparatus. The extract was filtered and concentrated by distilling 
off the solvent and evaporated to dryness using water bath to get crude ethanol 
extract. The ethanolic extract was subjected to phytochemical screening. For 
different pharmacological tests, the extract was suspended in double distilled 
water containing carboxy methyl cellulose (0.5 %, w/v, CMC). 
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Experimental animals 
Antihistaminic and anticholinergic studies were conducted on guinea pigs (350-
500 g) of either sex fed on commercial pellet diet (Amrut, Pranav Agro Industries 
Ltd, India). They were housed in standard conditions of temperature (22 ± 20C), 
relative humidity (60 ± 5 %) and 12:12 light/dark cycle (lights on at 07:00 am and 
off at 19:00 pm). They were divided in groups of ten animals each. The saline fed 
group served as control and one group was treated with a standard drug. Before 
experimentation, the animals were kept on fast for 24 h but water was given ad 
libitum, Animals receiving different doses of plant extracts were also observed for 
any alteration in their general behavior. 
For the anti-inflammatory paradigms, Sprague–Dawley rats weighing 140–160 g 
of either sex were used. Five animals were group housed in polypropylene cages 
(640 x 410 x 250 mm high) and kept at departmental animal house in well cross 
ventilated room at the same experimental condition explained earlier. They were 
provided with standard rodent pellet diet (Amrut, India) and tap water ad libitum 
except the food was withdrawn 18–24 h before the experiment. All the 
experimental protocols were approved by the Institutional Animal Ethics 
Committee (IAEC), N. R. Vekaria Institute of Pharmacy and Research Centre, 
Junagadh (approval number NRVCP/IAEC/07/2k7/01). All the experiments and 
the care of the laboratory animals were according to current ethical guidelines by 
the Committee for the Purpose of Control and Supervision on Experiments on 
Animals (CPCSEA), Ministry of Environment and Forests, Government of India, 
New Delhi. 
Habituation to animals  
Rats and guinea pigs were habituated to handling by holding them and injecting 
vehicle through oral/i.p. routes to minimize non-specific stress and to simulate the 
actual protocol conditions. Handling also consisted of weighing and restraining 
animals on platform for 1 min and gently massaging on dorsal site as was done in 
the actual protocols. The same platform was used during drug administration.  
Moreover, the animals were familiarized with the diet in their home cage-
environment and laboratory environments before subjecting them to the tests. All 
the experiments commenced 24 hours following the final habituation and were 
conducted according to the protocols mentioned below. 
Acute toxicity test (Determination of LD50) 
The acute toxicity tests (LD50) for the different plant extracts were determined 
according to the procedure described by Lorke (1983). The crude ethanolic 
extracts were used for the test. Albino mice (20–25 g) of either sex were used. 
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This method involved an initial dose finding procedure, in which the animals 
were divided into three groups of three animals per group. Doses of 10, 100 and 
1000 mg/kg were administered intraperitoneally (i.p.), one dose for each group. 
The treated animals were monitored for 24 h for mortality and general behavior.  
From the result of the above step, four different doses of 200, 400, 800 and 1600 
mg/kg were chosen and administered (i.p.) respectively to four groups of one 
mouse per group. The treated animals were again monitored for 24 h. The LD50 
was then calculated as the geometric mean of the lowest dose showing death and 
the highest dose showing no death (12). 
Preparation of the test extracts 
EESX was suspended in 1% CMC in distilled water to prepare different doses 
(50, 100, 200, 300 mg/kg body weight) and administered orally with the help of 
gastric cannula. The control animals were given an equivalent volume of CMC in 
vehicle. In each protocol, one of the groups is reference standard group in which 
various standard anti-asthmatics were injected to animals. 
Histamine-induced bronchospasm in guinea pigs 
The guinea pigs fasted for 24 h were exposed to an atomised fine mist of 2% 
histamine dihydrochloride aerosol (dissolved in normal saline) using nebulizer at 
a pressure of 300 mm Hg in the histamine chamber (24 x 14 x 24 cm, made of 
perplex glass). Guinea pigs exposed to histamine aerosol showed progressive 
signs of difficulty in breathing leading to convulsions, asphyxia and death. The 
time until signs of convulsion appeared is called pre-convulsion time (PCT). By 
observation, experience was gained so that the preconvulsion time can be judged 
accurately. As soon as PCT commenced, animals were removed from the 
chamber and placed in fresh air to recover. In the present experiments, the 
criterion used was time for onset of dysponea and percent protection was 
calculated. Those animals which developed typical histamine asthma within 3 min 
were selected out three days prior to the experiment and were given habituation 
practice to restrain them in the histamine chamber. They were divided in groups 
of ten animals each. Mepyramine 8.0 mg/kg, ip and different doses of plant 
extract, intraperitonially were administered 30 min prior to exposure. Animals, 
which did not develop typical asthma within 6 min were taken as protected (13). 
Acetylcholine-induced bronchospasm in guinea pigs  
Similar procedure was repeated by exposure of aerosol of 0.5% acetylcholine in 
another set of animals (each group having ten animals) using Atropine sulphate (2 
mg/kg) as a standard (14). 
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Mast cell degranulation by compound 48/80 
This was carried out as per the method described by Kaley and Weiner (1971) 
with little modification. Male albino rats were sacrificed by cervical dislocation. 
The animals were immediately injected with 15 ml of pre-warmed (37°C) 
buffered salt solution (BSS; NaCl 137 mM; KCl 2.7 mM; MgCl2; 1.0 mM; CaCl2 
0.5 mM; NaH2PO4 0.4 mM; Glucose 5.6 mM; HEPES 10 mM) into the peritoneal 
cavity, and massaged gently in this region for 90 s, to facilitate cell recovery. A 
midline incision was made and the peritoneum was exposed (Figure 4.10). The 
pale fluid was aspirated using a blunted plastic Pasteur pipette, and collected in a 
plastic centrifuge tube. The fluid was then centrifuged at 1000 rpm for 5 min, and 
the supernatant discarded to reveal a pale cell pellet. The cell pellets were re-
suspended in fresh buffer and re-centrifuged. Aliquots of the cell suspension were 
incubated with the test compounds or disodium cromoglycate, before challenge 
with compound 48/80. The aliquots were carefully spread over glass slides and 
the mast cells were stained with 1% toluidine blue and counterstained with 0.1% 
light green. The slides were dried in air and the mast cells counted from randomly 
selected high power objective fields (X450). The effect of EESX on mast cell was 
studied by incubating the mast cells for 10 min with the above compounds in a 
concentration of 1, 10 or 100 µg/ml. In another set of experiments the mast cells 
which were pre-incubated with different plant extracts or polyherbal formulations 
were exposed to the mast cell degranulator, compound 48:80 (10 µg/ml) and the 
incubation continued for a further 10 min. Then, the mast cells were carefully 
spread over glass slides. The percent degranulation of the mast cells in each 
treatment was calculated. Disodium cromoglycate (DSCG) 20 µg/ml was also 
included in the study for comparison (15). 
Histamine-induced hind paw edema in rats. 
The method of Horakova and Moratova (1964) was followed. Oedema in one of 
the hind paws of the rat was induced by the subplantar injection of 0.1 ml freshly 
prepared 0.1% (w/v) histamine (a phlogistic agent) in normal saline. The pedal 
volume was measured just before (0 h) and 3 h after the phlogistic challenge. 
ASA (300 mg/kg, p.o.) was employed as reference standard in the experiment. 
EESX (50, 100, 200 and 400 mg/kg, p.o.) or ASA (30 mg/kg, p.o.) was given 1 h 
before the phlogistic challenge (16). 
Carrageenan-induced hind paw edema in rats (acute inflammation) 
The acute hind paw edema was produced by injecting 0.1 ml of carrageenan 
(freshly prepared as 1% suspension in 1% CMC) locally into the plantar 
aponeurosis of the right hind paw of rats (17). EESX (50, 100, 200 and 400 
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mg/kg, p.o.) was administered to four different groups while the other two groups 
served as negative and positive controls and received vehicle (1 ml/kg, p.o.) and 
standard drug, acetylsalicylic acid (ASA, 300 mg/kg, p.o.), respectively. For each 
treatment group six animals were used. EESX and ASA were administered 1 h 
prior to the injection of carrageenan. A mark was made at the ankle joint of the 
paw of rat and pedal volume up to this point was measured using plethysmometer 
(Ugo Basile, Italy) at 0 h (just before) and 1-, 2- and 3-h post-carrageenan 
injection. Increase in the paw edema volume was considered as the difference 
between 0 and 1-, 2-, or 3-h. Percent inhibition of edema volume between treated 
and control groups was calculated as follows:  
Percent inhibition = 1 – VT/VC × 100; Where, VC and VT represent the mean 
increase in paw volume in control and treated groups, respectively. 
All the animals were fasted for 12 h and deprived of water only during the 
experiment. The deprivation of water was to ensure uniform hydration and to 
minimize variability in oedematous response 
Dextran-induced oedema in rats (subacute inflammation) 
Acute oedema in one of the hind paws of the rat was induced by the subplantar 
injection of 0.1 ml freshly prepared 6% (w/v) dextran (a phlogistic agent) (Sigma 
Chemical Co., St. Louis, MO) in normal saline. The paw volume was measured 
before and 3 h after the phlogistic injection. Different doses of the test and 
reference drug dissolved in normal saline was given p.o. 1 h before the dextran 
injection (18). 
Formaldehyde-induced hind paw volume 
The test was performed according to the technique developed by Brownlee 
(1950). Pedal inflammation was induced by injecting 0.1 ml of 4% formaldehyde 
solution below the plantar aponeurosis of the right hind paw of the rats. The paw 
volume was recorded immediately prior to compound administration (0 h) and 
then at 1.5 h after formaldehyde injection. Vehicle (1 ml/kg, p.o.), EESX (50, 
100, 200 and 400 mg/kg, p.o.) and standard drug, ASA (300 mg/kg, p.o.) were 
administered 1 h prior to formaldehyde injection (19). 
Cotton pellet granuloma in rats (chronic inflammation)  
The effect of EESX on chronic or proliferative phase of inflammation was 
assessed in cotton pellet granuloma rat model (20). Autoclaved cotton pellets 
weighing 10 ± 1mg each were implanted subcutaneously through small incision 
made along the axilla region of the rats anesthetized with thiopental sodium (45 
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mg/kg, i.p.). The different groups of rats were administered the EESX (50,100, 
200 and 400 mg/kg, p.o.) and prednisolone (10 mg/kg, p.o.) once daily for 7 
consecutive days from the day of cotton pellet insertion. The control group 
received vehicle (1 ml/kg, p.o.). On the eighth day, all the rats were anaesthetized 
and the cotton pellets covered by the granulomatous tissue were excised and dried 
in hot air oven at 60 0C till a constant weight was achieved. Granuloma weight 
was obtained by subtracting the weight of dry cotton pellet on 0 day (before start 
of experiment) from the weight of the dry cotton pellet on eighth day. 
Data analysis  
The data are presented as mean ± SEM.  Statistical significance was determined 
using ANOVA followed by dunnett t-test or Chi-square test with Yate’s 
correction factor. Differences were considered significant at P < 0.05. 
Results and discussion 
Ayurveda has recommended a number of plants for the treatment of asthma and 
other allergic disorders and has been successful in controlling the disease as well 
(21). Large numbers of medicinal plant preparations have been reported to 
possess bronchodilatory effects; these include Adhatoda vasica (11), Albizzia 
lebbeck (11), Cissampelos sympodialis (22) and Sarcostemma brevistigma (23). 
Phytoconstituents like alkaloids and flavonoids are attributed to possess 
bronchodilatory activity (11, 23). 
 
The present study for the first time demonstrates the potent bronchodilator, mast 
cell stabilization and anti-inflammatory activity of the EESX in different models 
of inflammation, i.e., acute exudative (carrageenan-induced rat paw edema), sub 
acute (dextran-induced rat paw edema) and chronic proliferative inflammation 
(cotton pellet granuloma). 
The intraperitoneal injection of carrageenan and dextran caused a time-dependent 
paw edema in the rat, although saline injection caused no swelling. In carrageenan 
and dextran-induced paw edema in rats, intraperitoneal administration of EESX 
(100, 200, and 300 mg/kg) significantly inhibited paw swelling at 1, 2 and 3 h 
after carrageenan (Table 1) and at 3 h after dextran injection (Table 2). ASA (300 
mg/kg, p.o.), the reference standard drug, inhibited oedema formation at 3 h in 
carrageenan and dextran models. The effect of EESX was well comparable to 
ASA. Percent increment in paw swelling was calculated by using the values 
before and after the injection of these phlogistic agents.   
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The edema and inflammation induced by carrageenan is shown to be mediated by 
histamine and 5-HT during first 1 h, after which increased vascular permeability 
is maintained by the release of kinins up to 2.30 h and from 2.30 to 6 h, the 
mediators appear to be prostaglandins, the release of which is closely associated 
with migration of leucocytes into the inflamed site (24). The Carrageenan induced 
paw edema model in rats is known to be sensitive to cycloxygenase (COX) 
inhibitors and has been used to evaluate the effect of non-steroidal anti-
inflammatory agents (NSAIAs). All NSAIAs are effective in late phase and do 
not inhibit early phase oedema (25). Our results are consistent with these facts. 
In the early stage of asthma, release of inflammatory mediators like histamine, 
tryptase, acetylcholine, leukotrienes, and prostaglandins are triggered by exposure 
to allergens, irritants, cold air or exercise (26). Some of these mediators directly 
cause acute bronchoconstriction. Spasmolytic drugs like beta adrenergic agonists, 
xanthine derivatives and anticholinergics are used as quick relief medications in 
such acute asthmatic attacks (27).  
The EESX at the doses 100, 200 and 300 mg/kg, p.o. significantly reduced the 
granuloma formation to 65.7 ± 1.93 mg, 55.8 ± 1.51 mg, and 55.4 ± 1.32 mg, 
respectively (percentage inhibition of granuloma formation was 40.32%, 49.31%, 
and 49.68%, respectively) which was highly significant (p < 0.01), when 
compared to the control group of animals (Table 3).  
In the present study, we have used histamine (Table 4) and acetylcholine (Table 
5) as spasmogens in the form of aerosols to cause immediate bronchoconstriction 
in guinea pigs. The EESX (200 and 300 mg/kg) have shown significant 
bronchoprotection (p < 0.001) against histamine but not on acetylcholine aerosol 
as compared to control group. The bronchodilatory effect of EESX was found 
comparable to the protection offered by the reference standard drug mepyramine. 
EESX failed to produce any significant effect in the acetylcholine aerosol test. 
In the histamine-induced paw edema, EESX at the doses 100, 200 and 300 
mg/kg, p.o. significantly reduced the paw edema to 0.26 ± 0.01 ml, 0.17 ± 0.02 
and 0.14 ± 0.01 ml, respectively at 3 h (percentage inhibition of oedema was 
27.77%, 52.77%, and 61.11%, respectively) which was highly significant (p < 
0.01), when compared to the control group of animals (Table 6). 
In the mast cell stabilization test, 33% of mast cells were degranulated in the 
control group. Addition of DSCG (20 µg/ml) and EESX (10-100 µg/ml) reduced 
the percentage of degranulation (p < 0.01) as compared to the control group. 
Compound 48/80 (10 µg/ml) produced about 76% degranulation of mast cells. 
Pretreatment with DSCG (20 µg/ml) and EESX (10-100 µg/ml) significantly 
reduced (p < 0.01) degranulation of mast cells as compared to compound 48/80-
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tretaed control group (Table 7). The protection given by it at higher 
concentrations was comparable to that of DSCG, a potent mast cell stabilising 
agent. The LD50 value of EESX was 2262.7 by i.p. 
Although our results demonstrate the anti-histaminic, mast cell stabilizing and 
anti-inflammatory (acute, sub-acute and chronic) activities of EESX, the exact 
mechanism of these actions could not be stated at present. The anti-inflammatory 
effect of the plant extract may be due to its possible antihistaminic activity or by 
the protecting mast cell membrane and thus inhibiting release of inflammatory 
mediators. Taken together, further studies on the mechanism and safety of this 
plant is needed in order to develop EESX as the cheaper, safer and potent anti-
inflammatory and anti-asthmatic therapeutic agent. 
 
Table 1: Effect of S. xanthocarpum leaves on carrageenan-induced rat paw oedemaa 
 
Treatment 
Dose 
(mg/kg, 
p.o.) 
Paw oedema volume (ml) Inhibition (%) 
  1 h 2 h 
 
3 h 1 h 2 h 3 h 
Control 
saline, 
1 ml 
0.72 ± 0.02 0.86 ± 0.01 0.95 ± 0.01 - - - 
ASA 300 0.69 ± 0.04 0.78 ± 0.03 0.46 ± 0.02 4.16ns 9.3ns 51.57** 
EESX 50 0.70 ± 0.04 0.82 ± 0.03 0.94 ± 0.03 2.77ns 4.65ns 1.05ns 
EESX 100 0.55 ± 0.03 0.58 ± 0.02 0.65 ± 0.02 23.61** 32.55** 31.57** 
EESX 200 0.35 ± 0.03 0.39 ± 0.02 0.51 ± 0.02 51.38** 54.65** 46.31** 
EESX 300 0.33 ± 0.03 0.41 ± 0.02 0.52 ± 0.03 54.16** 52.32** 45.26** 
 
aValues are mean ± S.E.M. (n=6); nsNot significant, **P < 0.01 vs. control; 
Dunnett’s t-test after one-way ANOVA. 
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Table 2: Effect of S. xanthocarpum leaves on dextran-induced paw oedema in ratsa 
 
Treatment Dose (mg/kg, p.o.) Paw oedema volume (ml) 
Inhibition (%) 
 
Control saline, 1.0 ml/kg 0.95 ± 0.02 - 
ASA 300 0.25 ± 0.02 73.68** 
EESX 50 0.93 ± 0.02 2.1ns 
EESX 100 0.65 ± 0.01 31.57** 
EESX 200 0.45 ± 0.01 52.63** 
EESX 300 0.41 ± 0.01 56.84** 
aValues are mean ± S.E.M. (n=6); nsNot significant, **P < 0.01 vs. control; 
Dunnett’s t-test after one-way ANOVA. 
 
 
Table 3: Effect of ethanolic extract of S. xanthocarpum leaves on cotton pellet granuloma in ratsa 
 
Treatment 
Dose  
(mg/kg, p.o.) 
Weight of 
granuloma (mg) 
Inhibition (%) 
Control saline, 1 ml/kg 110.1 ± 2.20 - 
Prednisolone 10 63.4 ± 1.16 42.41** 
EESX 50 108.5 ± 1.83 1.45ns 
EESX 100 65.7 ± 1.93 40.32** 
EESX 200 55.8 ± 1.51 49.31** 
EESX 300 55.4 ± 1.32 49.68** 
 
aValues are mean ± S.E.M. (n=6); nsNot significant, **P < 0.01 vs. control; 
Dunnett’s t-test after one-way ANOVA. 
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Table 4: Effect of ethanolic extract of S. xanthocarpum leaves on histamine-aerosol in guinea pigsa 
 
Treatment Dose (mg/kg, i.p.) 
 
Protection (%) 
 
Control saline, 1.0 ml/kg 0 
Mepyramine 8 90*** 
EESX 50 10 
EESX 100 30 
EESX 200 80** 
EESX 300 70** 
an=10 in each group; bIntraperitoneal injection; nsNot significant, **P < 0.01, 
***P < 0.001 vs. control; (χ2 with Yate’s correction) 
 
Table 5: Effect of ethanol extract of S. xanthocarpum leaves on acetylcholine-
aerosol-induced bronchospasm in guinea pigsa 
 
Treatment Dose (mg/kg, i.p.) Preconvulsion time (sec) 
Protection (%) 
 
Control saline, 1.0 ml/kg 128 ± 2.72 - 
Atropine 2 460 ± 4.33 72.17** 
EESX 50 130 ± 1.38 1.53ns 
EESX 100 135 ± 2.98 5.18ns 
EESX 200 133 ± 2.32 3.76ns 
EESX 300 130 ± 2.02 1.53ns 
aValues are mean ± S.E.M. (n=5); nsNot significant, **P < 0.01 vs. control; 
Dunnett’s t-test after one-way ANOVA. 
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Table 6: Effect of ethanol extract of S. xanthocarpum leaves on histamine-
induced rat paw oedemaa 
 
Treatment Dose (mg/kg, p.o.) Paw oedema volume (ml) Inhibition (%)  
Control saline, 1.0 ml/kg 0.36 ± 0.02 - 
Mepyramine 10 0.12 ± 0.01 66.66** 
EESX 50 0.31 ± 0.01 13.88ns 
EESX 100 0.26 ± 0.01 27.77** 
EESX 200 0.17 ± 0.02 52.77** 
EESX 300 0.14 ± 0.01 61.11** 
aValues are mean ± S.E.M. (n=6); nsNot significant, **P < 0.01 vs. control; 
Dunnett’s t-test after one-way ANOVA. 
 
Table 7: Effect of ethanolic extracts of S. xanthocarpum on mast cell 
degranulationa 
 
Pre-treatment 
(µg/ml) 
Degranulation after treatment (%) 
 Vehicle 
Compound 48/80 
(10 µg/ml) 
Vehicle 33.4 ± 0.93 75.8 ± 1.36 
DSCG (20) 12.8 ± 3.07** 20 ± 1.79## 
EESX (1) 24 ± 2.91ns 68.4 ± 2.42ns 
EESX (10) 20.6 ± 2.64* 32.8 ± 1.96## 
EESX (100) 17.8 ± 1.59** 41.6 ± 3.33## 
 
aEach value represents the mean ± S.E.M. of five observations; nsNot significant,  
*P < 0.05, **P < 0.01 vs. control (vehicle treated), one-way ANOVA followed by 
Dunnett’s t-test; ##P < 0.01 vs. control (Compound 48/80 treated), one-way 
ANOVA followed by Dunnett’s t-test. 
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Conclusions 
The present data clearly showed that ethanol extract of S.Xanthocarpum exhibit 
acute, sub acute and chronic anti-inflammatory activity by inhibiting carrageenan 
and dextran-induced oedema and cotton pellet granuloma. It prevented histamine 
and acetylcholine, well known spasmogens, induced bronchoconstriction in 
guinea pigs. These data clearly show anti-asthmatic action of the plant. Further 
studies must be conducted in order to clarify the exact anti-inflammatory 
mechanism of this plant extract. Taken together, the present study clearly showed 
anti-asthmatic potential of EESX and validated the traditional use of this plant for 
treating inflammatory disorders. 
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ABSTRACT 
 
Solanum xanthocarpum (Solanaceae) (SX) is an important medicinal herb in Ayurvedic 
medicine. Since, there are few articles on this plant, the present review is undertaken to 
summarize available data and compile all the updated information on its phytochemical and 
pharmacological activities.  Various studies indicated that SX possesses antiasthmatic, 
hypoglycemic, hepatoprotective, antibacterial and insect repellent properties. Although the 
results are very encouraging and indicated that some of the constituents of the plant like 
solasodine and diosgenin are important therapeutically, the herb should be studied more 
extensively to confirm these results and reveal other potential therapeutic effects. Various 
traditional claims like immunomodulation, anti-inflammatory, antiallergic, antianaphylactic and 
antitumor effects of the plant are still remain to be validated scientifically. Clinical trials for the 
reported preclinical studies should be performed urgently to further validate the claims on 
humans. 
 
Key Words: Solanum xanthocarpum, phramacological activities, phytochemistry, Solasodine, 
Traditional uses. 
______________________________________________________________________________ 
 
INTRODUCTION 
 
Herbal medicines are being used by nearly about 80% of the world population, primarily in 
developing countries for primary health care [1]. Assessing the current status of health care 
system in adequacies of synthetic drugs is likely to be more glaring in the coming years. It has 
been reported that there has been an alarming increase in number of diseases and disorders 
caused by synthetic drugs prompting a switch over to traditional herbal medicine [2]. India has 
over 1, 08,276 species of bacteria, fungi, animals and plants already identified and described [3]. 
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Out of these about 84% species constitutes fungi (21.2%), flowering plants (13.9%) and insects 
(49.3%). 
 
Ayurveda is a traditional Indian Medicinal System practiced for thousands of years. 
Considerable research on pharmacognosy, chemistry, pharmacology and clinical therapeutics has 
been carried out on ayurvedic medicinal plants. Natural products, including plants, animals and 
minerals have been the basis of treatment of human diseases. The current accepted modern 
medicine or allopathy has gradually developed over the years by scientific and observational 
efforts of scientists. However, the basis of its development remains rooted in traditional medicine 
and therapies [4]. 
 
Selection of scientific and systematic approach for the biological evaluation of plant products 
based on their use in the traditional systems of medicine forms the basis for an ideal approach in 
the development of new drugs from plants. One such plant is Solanum xanthocarpum (SX) 
Schrad. & Wendl. (Family: Solanaceae) commonly known as the Indian night shade or Yellow 
berried night shade (English) and kantakari (Sanskrit). It is a prickly diffuse, bright green 
perennial herb, woody at the base, 2–3 m height, found through out India, mostly in dry places as 
a weed along roadsides and waste lands [5]. SX has held a place of some importance in the 
Hindu Materia Medica, primarily as an expectorant and antipyretic. Various medicinal properties 
are attributed to it, particularly in the treatment of asthma, chronic cough and catarrhal fever [6]. 
It is one of the members of the dashamula (ten roots) of the Ayurveda [7].  
 
Taxonomic classification 
Kingdom - Plantae 
Subkingdom - Tracheobionta 
Division - Magnoliophyta 
Class - Magnoliopsida 
Subclass - Asteridae 
Order - Solanales 
Family - Solanaceae 
Genus - Solanum 
 
Botanical description 
Synonyms  
Latin:  Solanum surattense, Syn. S. Xanthocarpum 
Sanskrit: Kantkari, Nidigdhika 
Hindi:  Kateri, Kattay 
Gujarati: Bhoringni, Bhonya-ringani 
Tamil:  Kantankattiri 
Malayalam: Kantkariccunta, Kantakarivalutana, Kantankattiti 
Telugu: Callamulaga, Pinnamulaka, Nelamulaka, Vakudu 
Kannad: Nelagulle 
 
 
 
Sachin Parmar et al                                                  Der Pharmacia Lettre, 2010, 2(4): 373-383  
______________________________________________________________________________ 
375 
Scholar Research Library 
Geographical Source  
It occurs throughout India, in dry situations as a weed along the roadsides and wastelands. It is 
naturally propagated by seed in waste lands. It is also distributed in Ceylon, Asia, Malaya, 
Tropical, Auastrana and Polynessia [8]. 
 
Morphology  
A very prickly diffuse bright green perennial herb, somewhat woody at the base; stem is 
somewhat zigzag; branches are numerous, the younger ones clothed with dense stellate 
tomentum; prickles are compressed, straight, yellow, glabrous and shining, often exceeding 1.3 
cm. Leaves are usually 5-10 in numbers and 2.5-5.7 cm in length, ovate or elliptic, sinuate or sub 
pinnatified, obtuse or sub acute, stellately hairy on both sides, sometimes becoming nearly 
glabrous in age, armed on the midrib and often on the nerves with long yellow sharp prickles, 
base usually rounded and unequal-sided; petiole 1.3-2.5 cm long, stellately hairy. The berries are 
green and white strips when young but yellow when mature. They are 1.3-2 cm in diameter, 
yellow, or white with green veins, surrounded by the enlarged calyx. Seeds are 2.5 mm in 
diameter and glabrous. Calyx is nearly 1.3 cm long, densely hairy and prickly; tube short, 
globules. Lobes are 11 mm long, linear-lanceolate, acute and hairy outside. Filaments are 1.5 
mm long, glabrous; anthers 8 mm long, oblong lanceolate, opening by small pores. Ovary is 
ovoid, glabrous; style glabrous [9].  
 
Traditional uses 
In ancients Ayurveda, plant is described as pungent, bitter, digestive, alternative astringent. 
Stems, flowers, fruits are bitter, carminative. Root decoction used as febrifuge, effective diuretic 
and expectorant [10]. Charaka and Sushruta used the extract of entire plant and fruits in internal 
prescription for bronchial asthma, tympanitis, misperistalsis, piles and dysuria and for 
rejuvenation. Kantkari Ghrita of Charaka is specific for cough and asthma [11]. Linctuses 
prepared from the stamens of flowers is prescribed for chronic cough in children (Bangasena). 
The whole plant is used traditionally for curing various ailments. Decoction of the plant is used 
in gonorrhea; paste of leaves is applied to relieve pains; seeds act as expectorant in cough and 
asthma; roots are expectorant and diuretic, useful in the treatment of catarrhal fever, coughs, 
asthma and chest pain [12]. The plant is also known to have pest repellent properties and used as 
a contact poison and mollusicide. Roots are one of the constituents of well known Ayurvedic 
preparation “Dasmul Asava” and used as an expectorant, cough, asthma, and chest pain in 
Ayurvedic medicine [11].  
 
Fruits are edible and used by the local people as folk medicines in treating throat infections and 
other inflammatory problems [13]. The stem, flowers and fruits are prescribed for relief in 
burning sensation in the feet accompanied by vesicular eruptions. The antispasmodic, antitumor, 
cardiotonic, hypotensive, antianaphylactic and cytotoxic activities are also reported [14]. Fruit 
juice is useful in sore throats and rheumatism. A decoction of the fruits of the plant is used by 
tribal and rural people of Orissa, India for the treatment of diabetes [15]. The fruits are eaten as 
an anthelmintic and for indigestion. 
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Phytochemistry  
Chemical examinations of berries of SX were initially done by Saiyed and Kanga, (1936) [16] 
which led to the isolation of glycoalkaloid, solasonine. From the non alkaloidal portion, a 
glycoside of β-sitosterol with galactose as a sugar moiety has been obtained along with two 
phenolic substances, which could be identified as methyl caffeate and caffeic acid [6]. 
 
The fruits are reported to contain several steroidal alkaloids like solanacarpine [17] and 
solamargine [6]. Other constituents like caffeic acid coumarins like aesculetin and aesculin [18], 
steroids carpesterol, diosgenin, campesterol, daucosterol and triterpenes like cycloartanol and 
cycloartenol were reported from the fruits [19]. Steroidal glycoalkaloids are naturally occurring, 
secondary plant metabolites that are formed in a number of foods including potatoes, tomatoes, 
and eggplants [20]. Although they are reported to be potentially toxic, glycoalkaloids and 
hydrolysis products without the carbohydrate side chain (aglycons) also have beneficial effects. 
These include lowering of cholesterol [21], protection against infection by Salmonella 
typimurium [22] as well as against cancer [23], and potentiation of general anesthetics that act by 
inhibiting cholinesterase [24] and of a malaria vaccine [25]. Solanidine, but not the parent 
glycoalkaloids, exhibited estrogenic activity in an in vitro assay [26]. Structures of some isolated 
phytoconstituents from SX are shown in Figure 1. 
 
The fruit of SX contains alkaloid saponins which can be extracted in alcohol and have a heart-
stimulating function [27]. The detailed study on this plant resulted in the isolation of solasonine 
and solasodine [16], ß-sitosterol [19], and carpesterol [28].   
 
The fruits contained 20.71% of dry seeds, 4.62 of pericarp and 74.67 percent of moisture. The 
powdered seeds were extracted with benzene and yielded 19% of greenish-yellow oil which did 
not contain nitrogen or sulphur. The composition of the oil was calculated as oleic acid, 42.93; 
linolic acid, 36.18; palmitic acid, 5.37; steric acid, 9.77; arachidic acid, 0.35, and unsaponifiable 
matter, 1.2 percent [17]. 
Solasodine 
 
SX has a high concentration of solasodine alkaloid, a spiroketal alkaloid sapogenin with a 
heterocyclic nitrogen atom, which is the starting material for the manufacture of cortisone and 
sex hormones [29]. 
 
The berries are the main source of solasodine and diosgenin. Solasodine is N-analogue of 
diosgenin and used as a steroidal precursor in the steroid drug industry for the manufacture of 
corticosteroids, antifertility drugs, anabolic steroids etc. It is present in the form of a glycoside in 
most of the berries of the plant belonging to the genus solanum and the glycoalkaloids are 
variously known as solasonine, solamargine etc. with the common spiro aminoketal alkaloid or 
aglycon namely solasodine. The solasodine content of the berries of SX is reported to vary from 
1.1% to 4.6% [30] depending apparently on climatic and soil conditions. It has been observed 
that berries collected in autumn (September, October) yielded only solasonine and solamargine 
without any trace of solasurine which was obtained from the material collected in summer (May, 
June). The solasodine content of the unripe berries was 1.7% (on dry weight basis) as against 
0.75% noted for the ripe berries. 
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Solasodine has been estimated by various methods by many workers viz. gravimetric, non-
aqueous, potentiometric, Chromatography, Colorimetric and even RIA. A number of analytical 
methods like high performance thin-layer chromatography (HPTLC) [31], and high-performance 
liquid chromatography (HPLC) [32], capillary electrophoresis, gas chromatography (GC) [33], 
are available for determination of solasodine from its plant. Solasodine does not have a 
conjugated double bond in its structure [34]. 
 
S. Emmanuel et al. (2006) reported satisfactory content of solasodine (0.84%) in the plant. 
Further, they reported that the control of temperature, time of extraction and concentration of 
hydrochloric acid has some influence on the percentage recovery of solasodine.  In no case 
extraction, hydrolysis, basification and purification temperature should be high throughout the 
process of estimation as it may affect in actual recovery of solasodine due to over heating [35]. 
 
Pure white crystals of solasodine could be obtained with 196-197°C m.p. Solasodine is a 
nitrogenous analogue of diosgenin which can be converted to progesterone a steroidal sex 
hormone used in the oral contraceptive industry [35]. 
 
The studies of S. Emmanuel, (2006) revealed that solasodine showed anti-inflammatory activity 
against carrageenan induced paw oedema in rats. The tested extract and its constituent solasodine 
showed significant reduction of the inflammatory reaction from 19.5 to 56.4% [35]. 
 
M. R. Heble et al. (1968) reported the isolation and identification of ß-sitosterol and diosgenin 
from callus tissues of SX. Chemical examination of SX berries also resulted in the isolation of 
diosgenin. Although only trace amounts of the steroidal alkaloid solasonine and solanine were 
detected earlier, the tissue cultures of SX have yielded ß-sitosterol and diosgenin in quantities 
much higher than that obtained from the growing plant [28].  
 
Carpesterol 
Carpesterol was the first compound isolated from the lipid fraction of plant, more than three 
decades ago no structural studies of the sterol have been reported. Because it was hoped that a 
structural knowledge of  carpesterol would shed some light on the biogenetic pathway leading to 
solasodine  ,which is the major alkaloid accompanying  carpesterol in SX and  commonly found 
among many other solanum species. 
 
Saiyed and Kanga (1936) isolated the substance carpesterol along with a steroidal alkaloid 
glycoside [16]. Subsequent investigations of extracts from SX showed the presence of diosgenin 
[19, 28], and β-sitosterol. 
 
Jolly et al. (1989) have reported the variation in the solasodine content, at different stages of fruit 
maturity viz. berries when green in color, color changing from green to yellow color. It was 
concluded that the berries of SX in the initial stages of fruit development are very small, green in 
color with white blotched stripes [36]. On growing, it develops yellow color which signifies the 
beginning of ripening. On ripening it attains yellow color.  Berries on further standing in the 
plant becomes deep yellow in color, at which stage the stalk through which the berries are 
attached turns brown in color from the original green.  During fruit development or maturity, an 
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associated change in the steroidal glycoalkaloid content and therefore in the steroidal alkaloid 
content was observed. The colorimetric method was used for the determination of the solasodine 
content. Solasodine forms yellow colored complex with methyl orange extractable in 
chloroform. It gave maximum absorbance at 425 nm. 
 
                                    (A) Solasodine     (B) Solanidine  
 (C) Solasonine    
 (D) Solanine 
   (E) Diosgenin (steroidal saponin)  (F) Campesterol (sterol) 
 
Figure 1. Structures of some phytoconstituents isolated from Solanum xanthocarpum 
 
From berries collected during various months from the same area, it was greatest when berries 
are yellow in color (i.e. when the berries are ripe) [36]. 
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From the fruit extract of SX, cycloartanol, cycloartenol, sitosterol, stigmasterol, campesterol, 
cholesterol, sitosteryl glucoside, stigmasteryl glucoside, solamargine, and β-solamargine were 
identified and an isolated steroid was identical with 4α-methyl-(24R)-ethylcholest-7-en-3β-ol 
synthesized from carpesterol. 
 
Pharmacological actions 
Antiasthmatic properties  
Bronchial asthma is an inflammatory disorder of the airways characterized by various airway 
obstruction, airway eosinophilic inflammation and bronchial hyper responsiveness [37] and is a 
global health problem that results from a complex interplay between genetic and environmental 
factors [38]. Among several respiratory diseases affecting man, bronchial asthma is the most 
common disabling syndrome. Nearly 7–10% of the world population suffers from bronchial 
asthma. Despite the availability of a wide range of drugs, the relief offered by them is mainly 
symptomatic and short lived. Moreover the side effects of these drugs are on going to identify 
effective and safe remedies to treat bronchial asthma.  
 
A pilot study on the clinical efficacy of SX and Solanum trilobatum in bronchial asthma were 
undertaken to prove the significant use of herbs in treatment of asthma [7]. Major literature data 
supports use of whole plants. Gautam et al. (2008) evaluated the therapeutic effect of ethanolic 
extract of SX i.e. asthma relieving or antihistaminic, antiallergic property [10]. 
 
Gautam et al. (2008) studied effects of SX extract on some of the parameters like smooth muscle 
relaxation, and antagonism of asthma mediators such as histamine, eiosinophils and protection 
against mast cell degranulation which seemed to be prominent in pathophysiology of asthma 
[10]. Further they showed that ethanol extract of SX shown a significant antihistaminic activity 
in histamine induced contraction in goat tracheal chain preparation. Thus, the significant 
inhibition of histamine induced contractions produced by ethanol extract of SX flower on 
isolated goat tracheal chain preparation indicates that the SX flower has antihistaminic (H1-
receptor antagonist) action. While screening the all three extracts of flowers of SX, results were 
indicative that only ethanolic extract of SX at a dose of 50 and 100 mg / kg reduced milk-
induced eiosinophilia of statistical significance. SX at a dose of (50-100 mg/kg, i.p) showed 
significant mast cell stabilization as compared to standard drug Disodiumchromoglycate 
(DSCG).  
 
SX is widely used by practitioners of the Siddha system of medicine in southern India to treat 
respiratory diseases [15]. The powder of whole dried plant or a decoction is used for this 
purpose. Govindan et al. (1999) showed that treatment with SX improved the pulmonary 
functions to a significant level in patients suffering from mild to moderate asthma. Subjective 
relief from asthmatic symptoms was reported by the patients an hour after administration of SX 
powder. The effect lasted for about 6–8 h. However, responses observed were apparently less 
when compared to that of deriphilline or salbutamol. A decrease in forced expiration volume and 
peak expiration flow rates are indicative of both large and small airway obstruction and muscle 
power [39]. The dose of SX was well tolerated and no untoward effects were reported. SX is a 
safe medicine in the traditional system and has been used by mankind over many centuries. It 
was suggested that relief from the symptoms of bronchial asthma produced by SX may be due 
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to:(a) a bronchodilator effect, (b) reduction in the bronchial mucosal edema, and/or (c) reduction 
in the secretions within the airway lumen. 
 
Hypoglycemic activity  
The Kondh tribes of Dhenkanal district of Orissa, India use the hot aqueous extract of the 
matured fruits as a traditional medicine for the treatment of diabetes mellitus. 
 
The aqueous extract showed significant hypoglycemic effect in both normal and streptozotocin 
induced diabetic rats at dose of 100 and 200 mg/kg. The activity showed by aqueous extract was 
comparable to that of standard oral hypoglycemic agent glibenclamide. The experimental results 
indicated that it exhibited a potent blood glucose lowering property both in normal and 
streptozotocin induced diabetic rats. The LD50 of the extract was found to be high indicating high 
margin of safety [40].  
 
Hepatoprotective activity  
Jigrine is a polypharmaceutical herbal formulation containing aqueous extracts of 14 medicinal 
plants including SX and used for liver ailments. A. K. Najmi et al. [2005] investigated the 
DPPH-free radical scavenging activity, hepatoprotective and antioxidant activity of Jigrine 
against galactosamine induced hepatotoxicity in rats [41]. 
 
Cardiovascular effects  
Pasnani JS (1988) reported that Abana, a polyherbal formulation containing SX causes: (i) A 
direct sensitization of the atrium through an increase in permeability to Ca2+ and (ii) an effect 
similar to withdrawal of chronic ISO administration, i.e. down regulation of beta adrenoceptors 
[42]. 
 
Antifilarial effect  
Lalit Mohan et al. (2006) reported the larvicidal potential of crude extracts of SX and suggested 
its suitability as an ecofriendly, effective larvicide in the management of mosquito populations 
and in limiting the outbreak of various vector borne epidemics [43]. 
 
Mosquito larvicidal effect  
The plant has been used in the various fields of pest management [45] but it is not exploited in 
vector control. The fruit extracts of SX revealed larvicidal activity against An. stephensi and Cx. 
Quinquefasciatus and one culicine species Ae. aegypti [46]. Volatile oil obtained from SX 
exhibited repellency against mosquito Cx. quinquefasciatus at a very lower concentration than 
those of the plants studied earlier. The lethal concentrations of fruit extract at LC50 and LC90 
levels against An. culicifacies, An. stephensi and Ae. aegypti were determined as 0.112 and 0. 
258, 0.058 and 0.289 and 0.052 and 0.218% respectively. The root extract is also effective 
against anopheline and culicine mosquito species, though at higher concentrations in comparison 
to fruit extract [44].  
 
Miscellaneous activities 
Dixit VP (1982) reported antiandrogenic activity of solasodine, an alkaloidal constituent of the 
plant [47]. Further study showed antifertility effects of solasodine in male rats and dogs [48]. 
Sachin Parmar et al                                                  Der Pharmacia Lettre, 2010, 2(4): 373-383  
______________________________________________________________________________ 
381 
Scholar Research Library 
Carpesterol and four steroidal glycosides isolated from methanol extract of SX fruits exhibited 
inhibitory effects on the radial growth of Aspergillus niger and Trichoderma viride [49]. 
Methanolic extract from dried fruit tissues of SX showed antifungal activity against A. brassicae. 
The methanolic extract of SX aerial parts significantly and dose-dependently suppressed the 
frequency of acetic acid-induced abdominal constrictions in mice.  
 
SUMMARY AND CONCLUSION 
 
Alternative system of medicine is a major component of health care globally and many 
healthcare providers and organizations are being forced to consider integrating them into their 
practice and treatment guideline [50]. 
 
The extensive survey of literature revealed that SX is an important source of many 
pharmacologically and medicinally important chemicals, especially steroidal hormone solasodine 
and other chemicals like solasonine, campestrol, campeferol, diosgenin and various useful 
alkaloids. The solasodine is the most studied chemical constituent of SX which has a role in the 
production of sex hormones. The plant is extensively studied for the various pharmacological 
activities like antiasthmatic, hepatoprotective, cardiovascular, hypoglycemic and mosquito 
repellent properties. Various traditional claims like immunomodulation, hypolipidemic, 
antibacterial, sexual behaviour, tolerance and dependence is not studied till the date and needs 
attention in this area to explore further medicinal values of this plant.   Although the results from 
this review are quite promising for the use of SX as a multi-purpose medicinal agent, several 
limitations currently exist in the current literature.  While SX has been used successfully in 
Ayurvedic medicine for centuries, more clinical trials should be conducted to support its 
therapeutic use. Moreover, the therapeutic potential of the plant should also be checked when 
used in combination with other herbal drugs. 
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Evaluation of antiasthmatic activity of a polyherbal 
formulation containing four plant extracts. 
 
Sachin Parmar, Amit Gangwal and Navin Sheth 
 
 
ABSTRACT 
Objective: We evaluated the antiasthmatic potential of a polyherbal formulation using several 
experimental models. 
Materials & Methods: Adult Wistar albino rats were used for mast cell stabilization protocol. 
Acetylcholine and histamine-induced bronchospasm were conducted on guinea pigs. 
Results: The results of the acetylcholine and histamine-induced bronchospasm paradigms 
demonstrate bronchospasmolytic activity of polyherbal formulation (300 mg/kg, p.o.). The 
spasmolytic effect was characterized by prolongation of onset of bronchospasm and reduction of 
asphyxia as compared to control group (P < 0.01). In the mast cell stabilization paradigm, 
compound 48/80 treatment produced 76% of mast cell degranulation. Polyherbal formulation (1, 
10, and 100 µg/ml) showed dose-dependent significant reduction in mast cell degranulation (P < 
0.01) as compared to the compound 48/80-treated animals. The probable mechanism for the 
antiasthmatic action of the polyherbal formulation could be antihistaminic, anticholinergic and 
mast cell membrane stabilization. The LD50 of polyherbal formulation was 2262.7 mg/kg, p.o. 
Conclusion: The results of our study, for the first time, show that the polyherbal formulation 
possesses antihistaminic, anticholinergic and mast cell stabilizing properties and therefore can be 
a candidate for the antiasthmatic treatment. Future research should focus on the molecular 
mechanism of responsible constituent for antiasthmatic action. 
 
Keywords: Antiasthmatic, Antihistaminic, Anticholinergic, Mast cell stabilization, Polyherbal 
formulation. 
 
 
 
1.  INTRODUCTION 
Bronchial asthma is an inflammatory disorder of the airways characterized by various 
airway obstruction, airway inflammation and bronchial hyper responsiveness (Djukanovic et al., 
1990) and is a global health problem that results from a complex interplay between genetic and 
environmental factors (Phillip, 2003). Nearly 7–10% of the world population suffers from 
bronchial asthma. Among several respiratory diseases affecting man, bronchial asthma is the most 
common disabling syndrome. Despite the availability of a wide range of drugs, the relief offered 
by them is mainly symptomatic and short lived. Moreover, these drugs produce side effects. 
Therefore, there is a dire need to identify effective and safe remedies to treat bronchial asthma 
(Govindan et al., 1999). The current accepted modern medicine or allopathy has gradually 
developed over the years by scientific and observational efforts of scientists. However, the basis of 
its development remains rooted in traditional medicine and therapies (Rana, 2008). 
Herbal medicines are being used by nearly about 80% of the world population, primarily 
in developing countries for primary health care (Kamboj, 2000). Assessing the current status of 
health care system in adequacies of synthetic drugs is likely to be more glaring in the coming 
years. It has been reported that there has been an alarming increase in number of diseases and 
disorders caused by synthetic drugs prompting a switch over to traditional herbal medicine (Ghule  
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& Patil, 2001). Ayurveda is a traditional Indian Medicinal System 
practiced for thousands of years. Considerable research on 
pharmacognosy, chemistry, pharmacology and clinical therapeutics 
has been carried out on ayurvedic medicinal plants. The polyherbal 
formulations described in Ayurveda have been the basis of 
treatment of various human diseases. Selection of scientific and 
systematic approach for the biological evaluation of herbal 
formulations based on their use in the traditional systems of 
medicine forms the basis for an ideal approach in the development 
of new drugs from plants. 
In the light of above background, the present study aimed 
at evaluation of a polyherbal formulation for the possible 
antiasthmatic action using experimental animals. 
2.  MATERIALS AND METHODS 
Collection of plant materials  
The leaves of Solanum xanthocarpum, Murraya koenigii, 
Aegle marmelos and Caesalpinia bonduc were collected from the 
out field of Junagadh city, Gujarat, India in February-March 2007. 
The plant materials were identified and authenticated by Dr. P. 
Parmar, Botanical Survey of India, Jodhpur, Rajasthan, India. 
Voucher specimens (SU/DPS/Herb/19-22) of the collected plant 
samples were deposited in the Department of Pharmaceutical 
Sciences, Saurashtra University, Rajkot, Gujarat, India for future 
reference. 
Drugs and chemicals 
Compound 48/80, disodium chromoglycate (DSCG), 
histamine dihydrochloride, acetylcholine chloride, atropine sulfate, 
mepyramine meleate, and toluidine blue were purchased from 
Sigma (St. Louis, MO, USA). Histamine solution was freshly 
prepared in normal saline (NaCl, 8.5 g/l). All the other chemicals 
were of analytical grade. 
Extraction 
Leaves of different plants were washed with distilled 
water to remove dirt and soil, and shade dried. The dried materials 
were powdered and passed through a 10-mesh sieve. The coarsely 
powdered materials (500 g) of each plant was defatted with 
petroleum ether (60-800) and then extracted separately with ethanol 
(95%, v/v) in a Soxhlet apparatus. The extracts were filtered and 
concentrated by distilling off the solvents and evaporated to 
dryness using water bath to get crude ethanol extract. 
Experimental animals 
Antihistaminic and anticholinergic studies were 
conducted on guinea pigs (350-500 g) of either sex. For mast cell 
stabilization paradigm, adult Wistar albino rats weighing 140–160 
g of either sex were used. All the experimental animals were fed on 
commercial pellet diet (Amrut, Pranav Agro Industries Ltd, India). 
They were group housed under standard conditions of temperature 
(22 ± 20C), relative humidity (60 ± 5%) and 12:12 light/dark cycle, 
where lights on at 0700 and off at 1900 h). They were divided in 
groups of ten animals each. The saline fed group served as control 
and one group was treated with a standard drug. Before 
experimentation, the animals were kept on fast for 24 h but water 
was given ad libitum. During experiments, animals were also 
observed for any alteration in their general behavior. 
All the experimental protocols were approved by the 
Institutional Animal Ethics Committee (IAEC), N. R. Vekaria 
Institute of Pharmacy and Research Centre, Junagadh, Gujarat, 
India (approval number-NRVCP/IAEC/08-2k7/01). All the 
experiments and the care of the laboratory animals were according 
to current ethical guidelines by the Committee for the Purpose of 
Control and Supervision on Experiments on Animals (CPCSEA), 
Ministry of Environment and Forests, Government of India, New 
Delhi. 
Preparation of the test extracts 
The polyherbal formulation was suspended in 1% SCMC 
in distilled water and administered orally or intraperitoneally. The 
control animals were given an equivalent volume of SCMC 
vehicle. The standard group received various standard anti-
asthmatic drugs.  
Phamacological screening (Antiasthmatic paradigms) 
Histamine-induced bronchospasm in guinea pigs (Armitage et 
al., 1961) 
The guinea pigs fasted for 24 h were exposed to an 
atomised fine mist of 2% histamine dihydrochloride aerosol 
(dissolved in normal saline) using nebulizer at a pressure of 300 
mm Hg in the histamine chamber (24 x 14 x 24 cm, made of 
perplex glass). Guinea pigs exposed to histamine aerosol showed 
progressive signs of difficulty in breathing leading to convulsions, 
asphyxia and death. The time until signs of convulsion appeared is 
called pre-convulsion time (PCD). By observation experience was 
gained so that the preconvulsion time can be judged accurately. As 
soon as PCD commenced, animals were removed from the 
chamber and placed in fresh air to recover. In the present 
experiments the criterion used was time for onset of dysponea and 
percent protection was calculated. Those animals which developed 
typical histamine asthma within 3 min were selected out three days 
prior to the experiment and were given habituation practice to 
restrain them in the histamine chamber. They were divided in 
groups of ten animals each. Mepyramine (8 mg/kg) and polyherbal 
formulation (300 mg/kg) were administered intraperitonially 30 
min prior to exposure. Animals, which did not develop typical 
asthma within 6 minutes were taken as protected. 
Acetylcholine-induced bronchospasm in guinea pigs (Kumar & 
Ramu, 2002) 
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Procedure was similar to the histamine aerosol study except that 
animals were exposed to aerosol of 0.5% acetylcholine in another 
set of animals (n = 10). Atropine sulphate (2 mg/kg) was used as a 
standard drug. 
Mast cell degranulation by compound 48/80 
This was carried out as per the method described by Kaley 
and Weiner (1971) with little modification. Male albino rats were 
sacrificed by cervical dislocation. The animals were immediately 
injected with 15 ml of pre-warmed (37°C) buffered salt solution 
(NaCl 137 mM; KCl 2.7 mM; MgCl2; 1 mM; CaCl2 0.5 mM; 
NaH2PO4 0.4 mM; Glucose 5.6 mM; HEPES 10 mM) into the 
peritoneal cavity, and massaged gently in this region for 90 s, to 
facilitate cell recovery. A midline incision was made and the 
peritoneum was exposed. The pale fluid was aspirated using a 
blunted plastic Pasteur pipette, and collected in a plastic centrifuge 
tube. The fluid was then centrifuged at 1000 rpm for 5 min, and the 
supernatant discarded to reveal a pale cell pellet. The cell pellets 
were re-suspended in fresh buffer and re-centrifuged. Aliquots of 
the cell suspension were incubated with the test compounds or 
disodium cromoglycate, before challenge with compound 48/80. 
The aliquots were carefully spread over glass slides and the mast 
cells were stained with 1% toluidine blue and counterstained with 
0.1% light green. The slides were dried in air and the mast cells 
counted from randomly selected high power objective fields 
(X450). The effect of polyherbal formulation on mast cells was 
studied by incubating the mast cells for 10 min with the above 
formulation in a concentration of 1, 10 or 100 µg/ml. In another set 
of experiments the mast cells which were pre-incubated with 
polyherbal formulations were exposed to the mast cell 
degranulator, compound 48:80 (10 µg/ml) and the incubation 
continued for a further 10 min. Then, the mast cells were carefully 
spread over glass slides. The percent degranulation of the mast 
cells was calculated. Disodium cromoglycate (DSCG) (20 µg/ml) 
was included in one of the study group for comparison. 
Table 1. Effect of polyherbal formulation on mast cell 
degranulationa 
Pre-treatment (µg/ml) Degranulation after treatment (%) 
 Vehicle 
Compound 48/80 
(10 µg/ml) 
Vehicle 33.4 ± 0.93 75.8 ± 1.36 
DSCG (20) 12.8 ± 3.07** 20 ± 1.79## 
Polyherbal formulation (1) 27.4 ± 2.16ns 57.4 ± 2.32## 
Polyherbal formulation (10) 25.8 ± 2.18ns 45.8 ± 2.31## 
Polyherbal formulation (100) 17.6 ± 1.94** 30.4 ± 0.81## 
 
aEach value represents the mean ± S.E.M. of five observations; nsNot significant,  
*P < 0.05, **P < 0.01 vs. control (vehicle treated), one-way ANOVA followed by 
Dunnett’s t-test; #P < 0.05, ##P < 0.01 vs. control (Compound 48/80 treated), one-
way ANOVA followed by Dunnett’s t-test. 
Acute toxicity test (Determination of LD50) 
The acute toxicity test (LD50) was determined according 
to the procedure described by Lorke (1983). Albino mice (20–25 g) 
of either sex were used. This method involved an initial dose 
finding procedure, in which the animals were divided into three 
groups of three animals per group. Doses of 10, 100 and 1000 
mg/kg were administered intraperitoneally (i.p.), one dose for each 
group. The treated animals were monitored for 24 h for mortality 
and general behavior.  
From the result of the above step, four different doses of 
200, 400, 800 and 1600 mg/kg were chosen and administered i.p. 
respectively to four groups of one mouse per group. The treated 
animals were again monitored for 24 h. The LD50 was then 
calculated as the geometric mean of the lowest dose showing death 
and the highest dose showing no death. 
Preparation of polyherbal formulations 
The polyherbal formulations was composed of ethanolic extracts of 
Solanum xanthocarpum (50 mg), Aegle marmelos (50 mg), 
Caesalpinia bonduc (100 mg), and Murraya koenigii (100 mg). 
Table 2. Effect of polyherbal formulation on histamine-aerosol in 
guinea pigsa 
Treatment Dose (mg/kg, i.p.) Protection (%) 
Control  saline, 1.0 ml/kg 0 
Mepyramine 8 90*** 
Polyherbal formulation 300 80** 
 
an=10 in each group; **P < 0.01, ***P < 0.001 vs. control; (χ2 test with Yate’s 
correction) 
 
3. RESULTS AND DISCUSSION 
The results of the present study revealed mast cell 
stabilization, antihistaminic and anticholinergic actions of 
polyherbal formulation. 
 In the mast cell stabilization paradigm, 33% of mast cells 
were degranulated in the control group. Addition of DSCG (20 
µg/ml), and the polyherbal formulation (100 µg/ml) reduced the 
percentage of mast cell degranulation (P < 0.01) compared to the 
control group. Compound 48/80 (10 µg/ml) produced about 76% 
degranulation of mast cells. Pretreatment with DSCG (20 µg/ml) 
and the polyherbal formulation (1, 10, and 100 µg/ml) significantly 
reduced (P < 0.01) degranulation of mast cells as compared to 
compound 48/80-tretaed control group (Table 1). The protection 
given by them at higher concentrations was comparable to that of 
DSCG, a potent mast cell stabilizing agent. These results suggest 
42
Journal of Current Pharmaceutical Research 2010; 2(1): 40-44 
 
that polyherbal formulation protects mast cells from compound 
48/80-evoked degranulation. 
In the histamine aerosol study, the control animals 
showed convulsion during the first 3 min of the experiment. Prior 
treatment of polyherbal formulation (300 mg/kg, i.p.) protected the 
animals (Table 2) to a significant extent (P < 0.01) from the 
development of asphyxia produced by histamine aerosol 
confirming that it has antihistaminic activity. The role of histamine 
in asthma is well established (Nelson, 2003). The close 
resemblance of pulmonary responses to histamine challenge in 
both guinea pigs and humans, as well as the anaphylactic 
sensitization made this species the model of choice. In the present 
study, guinea pigs were used because of the extreme sensitivity of 
their airways to the primary mediators of bronchoconstriction, 
including histamine and leukotrienes, and their ability to be 
sensitized to foreign proteins. Although there are various model of 
asthma, guinea pig airways react to histamine, acetylcholine, 
leukotrienes, and other bronchoconstrictors in a manner similar to 
that seen in humans (Agrawal et al., 1991). Another similarity 
between the guinea pig model and asthmatic patients is that 
enhanced bronchoconstriction occurs in both species following 
sensitization, in response to β-adrenergic antagonists (Matsumoto 
et al., 1994). Thus, the guinea pig model resembles the human 
allergic pathology in several aspects, especially in terms of 
mediator release. Histamine antagonists can be conveniently 
recognized and assayed by their ability to protect guinea pigs 
against lethal effects of histamine-induced bronchospasm 
(Broadbent & Bain, 1964). Mepyramine, a standard anti-histaminic 
drug, (8 mg/kg, i.p.) significantly protected 90% of animals from 
asphyxia (P < 0.001). 
Table 3. Disease Severity Score of Azithromycin Vs Placebo 
Group 
Treatment 
Dose (mg/kg, 
i.p.) 
Preconvulsion time 
(sec) 
Protection 
(%) 
Control  saline, 1.0 ml/kg 128 ± 2.72 - 
Atropine 2 460 ± 4.33 72.17** 
Polyherbal 
formulation 
300 285 ± 3.70 55.08** 
 
aValues are mean ± S.E.M. (n = 10); **P < 0.01 vs. control; Dunnett’s t-test after 
one-way ANOVA. 
Acetylcholine-aerosol provoked bronchoconstriction in all animals 
of control group. The polyherbal formulation (300 mg/kg, i.p.) 
significantly protected animals (P < 0.01) from acetylcholine-
induced bronchoconstriction. Atropine sulphet (a standard anti-
muscarinic drug, 2 mg/kg, i.p.) significantly prolonged pre-
convulsion time to 460 ± 4.33 sec (P < 0.01) and protected animals 
from asphyxia (Table 3). The LD50 of the polyherbal formulation 
was calculated to be 2262.7 mg/kg, i.p. 
In the early stage of asthma, release of inflammatory mediators like 
histamine, acetylcholine, leukotrienes, and prostaglandins are 
triggered by exposure to allergens, irritants, cold air or exercise 
(Bosquet et al., 2000). Some of these mediators directly cause 
acute bronchoconstriction. Spasmolytic drugs like β-adrenergic 
agonists, xanthine derivatives and anticholinergic drugs are used as 
quick relief medications in such acute asthmatic attacks (Horwitz 
& Busse, 1995). In the present study, we have used histamine and 
acetylcholine as spasmogens in the form of aerosols to cause 
immediate bronchoconstriction in guinea pigs. Mepyramine (8 
mg/kg) and atropine sulphate (2 mg/kg) were used as reference 
standard against histamine and acetylcholine induced 
bronchospasm respectively (Shah & Parmar, 2003). The 
bronchodilatory effect of polyherbal formulation was found 
comparable to the protection offered by both the reference standard 
drug mepyramine and atropine sulphate.  
4. CONCLUSION 
In conclusion, the results of present investigation suggest 
that, polyherbal formulation have significant bronchodilatory 
activity against histamine and acetylcholine. However, further 
studies are suggested to establish molecular mechanism and also to 
isolate and characterize the active principles responsible for the 
action. 
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Mast cell membrane stabilization and anti-
histaminic actions- possible mechanism of action of 
anti-inflammatory action of Murraya koenigii 
    
Sachin Parmar, Amit Gangwal and Navin Sheth 
 
 
 
ABSTRACT 
Objective: The present study aimed to evaluate mast cell stabilizing action as a mechanism of 
action of anti-inflammatory action of Murraya koenigii using experimental paradigms. 
Materials & Methods: Adult Wistar albino rats were used for mast cell stabilization and 
carrageenan-induced inflammation protocol. 
Results: The results demonstrate mast cell stabilization and anti-inflammatory actions of 
Murraya koenigii in the experimental animals. Compound 48/80, a potent mast cell 
degranulator, provoked 76% degranulation of mast cells in the control group. Ethanolic extract 
of M. koenigii (EEMK) at the doses 1, 10, and 100 µg/ml protected from compound 48/80-
evoked degranulation (P < 0.01) in dose dependent manner. In the carrageenan-induced 
inflammation model, EEMK (300 and 400 mg/kg) showed significant anti-inflammatory 
activity. EEMK (300 and 400 mg/kg) showed antihistaminic actions in the histamine-aerosol 
protocol. The mast cell stabilization and antihistaminic effects of EEMK could be the probable 
mechanism for its anti-inflammatory action. The LD50 of EEMK was 1131.4 mg/kg, i.p. 
Conclusion: The results of our study, for the first time, show mast cell stabilizing properties of 
Murraya koenigii. The anti-inflammatory actions of this plant may be due to its potent mast cell 
stabilization property. This confirms traditional claims of the plant and therefore the plant can be 
used to treat asthma. Future strategies should focus on the isolation and molecular mechanism of 
responsible constituent for mast cell stabilizing action. 
 
Keywords: Antiasthmatic, Anti-inflammatory, Compound 48/80, Carrageenan, Mast cell 
stabilization, Murraya koenigii. 
 
 
 
1.  INTRODUCTION 
Ayurveda is a traditional Indian Medicinal System practiced for thousands of years. 
Herbal medicines are being used by nearly about 80% of the world population, primarily in 
developing countries for primary health care (Kamboj, 2000). Selection of scientific and 
systematic approach for the biological evaluation of herbal formulations based on their use in the 
traditional systems of medicine forms the basis for an ideal approach in the development of new 
drugs from plants.
 
One such plant is Murraya koenigii (Family-Rutaceae; synonym-curry leaves in 
English). 
Murraya koenigii (L.) is an aromatic more or less deciduous shrub or a small tree up to 6 
meter in height found throughout India. It is cultivated for its aromatic leaves (Anonymous, 1998). 
The plant has been used in traditional Indian medicine for a range of ailments. The whole plant is 
considered to be a tonic and stomachic. Roots and bark are stimulant and are applied externally for 
skin eruptions and poisonous bites. Green leaves are febrifuge and used in dysentery (Anonymous, 
1987; Anonymous, 1998; Prajapati et al., 2003). The plant has shown antibacterial, antifungal, 
antiprotozoal, hypoglycemic and antioxidant activities (Iyear & Devi, 2008).  
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M. koenigii has been used since ancient times in Ayurvedic 
Medical Practice for the treatment of inflammatory disorders like 
asthma. Lack of scientific data to support the ancient literature 
claims prompted us to study the anti-inflammatory activity of M. 
koenigii. In our previous work, we have evaluated the effect of 
ethanolic extract of M. koenigii (EEMK) in both acute and chronic 
inflammatory models, such as carrageenan-induced paw edema and 
cotton pellet granuloma in rats. Results of these studies indicated 
the possibility that the EEMK interfered in the release and/or 
action of mediators like histamine, serotonin, prostaglandins, 
leukotrienes, etc. (Parmar et al., 2009).  
 Therefore, with the aim to investigate the possible 
mechanism of its anti-inflammatory activity, in the present study 
ethanolic extract of M. koenigii was further evaluated using two 
models, i.e. compound 48/80-induced mast cell degranulation and 
histamine-induced bronchospasm using experimental animals. 
2.  MATERIALS AND METHODS 
Collection of plant materials  
The leaves of Murraya koenigii were collected from the 
out field of Junagadh city, Gujarat, India in February-March 2007. 
The plant materials were identified and authenticated by Dr. P. 
Parmar, Botanical Survey of India, Jodhpur, Rajasthan, India. 
Voucher specimen (SU/DPS/Herb/22) of the collected plant 
sample was deposited in the Department of Pharmaceutical 
Sciences, Saurashtra University, Rajkot, Gujarat, India for future 
reference. 
Drugs and chemicals 
Compound 48/80, disodium chromoglycate (DSCG), 
histamine dihydrochloride, mepyramine meleate, and toluidine 
blue were purchased from Sigma (St. Louis, MO, USA). Histamine 
solution was freshly prepared in normal saline (NaCl, 8.5 g/l). All 
the other chemicals were of analytical grade. 
Extraction 
Leaves of the plant were washed with distilled water to 
remove dirt and soil, and shade dried. The dried material was 
powdered and passed through a 10-mesh sieve. The coarsely 
powdered material (500 g) of plant was defatted with petroleum 
ether (60-800) and then extracted separately with ethanol (EtOH) 
(95%, v/v) in a Soxhlet apparatus. The extract was filtered and 
concentrated by distilling off the solvents and evaporated to 
dryness using water bath to get crude ethanolic extract of M. 
koenigii. 
Experimental animals 
Antihistaminic study was conducted on guinea pigs (350-
500 g) of either sex. For mast cell stabilization and carrageenan 
hind paw oedema paradigms, adult Wistar albino rats weighing 
140–160 g of either sex were used. All the experimental animals 
were fed on commercial pellet diet (Amrut, Pranav Agro Industries 
Ltd, India). They were group housed under standard conditions of 
temperature (22 ± 20C), relative humidity (60 ± 5%) and 12:12 
light/dark cycle, where lights on at 0700 and off at 1900 h). The 
saline fed group served as control and one group was treated with a 
standard drug in each protocol. Before experimentation, the 
animals were kept on fast for 24 h but water was given ad libitum 
except during experimental test period. During experiments, 
animals were also observed for any alteration in their general 
behavior. 
All the experimental protocols were approved by the 
Institutional Animal Ethics Committee (IAEC) of N. R. Vekaria 
Institute of Pharmacy and Research Centre, Junagadh, Gujarat, 
India (approval number-NRVCP/IAEC/08-2k7/01). All the 
experiments and the care of the laboratory animals were according 
to current ethical guidelines by the Committee for the Purpose of 
Control and Supervision on Experiments on Animals (CPCSEA), 
Ministry of Environment and Forests, Government of India, New 
Delhi. 
Preparation of the test extracts 
The ethanolic extract was suspended in 1% sodium 
carboxymethyl cellulose (SCMC) in distilled water just before the 
protocol. The control animals were given an equivalent volume of 
SCMC vehicle. The standard group received various standard anti-
inflammatory, mast cell stabilizing or anti-histaminic drugs. 
Phamacological screening (Antiasthmatic paradigms) 
Carrageenin-induced hind paw edema in rats (acute 
inflammation model) 
The acute hind paw edema was produced by injecting 0.1 
ml of carrageenin (freshly prepared as 1% suspension in 1% CMC) 
locally into the plantar aponeurosis of the right hind paw of rats 
(Winter et al., 1962). EEMK (100, 200, 300, and 400 mg/kg, p.o.) 
was administered to four different groups while the other two 
groups served as negative and positive controls and received 
vehicle (1 ml/kg, p.o.) and standard drug, acetylsalicylic acid 
(ASA, 300 mg/kg, p.o.), respectively. For each treatment group six 
animals were used. EEMK and ASA were administered 1 h prior to 
the injection of carrageenan. A mark was made at the ankle joint of 
the paw of rat and pedal volume up to this point was measured 
using plethysmometer at 0 h (just before) and 1-, 2- and 3-h post-
carrageenan injections. Increase in the paw edema volume was 
considered as the difference between 0 and 1-, 2-, or 3-h. Percent 
inhibition of edema volume between treated and control groups 
was calculated as follows:  
 
 
                      Percent inhibition = 1 – VT/VC × 100 
Where, VC and VT represent the mean increase in paw volume in control and 
treated groups, respectively. 
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All the animals were fasted for 12 h and deprived of water only 
during the experiment. The deprivation of water was ensured 
uniform hydration minimized variability in oedematous response 
Histamine-induced bronchospasm in guinea pigs (Armitage et 
al., 1961) 
The guinea pigs fasted for 24 h were exposed to an 
atomized fine mist of 2% histamine dihydrochloride aerosol 
(dissolved in normal saline) using nebulizer at a pressure of 300 
mm Hg in the histamine chamber (24 x 14 x 24 cm, made of 
perplex glass). Guinea pigs exposed to histamine aerosol showed 
progressive signs of difficulty in breathing leading to convulsions, 
asphyxia and death. The time until signs of convulsion appeared is 
called pre-convulsion time (PCD). By observation experience was 
gained so that the preconvulsion time can be judged accurately. As 
soon as PCD commenced, animals were removed from the 
chamber and placed in fresh air to recover. In the present 
experiments the criterion used was time for onset of dysponea and 
percent protection was calculated. Those animals which developed 
typical histamine asthma within 3 min were selected out three days 
prior to the experiment and were given habituation practice to 
restrain them in the histamine chamber. They were divided in 
groups of ten animals each. Mepyramine (8 mg/kg) and EEMK 
(100, 200, 300, and 400 mg/kg) were administered intraperitonially 
30 min prior to exposure. Animals, which did not develop typical 
asthma within 6 minutes were taken as protected. 
Mast cell degranulation by compound 48/80 (Kaley & Weiner, 
1971) 
Male albino rats were sacrificed by cervical dislocation. 
The animals were immediately injected with 15 ml of pre-warmed 
(37°C) buffered salt solution (NaCl 137 mM; KCl 2.7 mM; MgCl2;  
 
 
 
 
 
 
 
 
 
 
 
1 mM; CaCl2 0.5 mM; NaH2PO4 0.4 mM; Glucose 5.6 mM; 
HEPES 10 mM) into the peritoneal cavity, and massaged gently in 
this region for 90 s, to facilitate cell recovery. A midline incision 
was made and the peritoneum was exposed. The pale fluid was 
aspirated using a blunted plastic Pasteur pipette, and collected in a 
plastic centrifuge tube. The fluid was then centrifuged at 1000 rpm 
for 5 min, and the supernatant discarded to reveal a pale cell pellet. 
The cell pellets were re-suspended in fresh buffer and re-
centrifuged. Aliquots of the cell suspension were incubated with 
the test compounds or disodium cromoglycate, before challenge 
with compound 48/80. The aliquots were carefully spread over 
glass slides and the mast cells were stained with 1% toluidine blue 
and counterstained with 0.1% light green. The slides were dried in 
air and the mast cells counted from randomly selected high power 
objective fields (X450). The effect of EEMK on mast cells was 
studied by incubating the mast cells for 10 min with the above 
formulation in a concentration of 1, 10 or 100 µg/ml. In another set 
of experiments the mast cells which were pre-incubated with 
EEMK were exposed to the mast cell degranulator, compound 
48:80 (10 µg/ml) and the incubation continued for a further 10 
min. Then, the mast cells were carefully spread over glass slides. 
The percent degranulation of the mast cells was calculated. 
Disodium cromoglycate (DSCG) (20 µg/ml) was included in one 
of the study group for comparison. 
Acute toxicity test (Determination of LD50) 
The acute toxicity test (LD50) was determined according 
to the procedure described by Lorke (1983). Albino mice (20–25 g) 
of either sex were used. This method involved an initial dose 
finding procedure, in which the animals were divided into three 
groups of three animals per group. Doses of 10, 100 and 1000 
mg/kg were administered intraperitonially (i.p.), one dose for each 
group. The treated animals were monitored for 24 h  for   mortality 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Effect of ethanolic extracts of Murraya koenigii leaves on carrageenan-induced rat paw oedemaa 
Treatment 
Dose 
(mg/kg, p.o.) 
Paw oedema volume (ml) Inhibition (%) 
1 h 2 h 3 h 1 h 2 h 3 h 
Control saline, 1 ml/kg 0.72 ± 0.02 0.86 ± 0.01 0.95 ± 0.01 - - - 
ASA 300 0.69 ± 0.04 0.78 ± 0.03 0.46 ± 0.02 4.16ns 9.3ns 51.57** 
EEMK 100 0.70 ± 0.02 0.8 ± 0.01 0.83 ± 0.03 2.77ns 6.97ns 12.63* 
EEMK 200 0.66 ± 0.04 0.68 ± 0.02 0.78 ± 0.04 8.33ns 20.93** 17.89** 
EEMK 300 0.45 ± 0.03 0.56 ± 0.02 0.61 ± 0.02 37.5** 34.88** 35.78** 
EEMK 400 0.47 ± 0.03 0.57 ± 0.04 0.62 ± 0.04 34.72** 33.72** 34.73** 
                                             
                                Values are mean ± S.E.M. (n = 6); nsNot significant, *P < 0.05, **P < 0.01 vs. control; Dunnett‘s t-test after one-way ANOVA. 
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and general behavior.  
From the result of the above step, four different doses of 
200, 400, 800 and 1600 mg/kg were chosen and administered i.p. 
respectively to four groups of one mouse per group. The treated 
animals were again monitored for 24 h. The LD50 was then 
calculated as the geometric mean of the lowest dose showing death 
and the highest dose showing no death. 
Table 2. Effect of ethanolic extract of Murraya koenigii leaves on 
mast cell degranulationa 
Pre-treatment 
(µg/ml) 
Degranulation after treatment (%) 
 Vehicle 
Compound 48/80 
(10 µg/ml) 
Vehicle 33.4 ± 0.93 75.8 ± 1.36 
DSCG (20) 12.8 ± 3.07** 20 ± 1.79## 
EEMK (1) 26.4 ± 3.12ns 38.4 ± 2.54## 
EEMK (10) 24.8 ± 3.15ns 32.8 ± 1.56## 
EEMK (100) 17.4 ±1.03** 23.4 ± 1.97## 
 
aEach value represents the mean ± S.E.M. of five observations; nsNot significant,  
*P < 0.05, **P < 0.01 vs. control (vehicle treated), one-way ANOVA followed by 
Dunnett‘s t-test; #P < 0.05, ##P < 0.01 vs. control (Compound 48/80 treated), one-
way ANOVA followed by Dunnett‘s t-test. 
 
Data analysis  
The data are presented as mean ± SEM.  Statistical 
significance was determined using one-way analysis of variance 
(ANOVA) followed by dunnett‘s t-test or Chi-square test with 
Yate‘s correction factor. Differences were considered significant at 
P < 0.05. 
3. RESULTS AND DISCUSSION 
The results of the present study revealed anti-
inflammatory, mast cell stabilization, and antihistaminic actions of 
EtOH extract of Murraya koenigii. 
The EEMK (300 and 400 mg/kg, p.o.) at 1 h and EEMK 
(200, 300, and 400 mg/kg, p.o.) at 2 h and 3 h significantly reduced 
(P < 0.01) the paw edema as compared to the control group 
animals. Interestingly, EEMK at the dose of 100 mg/kg failed to 
produce any significant reduction in the inflammatory increase in 
paw volume at 1 h and 2 h. ASA (300 mg/kg, p.o.), a standard anti-
inflammatory drug, was devoid of any inhibitory action on 
reduction of paw oedema up to 2 h. However at 3 h time point, 
ASA markedly reduced the inflammatory increase in paw volume 
(P < 0.01) (Table 1). 
The edema (inflammation) induced by carrageenan is 
shown to be mediated by histamine and 5-HT during first 1 h, after 
which increased vascular permeability is maintained by the release 
of kinins up to 1.30 h and from 1.30 to 3 h, the mediators appear to 
be prostaglandins, the release of which is closely associated with 
migration of leucocytes into the inflamed site (Di-Rosa et al., 
1971). The Carrageenan-induced paw edema model in rats is 
known to be sensitive to cycloxygenase (COX) inhibitors and has 
been used to evaluate the effect of non-steroidal anti-inflammatory 
agents (Rao et al., 2005). It has been established that the 
carrageenan-induced oedema was expressed in two phases 
(Vinegar et al., 1969). When the first 3-h segment of the curve is 
analyzed, a biphasic response has been seen. A rapid rise in foot 
volume occurs immediately after sub-plantar injection of 
carrageenan. Subsequently, a diminution of foot volume occurs at 
the end of 1 h, which has been designed as the first phase or early 
phase oedema. A second period of oedema formation begins to 
develop at a slow rate from the end of 1 h. Around 90 min, a strong 
acceleration of oedema formation occurs which tapers off after 3 h. 
The oedema volume present at 3 h minus the oedema at 1 h 
represents the second phase or late phase oedema volume. It has 
been also established that the late phase oedema was mainly due to 
the release of prostaglandins (Matyas Kottai et al., 1991) and the 
early phase oedema may be due to some mediators like histamine, 
acetylcholine, and bradykinins, which are a powerful mediators of 
inflammation. In the present study, The EEMK reduced the 
oedema (inflammation) partially or completely at early or late 
phase. This indicates that the possible mechanism of action of the 
EMK as anti-inflammatory agent may be due to action on early 
phase mainly by inhibiting histamine, which is abundantly present 
in the pro-inflammatory cells like neutrophils and mast cells. It is 
well known fact that the ASA act by inhibiting the prostaglandins 
synthesis at late phase. 
Table 3. Effect of ethanolic extracts of Murraya koenigii leaves on 
histamine-aerosol in guinea pigsa 
Treatment 
Dose (mg/kg, 
i.p.) 
Protection (%) 
Control saline, 1 ml/kg 0 
Mepyramine 8 90*** 
EEMK 100 0 
EEMK 200 40 
EEMK 300 60* 
EEMK 400 70** 
 
an = 10 in each group; *P < 0.05, **P < 0.01, ***P < 0.001 vs. control; (χ2 with 
Yate‘s correction) 
 
In the light of above discussion, it was hypothesized that anti-
histaminic activity and mast cell stabilizing activity could account 
for the anti-inflammatory actions of EEMK. To test this 
hypothesis,    compound    48 / 80 -  induced   in   vitro   mast   cell 
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degranulation and histamine aerosol-induced bronchospasm 
models were selected. 
 In the mast cell stabilization paradigm, 33% of mast cells 
were degranulated in the control group. Addition of DSCG (20 
µg/ml), and EEMK (100 µg/ml) reduced the percentage of mast 
cell degranulation (P < 0.01) compared to the control group. 
Compound 48/80 (10 µg/ml) produced about 76% degranulation of 
mast cells. Pretreatment with DSCG (20 µg/ml) and EEMK (1, 10, 
and 100 µg/ml) significantly reduced (P < 0.01) degranulation of 
mast cells as compared to compound 48/80-tretaed control group 
(Table 2). The protection given by EEMK at higher concentrations 
was comparable to that of DSCG, a potent mast cell stabilizing 
agent. These results suggest that EEMK protects mast cells from 
compound 48/80-evoked degranulation. 
 In the histamine aerosol study, prior treatment of EEMK 
(300 and 400 mg/kg, i.p.) protected the animals (Table 3) to a 
significant extent (P < 0.01) from the development of asphyxia 
produced by histamine aerosol. This confirms that it has 
antihistaminic activity. The role of histamine in inflammation is 
well established (Nelson, 2003). The close resemblance of 
pulmonary responses to histamine challenge in both guinea pigs 
and humans, as well as the anaphylactic sensitization made this 
species the model of choice. In the present study, guinea pigs were 
used because of the extreme sensitivity of their airways to 
histamine, a primary mediator of bronchoconstriction. Histamine 
antagonists can be conveniently recognized and assayed by their 
ability to protect guinea pigs against lethal effects of histamine-
induced bronchospasm (Broadbent & Bain, 1964). Consistence 
with this, Mepyramine (8 mg/kg, i.p.) significantly protected 90% 
of animals from asphyxia (P < 0.001) in our study. 
 In the early stage of asthma, an inflammatory disorder, 
release of inflammatory mediators like histamine, acetylcholine, 
leukotrienes, and prostaglandins are triggered by exposure to 
allergens, irritants, cold air or exercise (Bosquet et al., 2000). 
Some of these mediators like histamine can directly cause acute 
bronchoconstriction. In the present study, we have used histamine 
as spasmogen in the form of aerosol to cause immediate 
bronchoconstriction in guinea pigs. The bronchodilatory effect of 
EEMK was found comparable to the protection offered by the 
reference standard drug mepyramine. Therefore, the plant can have 
therapeutic value as anti-asthmatic drug.  
4. CONCLUSION 
In conclusion, the results of present investigation suggest 
that, EtOH extract of Murraya koenigii has significant anti-
inflammatory, antihistaminic and mast cell stabilizing activities. 
The stabilization of mast cell membrane and antihistaminic action 
could be the mechanism of action for the anti-inflammatory action 
of this plant. However, further studies on other experimental 
models are needed to support the hypothesis. 
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Annexure-B: Authentication Certificates of plants
(1) Authentication Certificate of Solanum xanthocarpum
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(2)  Authentication Certificate of Aegle marmelos
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(3) Authentication Certificate of Caesalpinia bonducella
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(4)  Authentication Certificate of Murraya koenigii
